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ouTlINe AND SCoPe of ThIS TheSIS
The research performed in this thesis demonstrates that human natural killer cells and 
macrophages are able to mediate anti-cancer immune responses against osteosarcoma 
and Ewing sarcoma. Implications for harnessing natural killer cells and macrophages for 
potential anti-cancer immunotherapy are described. 
Osteosarcoma and Ewing sarcoma are the most common bone cancers in children and young 
adults. Despite advanced surgical techniques and multi-drug chemotherapy, one-third of the 
patients still succumb to recurrent disease with poor prognosis. Likewise, patients with metastatic 
and chemotherapy-resistant disease have a poor outcome. Thus, novel targeted therapies are 
needed that combine potent and specific anti-cancer activity with limited toxicity toward 
normal tissues. Previous research lines have provided evidence that natural killer (NK) cells and 
macrophages, both cell types of the innate immune system, are able to contribute to anti-cancer 
responses against osteosarcoma and Ewing sarcoma cells. 
The research in this thesis is performed with the aim to characterize cellular interactions of NK 
cells and macrophages with osteosarcoma and Ewing sarcoma cells in order to achieve favorable 
effects on anti-cancer immune cell functions. It is explored in preclinical studies, how the anti-
cancer potential of especially NK cells but also macrophages can be enhanced and directed to 
cancer cells. Modulation of tumor–immune cell interactions and the cytolytic activity of NK 
cells and macrophages may help to design novel immunotherapeutic approaches to harness anti-
cancer functions of (innate) immune cells against osteosarcoma and Ewing sarcoma.
In the following introductory chapter 1, clinical and biological properties of osteosarcoma and 
Ewing sarcoma are described, followed by an overview of cancer immunology and immunotherapy 
with the primary focus on innate immunity of NK cells and macrophages. The chapters 2 to 
6 compose the main body and are further outlined in section 3 of chapter 1. The thesis is 
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Osteosarcoma and Ewing sarcoma
1. oSTeoSARCoMA AND ewINg SARCoMA
1.1 Incidence and Anatomic Distribution 
Bone cancers of osseous and chondromatous origin are considered rare diseases, representing 
0.2% of cancers in the adult population (≥25 years of age) with an annual incidence rate of 8.1 
per 1×106 (Table 1) [1;2]. However, in children, adolescents and young adults (<25 years of age), 
bone cancers occur more frequently with a peak annual incidence of 16.5 per 1×106 in individuals 
between 15 and 19 years of age, representing up to 7.6% of all cancers (Table 1). In this age 
group (15–19 years), osteosarcoma and Ewing sarcoma are the most common malignant bone 
tumors (54% and 36% of bone cancers; 4.1% and 2.8% of all cancers) with an annual incidence 
of 9 and 6 per 1×106, respectively, in the United States (Table 1) [1-4]. In the Netherlands, the 
annual incidence of osteosarcoma can be more frequent with 10–16 per 1×106 in patients of 11–
18 years of age [5]. Primary osteosarcoma and Ewing sarcoma predominantly occur in the second 
decade of life (Table 1), suggesting an association with the adolescent growth spurt and bone 
remodeling. A second peak for osteosarcoma occurs in the elderly (often considered a secondary 
bone disease), while the occurrence of chondrosarcoma increases in patients with increasing age 
[3;4;6-8] (Table 1). Male individuals are more often affected than female individuals; Ewing 
sarcoma is hardly found in the African American population. 
Osteosarcoma commonly arises in the metaphysis of the long bones of the extremities (>80% 
of cases), in particular, in the distal femur, proximal tibia and proximal humerus [9;10]. The 
majority of patients (80%) presents with localized disease at diagnosis, while the remaining 
patients exhibit pulmonary (>90%) or bone metastases. Ewing sarcoma mainly occurs in the 
diaphysis of long bones of the appendicular skeleton (>50% of cases), in particular, in the femur, 
but can additionally affect bones of the axial skeleton, such as the pelvis or ribs, and is frequently 
associated with a large soft tissue mass [9;11]. Approximately 20–25% of patients harbor 
pulmonary (50%), bone (25%) or bone marrow (25%) metastases at diagnosis. 
1.2 Cancer Cell Characteristics 
Osteosarcoma cases, and sarcomas of long bones and skull in general, have been documented since, 
at least, the first half of the 19th century and were extensively reviewed by Henry Meyerding in 
1938 [12-17]. In 1957, his successors Mark Coventry and David Dahlin classified osteosarcoma 
(often named osteogenic sarcoma) as a rare, radiotherapy-insensitive malignant bone tumor 
producing osteoid, involving primarily the metaphysis of long bones and predominantly 
affecting adolescents and young adults with poor prognosis [18]. Morphologically, osteosarcoma 
is composed of a diverse mixture of epithelioid, plasmacytoid, spindle-like and small-round cells 
and can be grouped in histological subtypes which, however, does not affect treatment or prognosis 
[1]. In many patients, osteosarcoma cells bear alterations in the p53 gene, retinoblastoma-like 
gene or MDM2 gene and display aberrant expression/activation of growth factor receptors (e.g., 
insulin-like growth factor receptor) [9;19]. 
In 1921, James Ewing reported a rapidly progressing, radiotherapy-sensitive, round cell sarcoma 
with low cytoplasm content and frequently arising in children and adolescents in the shaft of 
bones of the extremities [20]. Before that time, presumably, Ewing sarcoma had generally been 
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Osteosarcoma and Ewing sarcoma
further reviewed and categorized as a distinct bone cancer, markedly different to radiotherapy-
insensitive osteogenic cancers (i.e., osteosarcoma) [7;21]. The uniform, small-round blue cells 
(high content of eosin-staining nuclei) of Ewing sarcoma are characterized by their distinctive 
strong membranous CD99 expression, whereas the small-round cell subtype of osteosarcoma 
only exhibits intracellular CD99 [1]. 
1.3 Clinical Presentation and Diagnosis
Osteosarcoma and Ewing sarcoma is commonly recognized subsequent to physical activity-
related injuries and initially diagnosed by non-specific symptoms such as intermittent and 
later persistent severe pain, swelling, a palpable mass, limited mobility and rarely spontaneous 
fractures [1;22]. In contrast to osteosarcoma patients, Ewing sarcoma patients especially with 
advanced tumors may also present with systemic inflammatory symptoms like mild fever. Lactate 
dehydrogenase levels, leukocyte counts or erythrocyte sedimentation rates may be elevated in 
Ewing sarcoma patients.  Alkaline phosphatase levels may be elevated in osteosarcoma patients. 
Diagnosis of osteosarcoma or Ewing sarcoma is further evidenced by plain X-ray radiographs, 
illustrating mixed radiolucent and radiodense periosteal bone-forming lesions with associated 
calcified soft tissue masses [22]. Magnetic resonance imaging is employed to determine the size, 
intramedullary and soft tissue extent of the bone tumor to facilitate subsequent complete surgical 
resection as well as limb-preserving surgery [22;23]. Presence of pulmonary and skeletal metastases 
is assessed by computed tomography of the thorax and whole-body radionuclide bone scans plus 
bilateral bone marrow aspirations, respectively. Biopsy of the tumor (core) by trephine needle 
puncture or incision is essential to establish the definite diagnosis on the basis of the histological 
and immunohistochemical cell characteristics [22]. In addition, diagnosis of Ewing sarcoma can 
be confirmed by the presence of distinctive spontaneous chromosomal translocations, detected 
by RT-PCR or fluorescence in situ hybridization (FISH) techniques [24]. In the majority of 
cases, the transcriptional activation domain of the EWS gene on chromosome 22 is fused in-
frame to the DNA-binding domain of the FLI1 gene on chromosome 11 (t(11;22)(q24;q12)) 
or other members of the ETS family of transcription factors [25]. In contrast, osteosarcoma cells 
do not harbor such specific cytogenetic characteristics. The generated fusion proteins in Ewing 
sarcoma cells possess enhanced transcription-modulating (activating and inhibiting) properties 
and are involved in tumor development, increasing tumor cell proliferation and survival as well 
as escape from growth inhibition and apoptosis [26;27]. 
1.4 Treatment, Prognosis and outcome
Prior to the availability of chemotherapy (<1970), the principal treatment of patients with bone 
tumors consisted of dubious toxic chemicals (e.g., mercury), Coley’s toxin (see below, section 
2.2) and particularly surgical resection or amputation, and later partly effective radiotherapy 
techniques [6-9;15;28;29]. The prognosis of patients even without overt metastatic disease was 
considered poor with a five-year survival rate of <25% [6;30]. Most patients rapidly developed 
recurrent disease and pulmonary metastases which led to the hypothesis of the presence of 
subclinical micro-metastases at the time of diagnosis of localized disease [18;30;31]. Superior 
imaging and surgical techniques, advanced detection and removal of lung metastases and 
especially the introduction of tumor cell-cytotoxic chemotherapeutic agents (e.g., doxorubicin) 




(i.e., adjuvant) multi-drug chemotherapy was subsequently confirmed to delay the development 
of metastases and substantially improved event-free and overall survival in osteosarcoma and 
Ewing sarcoma patients [37-40]. 
The current treatment of osteosarcoma patients includes pre-operative (i.e., neoadjuvant) 
chemotherapy, to initially reduce tumor viability and micro-metastases,  followed by resection of the 
primary tumor and overt metastatic lesions and subsequent (maintenance) adjuvant chemotherapy, 
to ablate residual tumor cells and micro-metastases [22;41;42]. The chemotherapeutic regimen 
consists of a three drug cocktail (methotrexate, doxorubicin and cisplatin) or a comparably 
effective four drug cocktail (+ ifosfamide) [37;43]. Ewing sarcoma patients are treated with 
vincristine, ifosfamide, doxorubicin and etoposide (+/- cyclophosphamide +/-dactinomycin), 
followed by local control using surgery +/- radiotherapy, and adjuvant chemotherapy [22;42]. 
Radiotherapy is less commonly used due to the risk of secondary cancers [9]. Patients achieving 
remission may be subjected to surgical reconstruction of the affected limb or prosthetics [23]. 
Good prognostic factors include: no or few metastatic lesions at diagnosis; response to neoadjuvant 
chemotherapy and radiotherapy; low levels of serum-alkaline phosphatase at diagnosis; small 
tumor size; (resectable) metastasis in the lung only and not at other sites like bone marrow; 
tumor location in the appendicular skeleton [10;11;22;44;45]. Adverse factors are metastatic 
lesions at diagnosis and recurrent disease. Despite their merits, certain chemotherapeutic drugs 
can result in considerable adverse effects, such as infertility (ifosfamide), renal impairment 
(ifosfamide), hearing disorders (cisplatin), cardiomyopathy (doxorubicin), secondary cancers 
(ifosfamide, cisplatin, cyclophosphamide) [9;42]. Chemotherapy can inflict adverse effects such 
as lymphopenia (cyclophosphamide) but also beneficial effects on anti-cancer immunity such as 
immunogenic cell death (e.g., doxorubicin) and regulatory T cell depletion (cyclophosphamide) 
[46]. 
With current therapies, up to 70% of patients with localized disease accomplish continuous 
remission, achieving 5-years event-free and overall survival rates of 55–80% and 10-years survival 
rates of 50–60% [43;47-51]. Notably, up to 30% of these patients develop local relapses or 
distant metastases [44;52;53]. In spite of intensification of modern multi-drug chemotherapy 
regimens, patient prognosis has not significantly further improved during the last two to 
three decades [37;49;54]. In particular, patients with metastatic, recurrent and chemotherapy-
refractory disease have a very poor prognosis and survival rates of less than 30%, highlighting the 
need for novel therapeutic strategies. 
2. CANCeR IMMuNology & IMMuNoTheRAPy
Conventional chemotherapy primarily aims at proliferating cells. Cancer cells which are dormant 
or acquiring resistance to cytotoxic drugs, such as cancer stem cells, may escape chemotherapy, a 
scenario presumably involved in metastatic and recurrent disease [55;56]. Thus, novel therapeutic 
strategies are warranted that potently target chemotherapy-refractory cancer cells and have a 
favorable toxicity profile toward normal cells. 
In 2011, Hanahan and Weinberg refined their concept of the hallmarks of cancer [57;58]. These 
hallmarks envisage the complex factors involved in transforming homeostatic cells to aberrantly-
1
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proliferating cells, local tumor growth and dissemination: sustained proliferative signaling; 
evasion of growth suppression; resistance to cell death; replicative immortality; angiogenesis; 
invasion, metastatic spread and colonization; and  reprogramming of the energy metabolism. The 
authors included the phenomenon that the cancer microenvironment can evolve mechanisms 
to modulate the immune system in such a way that anti-cancer immune responses become 
suppressed and that immune cells ignore or even support tumor development [58]. Noteworthy, 
this notion implies that immune cells play a fundamental role in protecting from initial cancer 
growth. The existence of natural cancer immunosurveillance was originally proposed by Paul 
Ehrlich (1909) and later by Macfarlane Burnet, Lewis Thomas and contemporaries and was based 
on the discrimination between ‘self ’ and ‘non-self ’ by means of specific tumor antigens expressed 
on cancer cells [59-61]. However, cancer immunosurveillance has not been fully appreciated 
for a long time (e.g., due to the lack of inbred mouse strains and tumor antigens of non-viral 
cancers at that time) and only evidenced in the last decades [62;63]. The concept of immune 
evasion by cancer cells, termed ‘cancer immunoediting’ by Gavin Dunn, Robert Schreiber and 
colleagues in 2002, describes that initial tumor cell elimination by immune cells results in the 
selection of less immunogenic tumor cell variants which can then escape immunosurveillance 
and destruction (Figure 1, panel A) [62-64]. Comprehension of the interaction of cancer cells 
and immune cells has generated a multitude of immunotherapeutic strategies to exploit, induce, 
enhance and restore anti-tumor immune cell functions or to (re)-sensitize tumor cells to immune 
cell recognition [65-67].
2.1 A Rationale for inducing Anti-Cancer Immune Responses by mimicking Acute 
Infections in the Tumor Microenvironment
Similar to the concept of ‘cancer immunoediting’ (Figure 1, panel A), viruses establishing 
chronic infections, such as hepatitis C virus (HCV), evolve genetic variants under the pressure 
of the immune system. These virus variants may have acquired selected adaptations to evade 
and exhaust innate and adaptive immune responses, and cause an immunosuppressive milieu 
that subverts immunological protection of the host [68;69]. As a consequence, chronic viral 
infections (e.g., Epstein-Barr virus, HCV and human papilloma virus (HPV)) and chronic 
bacterial infections (e.g., Helicobacter pylori) can trigger or predispose to cancer development, 
respectively [70]. Furthermore, chronic infections, chronic inflammation and accelerated 
tissue regeneration can impair anti-cancer immune responses and provoke tumor formation, 
which can actually be supported by certain immune cells such as tumor-promoting M2-type 
macrophages, myeloid-derived suppressor cells and regulatory T cells (Figure 1, panel A) [64;71-
73]. On the other hand, for a long time acute infections have been associated with spontaneous 
cancer regression and a lower risk for cancer development [70]. While elimination of cancer 
cells by immune cells becomes suppressed during cancer development, acute infections may 
rescue anti-cancer immunosurveillance due to non-specific activation of immune cells in 
response to harmful pathogens [63]. Similar to certain chemotherapeutic agents, acute infections 
in the tumor microenvironment may trigger immunogenic cell death and improve cancer cell 
detection by immune cells (Figure 1, panel B)[74]. Hence, acute infections may cause the release 
and display of ‘danger’ and ‘stress’ molecules such as calreticulin, high-mobility group box 1 
protein (HMGB1), heat-shock proteins, NK cell activating-receptor ligands, microbial toll-




Figure 1: Cancer Immunosurveillance, Cancer Immunoediting and Re-activation of Anti-Tumor Immunity
(A)  taken and adapted from Vesely et al., 2011, Annual Review of Immunology [reference 64]. 
(B) Hypothetical model of the re-activation of anti-tumor immune responses after an acute infection or infection-
mimicking agents in the cancer microenvironment, or chemotherapy in the presence of endogenous/exogenous immune 
cell-activating stimuli.
NK: natural killer cell, T: T cell, M1/2: M1/M2 macrophage, DC: dendiritc cell, MDSC: myeloid-derived suppressor 
cell, Treg: regulatory T cell, TLR-L: TLR ligands.   
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Cancer Immunology and Immunotherapy
(NLR) ligands like muramyl dipeptide (MDP), and secretion of pro-inflammatory cytokines 
and chemokines [64;74-79]. As a hypothesis, local and attracted innate immune cells such as 
NK cells, macrophages and dendritic cells may then be activated to combat infected cells. Due 
to enhanced tumor cell recognition and cytotoxic function, NK cells and macrophages could 
contribute to the destruction of infected and bystander cancer cells and thus interfere with cancer 
progression. Ideally, cancer cell destruction by innate immune cells may also liberate potential 
cancer-associated antigens which could be (cross-)presented by dendritic cells or macrophages 
to CD4 helper T cells and CD8 cytotoxic T cells. This may favor the induction of a primary 
or previously suppressed anti-cancer Th1 response. Hence, (re-)activation of anti-cancer innate 
immune responses of NK cells and macrophages by an acute infection may contribute to the 
generation of an adaptive anti-cancer T cell response, an immunological prerequisite for systemic, 
long-lasting and effective immunity.
Several immunotherapeutic approaches have emerged to mimic acute infections in the tumor 
microenvironment and to mobilize anti-cancer (innate) immune responses. In the following 
sections, examples of anti-cancer immune responses and their applications for cancer 
immunotherapy are illustrated with the primary focus on innate immunity of NK cells and 
macrophages; some highlights of adaptive immunity-related immunotherapy are additonally 
noted.
2.2 Coley’s Toxin and Acute Infections as the onset for Modern Immunotherapy
As early as in the middle of the 19th century, physicians noted that some cancer patients 
spontaneously experienced cancer regression and remission if contracting acute erysipelas [80], 
an infectious skin inflammation [81]. Therefore, Wilhelm Busch (<1866) attempted to transfer 
the (at that time) undetermined infectious agent of erysipelas to cancer patients, for instance, 
by cauterizing the tumor surface and covering it in the sheets of a patient who had naturally 
contracted the infection [80]. Temporary tumor regression (called absorption) was noted to be 
associated with severe or even lethal febrile symptoms and local influx of leukocytes at the site 
of infection; it was hypothesized that the severity of fever contributed to the anti-tumor effect. 
The causative bacteria of erysipelas infection, Streptococcus pyogenes, were identified in ~1882, 
propagated and tested in rabbits and first used in the treatment of patients with inoperable 
cancers by Friedrich Fehleisen and contemporaries [82]. 
Inspired by cases of spontaneous tumor regression after acute erysipelas, the bone surgeon 
William Coley injected sarcoma patients with live Streptococcus pyogenes in 1891 and beyond 
[28]. Despite dramatic tumor regression in a few patients, the infection was difficult to control 
or even fatal due to the lack of antibiotics at that time [83]. Hence, a safe heat-inactivated 
preparation of gram-positive Streptococcus pyogenes and gram-negative Serratia marcescens was 
developed which conferred anti-tumor activity particularly subsequent to tumor resection. The 
anti-tumor effect of this preparation, referred to as Coley’s toxin, was essentially attributed to 
the strong immunostimulatory effect of Serratia marcescens containing, for instance, relatively 
heat-resistant endotoxin [84;85]. Treatment of hundreds of patients with Coley’s toxin achieved 
at least in a part of the patients, with local and metastatic disease, considerable tumor regression 




However, William Coley’s work was heavily disputed due to inconsistencies in his documentation, 
multiple refinements of the bacterial preparations and the lack of a standardized treatment 
schedule because it required individual dosing, administration and patient monitoring over a 
long time. Eventually, treatment with Coley’s toxin was superseded by the introduction of more 
feasible and broadly applicable radiotherapy and later chemotherapy [87]. Nevertheless, Coley’s 
work has contributed to the development of some modern immunotherapeutic treatments as 
presented below.
2.3 enhancing Innate Immunity by Immunomodulators 
As one of the most successful adjuvant treatments, live-attenuated Mycobacterium bovis-based 
Bacillus Calmette-Guérin (BCG) is included in the treatment of patients with bladder cancer 
and significantly reduces cancer progression and the risk for recurrent disease [75;88]. The anti-
cancer effects of Coley’s toxin and BCG have been linked, at least in part, to the bacterial cell 
wall constituents lipopolysaccharide (LPS, endotoxin) and peptidoglycan subunits like muramyl 
dipeptide, which were identified in these bacterial preparations as minimal active moieties 
to trigger inflammatory responses [75;85;89-91]. Furthermore these bacterial constituents 
can induce tumoricidal activity and production of pro-inflammatory and immunoregulatory 
cytokines by macrophages such as tumor-necrosis factor-α (TNF-α) and interleukin-12 (IL-
12) (this thesis, chapter 5), which furthermore may stimulate anti-tumor responses of NK cells 
[75;92;93]. 
In fact, stimulation of mice with BCG in combination with Coley’s toxin or LPS led to the 
discovery of TNF-α; TNF-α was described as the factor induced in the serum of these treated 
mice which presumably mediated ‘hemorrhagic necrosis’ of murine fibrosarcoma in vivo and 
anti-tumor effects in vitro, and was suggested to be implicated in the anti-tumor effects of LPS-
activated macrophages [94]. Since purified TNF-α was subsequently found to be cytotoxic 
against certain cancer cells [95], melanoma patients have been treated with recombinant TNF-α, 
improving the response to chemotherapy but not survival [46;96]. Notably, in certain conditions 
TNF-α and other pro-inflammatory cytokines support tumor development [64;72]. Interferon-α 
(IFN-α) was originally discovered to be produced upon virus infection and interfering with virus 
spread [97]. In addition, IFN-α was found to mediate anti-tumor effects in patients with, in 
particular, virus-derived cancers and inhibit growth of osteosarcoma cells in vitro; a cancer at that 
time (~1980) believed to be of viral origin [98;99]. Therefore, IFN-α has been included in the 
treatment of osteosarcoma patients in Sweden, and its clinical benefit to conventional therapy is 
currently evaluated in the European/American Euramos-1 trial [98;100]. In addition to its direct 
anti-tumor effect, IFN-α has been shown to enhance the cytotoxic activity of NK cells against 
osteosarcoma cells in vitro [101]. Other cytokines such as IL-2 and IL-15 have been used to 
enhance or maintain the viability and anti-tumor cytotoxic activity of endogenous or adoptively-
transferred ex vivo-activated NK cells [102] (see below, section 2.5). 
As an alternative to bacterial infections, oncolytic viruses such as genetically-modified poxviruses 
and adenoviruses are currently explored to selectively infect and directly kill cancer cells which 
may also induce anti-tumor innate and adaptive immune responses [103-108]. Of note, some 
but not all osteosarcoma and Ewing sarcoma cell lines are susceptible to lysis by wild-type or 
naturally selected mutant oncolytic reovirus [109] (and unpublished observation). 
1
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Upon release into the circulation, crude bacterial preparations as well as purified LPS have the 
potential to cause excessive inflammatory responses, culminating in severe adverse affects such 
as septic shock and extensive tissue damage [110]. As a ‘less toxic’ alternative, innate immune 
cells can be activated by less stimulatory equivalents of bacterial and viral constituents such as 
imiquimod (TLR7/8 ligand), Poly I:C (TLR3 ligand), unmethylated CpG-DNA motifs (TLR9 
ligand) [78;111]. TLR ligands can improve maturation and the antigen-presenting capacity of 
dendritic cells and thus the generation of adaptive T cell responses. Dendritic cell-based protein/
peptide vaccines such as applied in prostate cancer generally confer low clinical activity [112]. 
Hence, TLR ligands as well as IL-12 and granulocyte–macrophage colony stimulating factor are 
investigated for adjuvant effects on dendritic cell-based vaccines like in HPV-induced cervical 
cancer [65;113;114]. Notably, to mimic an acute bacterial infection in osteosarcoma, liposomal 
muramyl tripeptide, presumably activating the intracellular NOD2 receptor in myeloid cells, 
has recently been introduced in the treatment of osteosarcoma patients to induce anti-tumor 
cytotoxicity of monocytes and macrophages although with limited clinical efficacy [43;65;115] 
(and this thesis, chapter 5). 
2.4 Natural Anti-Cancer Activity of NK cells 
NK cells have originally been described by Rolf Kiessling and contemporaries as a distinct subset 
of lymphocytes (other than T and B cells) able to kill virus-induced murine leukemia cells in 
a contact-dependent manner but without the need for prior sensitization to these target cells 
[116-118]. NK cells were further characterized by Klaas Kärre and colleagues as cytotoxic cells 
which can respond to cells with incompatible or down-regulated expression of MHC class I 
molecules like allogeneic (‘non-self ’) and some virus-infected/tumor-transformed cells, escaping 
from MHC class I-restricted cytotoxic CD8 T cells; in contrast, NK cells spare normal MHC 
class I-sufficient (‘self ’) cells  [119]. This concept was termed ‘’missing-self hypothesis’, elegantly 
reviewed in [120]. Currently, NK cells are proposed to be grouped together with the emerging 
population of innate lymphoid cell subtypes [121]. 
NK cells are considered to bridge innate and adaptive immunity by their capability to produce 
significant amounts of IFN-γ [122]. IFN-γ increases MHC class I and II expression on abnormal 
cells and antigen-presenting cells, respectively, which supports the initiation of Th1 responses. 
In addition, IFN-γ enhances the bactericidal and tumoricidal activity of macrophages. Thus, 
in interplay with macrophages and dendritic cells, NK cells are involved in initial responses 
to virus-infected and tumor-transformed cells but may also contribute to the induction of 
adaptive anti-cancer (memory) T cell responses [123-125] (and this thesis, chapter 2 and 3). 
The cytotoxic activity of matured (i.e., ‘educated’) human NK cells is regulated by the balance 
of activating and inhibitory signals perceived from target cells via germ-line–encoded inhibitory 
and activating receptors [79;126-129]. Thus, NK cell-mediated lysis of cancer cells is determined 
by the combination of a) low expression of ligands for NK cell inhibitory receptors such as killer 
cell immunoglobulin-like receptors (KIR) (ligands: HLA-A, B and C alleles) [130] and NKG2A/
CD94 (HLA-E) [131] and b) high expression of ligands for NK cell activating receptors such 
as NKG2D (MICA, MICB, ULBP1-6) [132-137], DNAM-1 (CD112 and CD115) [138] 
and NKp30 (B7-H6) [139]. Osteosarcoma and Ewing sarcoma cells have been shown to be 




DNAM-1 and NKp30 interactions [140-143] (and this thesis, chapter 4). As one of the most 
effective NK cell-activating receptors [144], ligation of FcγIIIa/CD16 triggers substantial NK cell 
cytotoxicity against antibody-coated target cells (and against cells carrying thus far unidentified 
ligands [145]), eliciting antibody-dependent cellular cytotoxicity (ADCC) [146-148] (and this 
thesis, chapter 3). 
Human NK cells have been suggested to interfere with cancer development since individuals 
with low NK cell cytotoxic activity have a higher incidence of cancer [149]. Antibody-based 
immunotherapy has been reported to improve the outcome of cancer patients carrying the high-
affinity gene polymorphism in FcγIIIa/CD16 (-158V vs -158F) [150-154], which mediates 
stronger antibody-binding to FcγIIIa/CD16 and enhances NK cell cytolytic function [155-
157]. These observations suggest that CD16+ NK cells (and CD16+ macrophages) and ADCC 
are involved in the clinical effects of rituximab (anti-CD20), cetuximab (anti-EGFR) and 
trastuzumab (anti-Her2/neu). The biological relevance of NK cells to recognize human tumor 
cells by the absence of a complete ‘self ’ HLA-I repertoire was highlighted in the clinical setting 
of KIR-mismatched haploidentical (T cell-depleted) hematopoietic stem cell transplantation: 
a subset of alloreactive NK cells, generated from the donor graft in the recipient, presumably 
mediated the reduced risk for graft rejection, acute graft-versus-host disease and leukemia relapse, 
but contributed to graft-versus-leukemia effects [158]. These results renewed the interest in NK 
cells for immunotherapeutic strategies. Moreover, the clinical response to antibody-based and 
tyrosine kinase inhibitor-based immunotherapy has recently been shown to positively correlate 
with NK cell activation, NK cytotoxicity and tumor infiltration by NK cells in some cancer 
patients [159-163], implying a direct role for NK cells in anti-cancer responses in humans. 
2.5 enhancing NK cell function by Antibodies, Cytokines and Adoptive Cell Transfer 
Antibody-based immunotherapy with rituximab, cetuximab and trastuzumab has successfully 
been included in the treatment of B cell malignancies, colorectal cancer, head-neck cancer and 
breast cancer [164-169]. In addition to direct anti-cancer effects, the clinical effect of these 
therapeutic antibodies may involve CD16+ NK cells as well as CD16+ macrophages by the 
association with the high-affinity polymorphism in FcγIIIa/CD16 (-158V vs -158F) as noted 
above. A role for macrophages has additionally been suggested by the association with high-
affinity polymorphism in FcγIIa/CD32 (-131H vs -131R) reported in some studies. Furthermore, 
patients with higher numbers of tumor-infiltrating macrophages had a better clinical outcome in 
response to antibody therapy [153;154;170]. Therapeutic antibodies may mobilize the cytotoxic 
potential of NK cells which are functionally sufficient for FcγIIIa/CD16-dependent lysis but 
deficient for antibody-independent lysis; the latter as a result of NK cell education (due to the 
lack of inhibitory KIR receptors against ‘self ’ ligands) or tumor encounter [171;172] (and this 
thesis, chapter 4). 
In fact, NK cells (and T cells) are frequently rendered hyporesponsive or functionally exhausted 
in an inhibitory cancer microenvironment, presumably to escape from immunosurveillance 
[143;171;173-179]. To lower the threshold for NK cell cytotoxicity, counteract NK cell 
inactivation during cancer progression and exploit ‘missing-self ’ recognition, blockage of 
inhibitory KIR receptors with antagonistic antibodies is currently explored [180]. Similarly, 
blockage of the T cell inhibiting receptors CTLA-4 (ipilimumab) and PD-1 has been pursued 
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to disrupt T cell tolerance which has partly achieved encouraging clinical responses as well as 
significant autoimmune effects in some patients [181;182]. Depletion of M2-type macrophages 
or regulatory T cells has been suggested to counteract pro-tumor properties and inhibitory 
effects of these cells on anti-cancer functions of NK cells and other immune cells [183-185]. 
Using agonistic antibodies, NK cell functionality can be directly augmented by cross-linking 
of activating receptors like CD137 (induced upon ADCC in vivo), which has been shown 
to potentiate rituximab-mediated and trastuzumab-mediated ADCC in preclinical studies 
[186;187]. Similarly, agonistic antibodies against CD40 can improve the co-stimulatory activity 
of dendritic cells and the anti-tumor activity of macrophages, respectively [188;189]. 
In view of enhancing the function of endogenous NK cells by activating cytokines, infusion of 
high-dose IL-2 can result in adverse reactions and activation of regulatory T cells, while low-dose 
IL-2 may fail to sufficiently enhance NK cell cytotoxicity [102]. As an alternative, NK cells can 
be (re-)activated ex vivo and used for adoptive cell transfer therapy [102;143]. In the case of T 
cells, the potential of adoptive transfer using autologous tumor-reactive T cells (anti-MART-1 or 
cancer-testes antigens) and chimeric antigen receptor (CAR) T cells (anti-CD19-CD3ζ-CD28/
CD137, MHC class I-independent) has been highlighted; this approach resulted in remarkable 
cancer regression and remission in up to half of the patients with advanced melanoma or B 
cell malignancies [190-195]. Still, these T cells fail to control epitope-negative escape variants 
and have the potential for long-time adverse effects on epitope-positive normal cells [191;195]. 
Similar to CAR T cells, genetically-engineered CAR NK cells (anti-CD19-CD3ζ-CD137) 
are currently developed; CAR NK cells may possess enhanced cytotoxicity more specifically 
directed toward target cells (even if these target cells are normally insensitive to natural NK cell 
cytotoxicity) while retaining natural cytotoxicity against epitope-negative cells [196;197]. 
As already alluded to, several studies have investigated to introduce highly functional NK cells 
into cancer patients by adoptive cell transfer of (a) autologous and (b) haploidentical NK cells in 
combination with (a,b) ex vivo or (b) in vivo IL-2 stimulation [171;198-201]. Adoptive transfer 
of haploidentical NK cells, with the potential for ‘missing-self ’ recognition, has been shown to 
mediate complete remission with limited adverse effects in patients with advanced hematological 
malignancies [198-201]. Importantly, haploidentical NK cells did not cause graft-versus-host 
disease in the recipients. In contrast to patients with hematological malignancies, so far, objective 
clinical responses in patients with solid cancers have not been reported after adoptive transfer 
of haploidentical or autologous NK cells [171;198]. In fact, in melanoma patients, even IL-2–
activated (autologous) NK cells have been reported to lose cytotoxic activity after adoptive 
transfer, possibly as a consequence of trafficking through an inhibitory cancer microenvironment 
[171]. Recent studies in mice have demonstrated that NK cell functionality and viability after 
adoptive transfer is augmented and prolonged by pre-activation with a cytokine cocktail of IL-
12, IL-15 and IL-18 and further enhanced by endogenous IL-2 production of recipient CD4 T 
cells [202;203]. Thus, these recent studies indicate potential mechanisms to improve persistence 
and anti-tumor function of NK cells in the recipient after adoptive transfer, which has remained 
challenging so far.
As pointed out above, a multitude of research lines is currently devoted to the improvement 




more effectively exploit the cytotoxic potential of NK cells for anti-cancer immunotherapeutic 
strategies.
3. ouTlINe of The ChAPTeRS 2–6
In the following research chapters it is demonstrated in preclinical studies, how the anti-
cancer potential of especially NK cells but also macrophages can be enhanced and directed to 
osteosarcoma and Ewing sarcoma cells. First an experimental model for measuring NK cell 
activation in vitro is explored. 
In chapter 2, phenotypical and functional activation of NK cells is examined in response 
to a prototypical viral infection by adenovirus types 5 and 35. Cellular prerequisites and the 
requirement for interactions between NK cells and other immune cells (plasmacytoid dendritic 
cells and T cells) for NK cell activation are addressed. 
In chapter 3 it is investigated how sarcoma–NK cell interactions can be improved to enhance 
and direct the cytotoxic potential of NK cells to osteosarcoma and Ewing sarcoma cells. The 
potential of antibody-dependent cytotoxicity by NK cells against sarcoma cells is highlighted by 
targeting sarcoma cells with a tumor cell-reactive antibody. 
NK cells can exert cytolytic activity against osteosarcoma and Ewing sarcoma cell lines in short-term 
assays as shown in research chapter III. However, as illustrated in chapter 4, prolonged tumor–
NK cell interactions, potentially occuring in an immunosuppressive cancer microenvironment, 
can alter NK cell functionality. It is investigated how some of the sarcoma cell lines mediate 
significant down-regulation of NK cell activating receptors and NK cell cytolytic activity during 
two-day tumor–NK cell co-cultures. Furthermore, it is demonstrated that this inhibition can be 
prevented and bypassed by NK cell activation prior to tumor contact and presence of a tumor 
cell-reactive antibody, respectively.
The presence of tumor-infiltrating macrophages has recently been shown to positively correlate 
with survival of osteosarcoma patients, suggesting a role for macrophages in anti-cancer 
responses. In chapter 5 it is demonstrated that human macrophages are able to interfere with 
osteosarcoma cell growth. It is determined whether the anti-cancer activity of macrophages can 
be enhanced and directed to osteosarcoma cells using immunostimulatory bacterial derivates 
(such as liposomal muramyl tripeptide) and a tumor cell-reactive antibody, respectively.   
In the final chapter 6, the expression of the immunoregulatory protein CD70 is documented 
on osteosarcoma and Ewing sarcoma cell lines and in tumor tissue, as a potential mediator in 
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Adenovirus type 35, but not type 5, stimulates NK cell 
activation via plasmacytoid dendritic cells and TLR-9 signaling
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In hematopoietic stem cell transplant (HSCT) recipients, disseminated adenoviral infections 
during the first two months after HSCT can lead to severe complications and fatal outcome. 
Since NK cells are usually the first lymphocytes to reconstitute after HSCT and have been 
implicated in the clearance of adenovirus-infected cells, it was investigated whether NK cells are 
activated by adenovirus in vitro.  
Exposure of PBMC to human adenovirus type 5 (HAdV5) or HAdV35 resulted in up-regulation 
of the activation marker CD69 on NK cells and enhanced cytolytic activity of NK cells. HAdV5-
induced NK cell activation relied on the contribution of T cells as depletion of T cells from PBMC 
abolished NK cell activation. In contrast, NK cell activation in response to HAdV35 occurred in 
the absence of T cells. Plasmacytoid dendritic cells (pDC) were necessary and sufficient to mediate 
NK cell activation. HAdV35 induced significantly more interferon-α (IFN-α) production by 
pDC than HAdV5. The increased IFN-α production and NK cell activation correlated with a 
higher infection efficiency of viruses with the type 35 fiber. The IFN-α response of pDC was 
enhanced by the presence of NK cells, suggesting a reciprocal interaction between pDC and NK 
cells. Incubation with a toll-like receptor 9 (TLR-9) antagonist impaired the IFN-α production 
by pDC as well as NK cell activation, implying that TLR-9 signaling is critically involved in the 
IFN-α response of pDC and NK cell activation after HAdV35 exposure.  
In conclusion, two human adenovirus serotypes from two different species differ considerably in 
their capacity to stimulate pDC and NK cells.
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INTRoDuCTIoN
Human adenoviruses (HAdV) are non-enveloped double-stranded DNA viruses that are not 
considered a major risk for immunocompetent hosts. Adenoviral infections commonly occur 
in early childhood, are self-limiting and typically associated with asymptomatic or mild disease 
[1]. Among the human adenovirus family, 52 serotypes have been identified on the basis of 
neutralizing antibodies and are categorized in six HAdV species (A-F) according to their capacity 
to agglutinate erythrocytes [2].  
In the first line of immune defense, dendritic cells are considered the major sentinels for viral 
pathogens [3;4]. Plasmacytoid dendritic cells (pDC) selectively express the intracellular Toll-like 
receptor 9 (TLR-9), which detects unmethylated DNA with CpG-motifs frequently found in 
bacteria and in double-stranded DNA viruses [5-11]. Stimulation of TLR-9 initiates a signaling 
cascade in association with MyD88, resulting in type I interferon (IFN-I) production as well 
as enhanced expression of co-stimulatory molecules such as CD80, CD86 and CD40 [10;12]. 
IFN-α exhibits a direct antiviral effect and has a broad impact on cellular functions, bridging 
innate and adaptive immunity [12-16].  
In immunocompromised hosts, such as hematopoietic stem cell transplant (HSCT) recipients, 
adenoviral infections can disseminate and lead to severe complications and fatal outcome [17-
19]. Previously, it has been reported that in pediatric HSCT patients with disseminated HAdV 
infection the elimination of adenovirus relied on the recovery of immunity, i.e., lymphocytes 
[20;21]. HAdV-specific IFN-γ–producing CD4+ or CD8+ T cells were detected after virus 
clearance from blood [20;22]. However, evidence has been provided for the clearance of HAdV 
in the presence of NK cells only, and since NK cells constitute the majority of lymphocytes early 
after HSCT [23;24], we set out to study the requirements to activate NK cells in response to 
adenoviruses in vitro. We focused on the human wild type, replication-competent adenovirus 
serotypes HAdV5 (species C) and HAdV35 (species B) which utilize two distinct pathways of 
cell entry and considerably differ in their capacity to infect cells, such as DC [2;25-29]. We 
hypothesized that this difference has a major influence on the IFN -α production by pDC and, 
therefore, determined the differential cellular requirements for these two viruses to activate NK 
cells. 
MATeRIAlS AND MeThoDS
Cell isolations and depletions
Peripheral blood mononuclear cells (PBMC) were separated from buffy coats of healthy adult 
donors (Sanquin Blood bank, Region Southwest, Rotterdam, the Netherlands) by Ficoll-
Hypaque density gradient centrifugation. NK cells were purified from PBMC by negative 
selection, depleting non-NK cells through a combination of biotin-conjugated monoclonal anti-
human antibodies and MicroBeads using the “Human NK cell Isolation Kit” (Miltenyi Biotech, 
Bergisch Gladbach, Germany); NK cell purity was >95 % as determined by flow cytometry. NK 
cells were defined as NK cells as CD56+, CD3-, CD14- and CD19- cells. pDC were isolated 
from PBMC by negative selection using the “human Plasmacytoid Dendritic Cell Isolation 




expression of BDCA-2 (CD303) (BDCA-2+ pDC) were detectable by flow cytometry in the 
cell isolate; pDC purity was >99 %. pDC were depleted from PBMC by positive selection 
using APC-conjugated anti-BDCA-2 antibodies and anti-APC MicroBeads (Miltenyi Biotech), 
resulting in the depletion of >99 % of pDC. T cells were depleted from PBMC (TCD PBMC) 
by positive selection using anti-CD3 MicroBeads (Miltenyi Biotech); TCD PBMC contained 
less than 0.5 % of contaminating CD3+ T cells as analyzed by flow cytometry. 
Cell cultures and stimulations  
All cell cultures were performed in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10 % FCS and penicillin/streptomycin at 37 ºC under humidified and 5 % 
CO2-containing conditions. PBMC or TCD PBMC were cultured in round-bottomed 96-well 
plates (2x105 per 200 µl) to study NK cell activation, or in 24-well plates (2x106 per ml) to 
study pDC intracellular IFN-α production and maturation. Isolated NK cells and purified pDC 
were co-cultured in round-bottomed 96-well plates in RPMI medium at indicated cell ratios 
and cell concentrations. PBMC, isolated PBMC subsets and the co-cultures were stimulated 
with human wildtype adenovirus serotype 5 (HAdV5) and HAdV35 or with recombinant 
rAd5f35 at multiplicity of infection (MOI) 1 (at least one infectious virus particle per cell), 
10 and 100. In rAd5f35 the type 5 shaft and head sequences are replaced by the type 35 shaft 
and head sequences, which are fused to the type 5 fiber tail [27;30]. In addition, PBMC were 
stimulated with the recombinant replication-deficient, E1-deleted, GFP-encoding adenovirus 
variants rAd5-GFP, rAd35-GFP and rAd5f35-GFP at MOI 10 and 100 [27;31]. All adenovirus 
preparations were kindly provided by Drs. Jan de Jong (Erasmus Medical Centre, Rotterdam, 
Netherlands), Menzo Havenga (TNO Biosciences, Leiden, The Netherlands), and purified on 
a CsCl-gradient. Additional exogenous stimuli were as follows: IL-15 (10 ng/ml, Bender Med. 
Sys, Vienna, Austria); IFN-α (ranging from 125 to 25,000 IU/ml (Roche, Basel, Switzerland); 
inhibitory CpG TTAGGG (iCpG) ’5 -ttt agg gtt agg gtt agg gtt agg g -3’ (12.6 µM, Invivogen, 
San Diego, CA, USA). Blocking experiments were performed with the following antibodies: 
rabbit polyclonal anti-IFN-α, mouse monoclonal anti-interferon-Alpha/Beta Receptor 1 (both 
PBL Interferon Source, Piscataway, NJ, USA; cat.no. 31101-1 and 21385-1, respectively) 
and mouse monoclonal anti-IL-2 (R&D Systems, Minneapolis, MN, USA; clone 5334). As 
the kinetics of activation between pDC (i.e., intracellular IFN-α production and maturation) 
and NK cells (i.e., considerably induced levels of CD69 expression) in response to HAdV were 
different, pDC and NK cells were analyzed 18 h and 40 h following virus exposure, respectively. 
flow cytometry
pDC and NK cells were analyzed phenotypically by staining with fluorescently labeled antibodies 
and flow cytometry. The following antibodies were applied according to the manufacturer’s 
instructions: BDCA-2/CD303APC, BDCA-1/CD1cAPC (Miltenyi Biotech); CD3PerCP-Cy5.5, 
CD11cPE, CD14PerCP-Cy5.5, CD19PerCP-Cy5.5, CD20PerCP-Cy7, CD40FITC, CD69PE, HLA-
DRFITC (Becton Dickinson, Franklin Lakes, NJ, USA); CD19Pacific Blue (PB) (Dako, Glostrup, 
Denmark); CD3
PB (BD Biosciences, San Jose, CA, USA); CD56APC,CD56PE-Cy7 (IOTEST 
Immunotech, Marseille, France). After extracellular staining, intracellular staining of IFN-α with 
IFN-αFITC (PBL Interferon Source; cat.no. 21112-3) was performed in PBMC using the “FoxP3 
Staining Buffer Set” (eBiosciences, San Diego, CA, USA). FACS measurements were performed 
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with the FACSCalibur or the LSR II (BD Biosciences) and analyzed with the “BD Cell Quest 
ProTM” software (version 5.2.1) or “BD FACSDivaTM” software (version 6.1.2.).
Cytolytic activity of NK cells – 51chromium release assay
Cytolytic activity of NK cells against the cell lines K562 (sensitive to unstimulated and activated 
NK cells) and Daudi (sensitive to activated NK cells only) was measured in 4-hour 51chromium 
(51Cr) release assays. Effector cells were cultured for 72 h under conditions as indicated. K562 and 
Daudi target cells (ATCC, Manassas, VA, USA) were labeled with 100 µl Na-chromate (51Cr, 3.7 
MBq) for 1 hr. After washing, 2.5x103 target cells were added to effector cells in triplicate at the 
indicated effector-target (E:T) ratios and incubated for 4 h at 37°C. Supernatants were collected, 
and the release of 51Cr was measured with a gamma-counter (Wallac/PerkinElmer, Waltham, 
MA, USA). Spontaneous and maximum release were obtained by incubation with medium and 
2N HCl, respectively. The specific lysis was calculated by the following formula: percentage of 
specific lysis = 100 x (experimental release–spontaneous release / maximum release–spontaneous 
release).  
enzyme-linked immunosorbent assay (elISA)
Concentrations of IFN-α were determined in supernatants from cultures of PBMC, TCD 
PBMC or purified PBMC subpopulations using the “ELISA assay for human interferon-α pan” 
(Mabtech, Nacka Strand, Sweden) according to the manufacturer’s instructions.   
ReSulTS
Adenovirus serotype 5 and type 35 stimulate activation and cytolytic activity of NK 
cells in unseparated PBMC
To investigate the capacity of wildtype adenovirus serotypes 5 (HAdV5) and 35 (HAdV35) to 
induce activation of NK cells in PBMC in vitro, CD69 expression and the cytolytic activity 
against the HLA class I negative cell lines Daudi and K562 were assessed. Analogous to the effect 
of interleukin-15 (IL-15), 40 h stimulation of PBMC with escalating viral loads of HAdV5 
and HAdV35 increased the percentage of NK cells expressing the activation marker CD69 as 
compared to the unstimulated medium control (Figure 1, panel A, i). HAdV5 induced CD69 
expression only at MOI 100, whereas HAdV35 produced appreciable activation of NK cells at 
a 10-fold lower MOI. Similarly, HAdV35 has previously been shown to be more effective than 
HAdV5 in eliciting T cell responses [25]. Notably, stimulation with HAdV35 at MOI 100 
appeared to exhibit cytopathic effects because the percentage of CD14+ monocytes in PBMC was 
strongly reduced, whereas lower viral loads of HAdV35 or HAdV5 did not alter the percentage 
of monocytes (Figure 1, panel A, ii). For that reason, virus stimulations were performed with 
HAdV5 at MOI 100 and HAdV35 at MOI 10 in subsequent experiments. 
Stimulation of PBMC with either HAdV5 (MOI 100) or HAdV35 (MOI 10) induced NK 
cell cytolysis of Daudi cells, a target cell line which is naturally not lysed by resting but only by 
activated NK cells [32-34] (Figure 1, panel B). Additionally, NK cell-mediated lysis of K562 cells 




Hence, stimulation of PBMC with HAdV5 and HAdV35 resulted in enhanced expression of the 
NK cell activation marker CD69 and concomitantly increased the cytolytic activity of NK cells. 
hAdV5-induced NK cell activation requires the presence of T cells
To study whether the activation of NK cells by HAdV was due to a direct effect or required other 
cell populations of blood mononuclear cells, purified NK cells were stimulated with HAdV5 and 
HAdV35 for 40 h. On purified NK cells alone CD69 expression was not increased after HAdV5 
or HAdV35 exposure as compared to NK cells in HAdV-stimulated PBMC (Figure 2, panel A, 
i and ii). In contrast, IL-15 stimulation induced CD69 up-regulation, demonstrating that the 
purified NK cells were functional and responsive. Therefore, it can be concluded that at least one 
additional cell type of blood mononuclear cells was essential to mediate HAdV-induced NK cell 
activation.     
Since most healthy individuals have HAdV-specific T cells recognizing multiple serotypes, we 
reasoned that the activation of NK cells in HAdV-stimulated PBMC might be induced via the 
production of IL-2 by HAdV-specific T cells [29;35-38]. In order to investigate whether NK 
cell activation requires T cells, PBMC were depleted of CD3+ T cells (TCD PBMC). CD69 
up-regulation on NK cells in response to HAdV5 was abolished by T cell depletion. In contrast, 
HAdV35 still induced CD69 up-regulation in the absence of T cells (Figure 2, panel A, iii). 
Notably, HAdV5 and HAdV35 exposure of PBMC induced CD69 expression on both the 
CD56dim and the CD56bright NK cell population, whereas in the absence of T cells CD69 up-
regulation was mainly observed in the CD56dim NK cell population after HAdV35 exposure. 
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Figure 1: HAdV5 and HAdV35 induce 
NK cell activation in PBMC
(A) PBMC were stimulated with HAdV5 
and HAdV35 at MOI 1, 10 and 100 and 
controls (unstimulated medium as negative 
control or IL-15 as positive control) for 40 h. 
(i) NK cell activation was measured by the 
increased expression of the activation marker 
CD69 on NK cells. NK cells were gated as 
lymphocytes based on FSC/SSC plots and 
defined as the cell population positive for 
CD56 expression but devoid of CD3, CD14 
and CD19 expression. Data depicted are 
combined from 3 independent experiments 
(error bar represents SEM). (ii) The 
percentage of viable CD14+ monocytes was 
compared among virus stimulations. Data 
depicted are combined from 3 independent 
experiments (error bar represents SEM). 
(B) After stimulation of PBMC with HAdV5 
(MOI 100), HAdV35 (MOI 10) and controls 
for 72 h, the cytolytic potential of NK cells 
against Daudi and K562 cells was tested in 
triplicate in a 4 h 51chromium release assay. 
Effector:target (E:T) ratios were two-fold 
dilutions of effectors, starting with 5x105 
PBMC and 2.5x104 target cells. PBMC E:T 
ratios were adjusted to the frequency of NK 
cells in PBMC measured by FACS to obtain 
actual NK:T ratios. Data are representative 
for 2 independent experiments.
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Neutralization of IL-2 reduced CD69 expression on NK cells of HAdV5-exposed PBMC, 
suggesting that NK cell activation in response to HAdV5 is, at least partially, induced by IL-2 
production (Figure 2, panel B). 
Cytolysis of Daudi cells by NK cells after exposure to HAdV5 was strongly reduced in TCD 
PBMC as compared to non-depleted PBMC (Figure 2, panel C, i), whereas HAdV35-stimulated 
lysis of Daudi cells was unaffected after T cell depletion (Figure 2, panel C, ii). These results suggest 
that HAdV5 and HAdV35 can induce NK cell activation in PBMC by different mechanisms. 
HAdV5 activates NK cells via a T cell-dependent mechanism, whereas the activation of NK cells 
in response to HAdV35 can occur independently of T cells. 
Figure 2: HAdV5, but not HAdV35, requires T cells to activate NK cells 
(A) NK cells were isolated from PBMC by negative selection, i.e., depleting non-NK cells, with a purity of >95%. 
T cells were depleted from PBMC by positive selection (TCD PBMC); TCD PBMC contained less than 0.5% of 
contaminating CD3+ T cells. PBMC (2x105) (panel i), isolated NK cells (1x105) (panel ii) and TCD PBMC (2x105) 
(panel iii) were stimulated with HAdV5 (MOI 100), HAdV35 (MOI 10) and controls for 40 h. NK cell activation was 
measured by up-regulation of CD69 expression on CD56dim and CD56bright NK cell subsets. NK cells were gated as 
lymphocytes based on FSC/SSC plots and defined as the cell population positive for CD56 expression but devoid of 
CD3, CD14 and CD19 expression. Data are representative for 3 independent experiments. (B) CD69 expression on 
NK cells was assessed in PBMC exposed to HAdV5 with or without the addition of neutralizing antibodies against IL-2. 
Data depicted are combined from 3 independent experiments (error bar represents SEM). (C) Cytolytic potential of NK 
cells against Daudi cells was tested after stimulation of PBMC and TCD PBMC with HAdV5 (panel i) and HAdV35 
(panel ii) and compared to unstimulated medium controls. The 51Chromium release assay was performed in triplicate 
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Plasmacytoid dendritic cells mediate hAdV35-induced NK cell activation
NK cell activation in response to HAdV35 occurred in the absence of T cells but still required 
another cell population of PBMC as purified NK cells were not activated. Since pDC are known 
to sense viruses, it was investigated whether pDC were required for NK cell activation following 
HAdV35 exposure. Depletion of pDC from PBMC led to reduced CD69 expression on NK 
cells after both HAdV5 and HAdV35 stimulation, in particular at lower viral loads, indicating 
that pDC were involved (Figure 3, panel A). To explore whether pDC were sufficient to elicit 
NK cell activation following HAdV35 exposure, pDC were isolated by negative selection, added 
to purified NK cells and stimulated with both HAdV serotypes. HAdV35, but not HAdV5, was 
capable of inducing NK cell activation in the presence of pDC and, apparently, did not require 
the contribution of other cell types (Figure 3, panel B). Consequently, pDC were both necessary 
and sufficient for the activation of NK cells following the exposure to HAdV35.
HAdV35 induces IFN-α production by plasmacytoid dendritic cells
As pDC were able to mediate NK cell activation by HAdV35, activation of pDC was assessed 
by analyzing intracellular IFN-α production following virus exposure. In contrast to HAdV5, 
HAdV35 exposure of PBMC resulted in a higher percentage of IFN-α–producing cells which 
expressed the pDC marker BDCA-2 (Figure 4, panel A). There were practically no IFN-α+ 
cells detectable in the non-BDCA-2+ cell fraction. Detailed analysis of the phenotype of all 
IFN-α+ cells (Q2 + Q4; Figure 4, panel A) revealed a specific increase of pDC after HAdV35 
exposure (Table 1). The percentage of other PBMC subsets, such as myeloid dendritic cells 
(mDC), T cells, B cells, NK cells and monocytes, did not alter or decreased after HAdV35 
exposure. In addition, HAdV35, but not HAdV5, induced up-regulation of HLA-DR and 
CD40 as well as down-regulation of BDCA-2 on pDC, illustrating activation and maturation of 
pDC by HAdV35 (Figure 4, panel B). HAdV35 exposure resulted in considerable IFN-α levels 
in culture supernatants of unseparated PBMC (Figure 4, panel C). The depletion of pDC from 
Figure 3: Plasmacytoid dendritic cells directly mediate 
NK cell activation after HAdV35 exposure 
(A) pDC were depleted from PBMC by positive selection, 
resulting in the depletion of >99% of pDC. PBMC and 
pDC-depleted PBMC (each 2x105) were stimulated with 
HAdV5 (MOI 10 and 100) and HAdV35 (MOI 1 and 10) 
for 40 h. NK cell activation was measured by up-regulation 
of CD69 expression. Data depicted are combined from 4 
independent experiments (error bar represents SEM). (B) 
pDC were purified from PBMC by negative selection 
with a purity of >99 % and no CD3+, CD14+, CD19+ 
cells detectable. PBMC, isolated NK cells (1x105) and co-
cultures of NK cells (1x105) and pDC (1x104) (10:1 ratio) 
were stimulated with HAdV5 (MOI 100), HAdV35 (MOI 
10) and controls for 40 h. NK cell activation was measured 
by up-regulation of CD69 expression. Data depicted are 
combined from 4 independent experiments (error bar 
represents SEM). 
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Figure 4: HAdV35 induces IFN-α production and maturation of plasmacytoid dendritic cells
(A) PBMC (2x106) were cultured with HAdV5 (MOI 100), HAdV35 (MOI 10) and the medium control for 18 h. 
pDC were identified in PBMC as BDCA-2+ cells by extracellular staining followed by intracellular staining for IFN-α. 
The percentage of IFN-α+ cells was determined within the BDCA-2+ pDC population. Data are representative for 3 
independent experiments. (B) Activation and maturation of pDC was assessed by the expression of CD40 and HLA-DR 
as well as down-regulation of BDCA 2 on BDCA 2+ purified pDC after the exposure to HAdV5 (MOI 100) and 
HAdV35 (MOI 10) for 18 h. Data are presented as histograms, depicting the mean fluorescent intensity, MFI, of the 
four markers and the three conditions: medium, grey filled histogram, HAdV5, dotted line; HAdV35, black solid line. 
Data are representative for 3 independent experiments. (C) IFN-α levels were measured in culture supernatants of 
HAdV5 (MOI 10 and 100) and HAdV35-exposed (MOI 1 and 10) PBMC and pDC-depleted PBMC by ELISA. Data 
depicted are combined from 4 independent experiments (error bar represents SEM). 
Table 1: The percentage of pDC within the IFN-α+ cells increases following HAdV35 exposure
Percentage of PBMC subsets within IFN-α+ cells
Medium HAdV5 HAdV35
pDC 7.7 11.1 73.0
mDC 5.1 0.0 0.2
T cells 43.6 13.9 13.5
B cells 10.3 30.6 0.0
NK cells 18.0 11.1 3.8
monocytes 2.6 13.8 0.0
PBMC were cultured with HAdV5 (MOI 100), HAdV35 (MOI 10) and medium for 18 h. Extracellular stainings 
of PBMC subsets were followed by intracellular staining for IFN-α. Within all IFN-α+ cells, pDC were identified as 
BDCA-2+ cells which were negative for CD11c− and devoid of CD3+/14+/19+/20+/56+ cells; mDC as cells double 
positive for BDCA-1 and CD11c and devoid of CD3+/14+/19+/20+/56+ cells; T cells as CD3+ cells devoid of CD20+/56+ 
cells; NK cells as CD56+ cells devoid of CD3+/19+ cells; B cells as CD19+ and CD20+ cells devoid of CD3+/56+ cells; 
monocytes as cells double positive for CD14 and CD11c. The percentage of the various PBMC subpopulations within 




Figure 5: rAd5f35 induces high 
IFN-α production and activates NK 
cells
(A) PBMC were stimulated with 
HAdV5, HAdV35 and rAd5f35 (all 
MOI 10 and 100) for 40 h. IFN-α levels 
were measured in culture supernatants 
by ELISA. Data depicted are combined 
from 3 independent experiments (error 
bar represents SEM). (B) PBMC 
were stimulated with HAdV5 at 
MOI 100, HAdV35 at MOI 10 and 
rAd5f35 at MOI 10 and 100 for 40 
h. NK cell activation was measured by 
up-regulated expression of CD69 on 
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PBMC substantially diminished the IFN-α levels, confirming that IFN-α production was almost 
exclusively attributed to pDC (Figure 4, panel C). 
Adenovirus strains from different species utilize distinct surface molecules to enter cells. 
Internalization of HAdV5 involves binding of the HAdV5 fiber to the CAR receptor on target 
cells, while the HAdV35 fiber engages CD46 for cell entry [2]. To investigate the role of the 
fiber and its potential role in the way of entry into pDC, a recombinant rAd5f35 virus, which 
is a HAdV5 virus equipped with a HAdV35 fiber [27;30], was tested for its ability to induce 
IFN-α production and NK cell activation. At identical MOI, IFN-α production following 
rAd5f35 stimulation of PBMC was similar to the induction by HAdV35 and much higher than 
IFN-α production after HAdV5 exposure (Figure 5, panel A). Correspondingly, exposure of 
PBMC to rAd5f35 resulted in CD69 expression on NK cells comparable to HAdV35 exposure 
(Figure 5, panel B). To investigate whether the higher NK cell activation of type 35 fiber-equipped 
viruses was dependent on a higher infection rate of PBMC and in particular pDC, PBMC were 
stimulated with recombinant, replication-deficient rAd5-GFP, rAd35-GFP and rAd5f35-GFP 
and the percentage of GFP-expressing cells was assessed per PBMC subset. Exposure of PBMC 
with rAd5f35-GFP and rAd35-GFP resulted in a higher percentage of GFP-expressing pDC 
than rAd5-GFP in particular at high viral loads (Table 2). Infection of mDC and monocytes 
was also higher by rAd35-GFP and rAd5f35-GFP viruses, whereas only a minor percentage of T 
cells, NK cells and B cells (except for rAd5f35-GFP at MOI 100) was infected by both viruses. 
Table 2: rAd5f35 and rAd35 but not rAd5 are able to infect pDC
Percentage of GFP+ cells among PBMC subsets
Medium rAd5-GFP rAd35-GFP rAd5f35-GFP
MOI 10 100 10 100 10 100
pDC 0.0 0.0 0.2 4.5 6.1 0.5 6.1
mDC 0.0 22.3 22.5 17.8 30.4 42.5 70.9
T cells 0.0 0.1 0.4 0.5 0.8 1.0 4.5
B cells 0.0 0.2 1.8 1.4 1.7 3.5 11.6
NK cells 0.0 0.1 0.4 0.2 0.8 0.6 1.8
monocytes 0.0 2.2 16.5 8.9 26.0 31.8 70.8
PBMC were cultured with replication-deficient GFP-encoding rAd5-GFP, rAd35-GFP and rAd5f35-GFP at MOI 10 
and 100 for 18 h. pDC, mDC, T cells, B cells, NK cells and monocytes were identified in PBMC as described in Table 1. 
To determine infection by the adenoviruses, the percentage of GFP-expressing cells per PBMC subset was assessed.
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Therefore, the type of fiber and, likely, the rate of infection appeared to be responsible for the 
higher IFN-α production after exposure to HAdV35 than to HAdV5.
IFN-α production in response to HAdV35 relies on TLR-9 signaling and mediates NK 
cell activation
To further confirm whether IFN-α did mediate NK cell activation, CD69 expression on NK 
cells was assessed in the presence of neutralizing antibodies against soluble IFN-α and the 
IFN-I receptor [14;39]. In TCD PBMC exposed to HAdV35 at MOI 10, blockage of IFN-I 
reduced CD69 expression on NK cells by approx. 50 %, indicating that IFN-I was at least in 
part responsible for this activation (Figure 6, panel A). As far as other cytokines are involved, 
the presence of IL-12 or IL-15 in supernatants of HAdV35-exposed pDC-NK cell cultures was 
excluded (data not shown).
To explore whether IFN-α production by pDC requires sensing of adenovirus via the intracellular 
double-stranded DNA receptor TLR-9, the effect of inhibitory CpG (iCpG) was addressed. 
iCpG neutralizes the stimulatory effect of the TLR-9 agonist CpG and blocks IFN-α production 
by pDC in response to CpG and viruses [40-43]. IFN-α levels in supernatants of HAdV35-
stimulated TCD PBMC were considerably reduced by iCpG (Figure 6, panel B, i). Likewise, 
iCpG inhibited NK cell activation following exposure to HAdV35 (Figure 6, panel B, ii). The 
inhibiting effect of iCpG was most apparent when TCD PBMC were exposed to lower viral 
loads of HAdV35, i.e., MOI 1 compared to MOI 10. 
Overall, TLR-9 signaling appeared to be involved in the IFN-α production by pDC in response 
to HAdV35 which could mediate the activation of NK cells in response to HAdV35. 
Figure 6: Both NK cell activation and IFN-α production require TLR9 signaling
(A) TCD PBMC were stimulated with HAdV35 at MOI 10 for 40 h in the presence or absence of neutralizing antibodies 
against IFN-α and the IFN I receptor or an irrelevant antibody. CD69 expression on NK cells was measured. Data 
depicted are combined from 4 independent experiments (error bar represents SEM). (B) TCD PBMC were stimulated 
with HAdV35 at MOI 1 and MOI 10 for 40 h in the presence or absence of iCpG. (i) IFN-α levels in supernatants of 
these cultures as well as (ii) CD69 expression on NK cells was measured. Data depicted are combined from 5 independent 
experiments (error bar represents SEM). 
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Figure 7: IFN-α production by plasmacytoid dendritic cells is enhanced in the presence of NK cells
 (A) Purified pDC, purified NK cells and pDC-NK cell co-cultures (pDC: NK cells = 1:4) were stimulated with identical 
virus concentrations as for  pDC-NK cell cultures (MOI 10) for 18 h and 40 h, respectively. IFN-α levels were measured 
in the supernatants of these cultures. Data depicted are combined from 2 independent experiments (error bar represents 
SEM). (B) Purified NK cells were stimulated with decreasing amounts of recombinant IFN-α with or without the 
addition of HAdV35 (MOI 10) for 40 h, and CD69 expression on NK cells was analyzed. Data depicted are combined 
from 2 independent experiments (error bar represents SEM).  
The IFN-α production by plasmacytoid dendritic cells is amplified by NK cells
It was examined whether NK cells contribute to the IFN-α response of pDC [14]. Indeed, IFN-α 
levels were augmented in HAdV35-stimulated co-cultures of pDC and NK cells as compared to 
pDC alone (Figure 7, panel A). NK cells alone failed to produce IFN-α. After 18 h stimulation 
with HAdV35, the increase of IFN-α levels by the presence of NK cells was superior to the 
increase after 40 h stimulation, suggesting that the reciprocal interaction between pDC and NK 
cells boosted the IFN-α response of pDC in particular early after exposure to HAdV35. 
To investigate whether the increased response could be due to the NK cells becoming directly 
responsive to virus after exposure to pDC derived IFN-α, purified NK cells were stimulated 
with different concentrations of recombinant IFN-α in the presence and absence of HAdV35. 
However, HAdV35 hardly increased the CD69 expression on   IFN-α–induced NK cells, 
suggesting that NK cells themselves cannot sense HAdV35  (Figure 7, panel B). 
It can be concluded that there was cross-talk between NK cells and pDC characterized by the 
activation of NK cells through pDC-derived IFN-α and the amplification of IFN-α production 
by pDC through NK cells.
DISCuSSIoN
In this study we demonstrate that HAdV35 exposure results in considerable production of IFN-α 
by pDC, leading to NK cell activation. Conversely, under the same conditions HAdV5 does not 
induce significant IFN-α production and requires the contribution of T cells to activate NK 
cells. The difference in IFN-α production is specifically related to the virus fiber and, therefore, 
most likely due to the way of cell entry and infection efficiency of the virus. The IFN-α response 
of pDC to HAdV35 is mediated by TLR-9 signaling and is further enhanced by the reciprocal 
interaction of NK cells and pDC. 
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In patients post HSCT, the interplay between pDC and reconstituting NK cells may play a role 
in the immune response to HAdV early after HSCT, especially in the period when T lymphocytes 
are not yet detectable [20]. The presumed NK cell response to adenovirus in humans, however, 
has not yet been described as detailed as the NK cell response to other viruses, such as herpes 
simplex virus type 1, influenza virus or reovirus [14;39;44;45]. In mice, IFN-I and dendritic 
cell-dependent activation of NK cells has been implicated in the clearance of cells infected with 
adenoviral vectors [46;47]. However, since human adenovirus is known to result in only low 
yields of productive virus after infection of murine cells due to limited viral replication, imperfect 
protein synthesis and an abortive virus life cycle, mouse models are not optimal for studying 
immune responses to human adenovirus [48-51]. After infection with recombinant adenoviral 
vectors, human fibroblasts were more susceptible to lysis by NK cells in association with the NK 
cell-activating receptor NKG2D [52]. Inspired by these observations, we set out to study the 
activation of NK cells in PBMC of healthy adult donors in response to human adenovirus. 
Interestingly, the mechanisms of NK cell activation in response to the two tested HAdV 
serotypes, which belong to different species of the HAdV family, differed substantially. Most 
healthy individuals possess a highly cross-reactive T cell repertoire, recognizing a variety of 
different HAdV serotypes and species [29;35-37]. The addition of HAdV to PBMC results in 
T cell activation and, thereby, is likely to cause IL-2 production. As the T cell repertoire is 
highly cross-reactive this T cell activation occurs in response to both HAdV5 as well as HAdV35 
[36;53]. It is known that T cell-derived IL-2 stimulates NK cell proliferation, activation and 
IFN-γ production [38;54-56]. Neutralization of IL-2 indeed inhibited at least partially the NK 
cell activation in response to HAdV5. A similar mechanism was shown to account for NK cell 
activation after exposure to influenza, a virus that also elicits a strong T cell response in most 
healthy donors [38]. 
Surprisingly, although the depletion of T cells did abrogate NK cell activation in response to 
HAdV5, it did not abrogate HAdV35-induced NK cell activation. Accordingly, an additional 
mechanism for HAdV35-induced NK cell activation is operational that is independent of T cells. 
Compared to HAdV5, HAdV35 evoked considerably stronger IFN-α production by pDC which 
may be sufficiently high to induce NK cell activation via pDC [14;25]. 
IFN-I production by pDC in response to viral DNA or stimulatory CpG motifs requires TLR-9 
signaling [15]. IFN-α production in response to HAdV35 was also mediated by TLR-9 as most 
of the response was eliminated by the TLR-9 antagonist iCpG [41;57]. Since IFN-α was almost 
exclusively derived from pDC upon HAdV35 exposure, TLR-9-independent pathways of other 
cells, such as mDC or monocytes, do not seem to contribute to the IFN-α response as supported 
by the data on intracellular IFN-α in various subsets of mononuclear cells [14;39;58]. NK cell 
activation following HAdV35 exposure was at least partly mediated by IFN-α as the presence 
of neutralizing antibodies against IFN-α and the IFN-I receptor reduced CD69 expression on 
NK cells by approx. 50 % [14;39]. The lack of total inhibition suggested that either IFN-α was 
produced in large excess or that besides IFN-α additional (soluble) factors may be involved in 
mediating NK cell activation by pDC. While incubation of purified NK cells with IFN-α–
containing supernatants of HAdV35-stimulated pDC-NK cell co-cultures induced NK cell 
activation, neither IL-12 nor IL-15, two other NK cell-activating cytokines, were detected in 




Finally, we observed that cross-talk between NK cells and pDC boosted the IFN-α production 
of pDC in response to HAdV35, suggesting a reciprocally amplified antiviral innate immune 
response. In previous studies, cross-talk between NK cells and DC via direct cell-cell contact, 
such as NKG2D-NKG2D ligand interaction, has been associated with NK cell activation and 
can enhance IFN-α production [14;39;47]. Interestingly, the DNAM-1 ligand CD112 was 
expressed but not up-regulated on pDC after virus exposure whereas NKG2D ligands were not 
detectable on pDC (data not shown). Hence, interaction between NK cells and pDC could 
theoretically occur via DNAM-1 and CD112.
Our findings raised the question why HAdV35 was so much more effective than HAdV5 in 
inducing IFN-α production and maturation of pDC. The two virus serotypes differ in the type 
of cellular receptor necessary for cell entry. The HAdV5 fiber binds to the CAR (coxsackie 
adenovirus receptor) receptor which is absent from pDC, while the type 35 fiber binds to 
the cellular surface protein CD46 (complement regulatory protein [59]) which is abundantly 
expressed on pDC [2;25]. As reported previously, especially myeloid cells such as mDC and 
monocytes were infected by rAd5-GFP, rAd35-GFP and rAd5f35-GFP (rAd5 equipped with 
the type 35 fiber), while lymphocytes such as T cells, B cell and NK cells were weakly infected 
[25-28]. Moreover, we show that rAd5f35 induced IFN-α levels similar to HAdV35 and likewise 
HAdV35 and rAd5f35 were able to infect pDC at comparable efficiencies, whereas HAdV5 
failed to infect pDC. Thus, the increased IFN-α production of rAd5f35 may be a result of higher 
infection rates of pDC due to the type 35 fiber. Correspondingly, the much higher infection 
efficiency of HAdV5f16 (HAdV5 equipped with the species B type 16 fiber) than HAdV5 has 
been associated with high IFN-α production by pDC [41]. The percentage of IFN-α producing 
pDC was higher than the percentage of GFP-expressing pDC, suggesting that also non-infected 
pDC might produce IFN-α (data not shown). 
The clinical relevance of NK cells with respect to HAdV clearance in humans is unresolved. In 
pediatric HSCT patients, the kinetics of lymphocyte recovery is different, i.e., NK cells usually 
reconstitute earlier than T cells. During the early post-HSCT period, HAdV may (re)activate 
and potentially cause a disseminated infection with a fatal course [36;60;61]. HAdV5 and other 
species C HAdV are predominantly encountered in these patients in our center and elsewhere 
[62-64]. In comparison to HAdV5, antibodies specific for the species B virus HAdV35 are 
rarely detected in sera of healthy donors, suggesting that the virus is not ubiquitously present 
in the human population [65;66]. In immunocompromised patients, HAdV35 causes disease 
only infrequently although it has been reported in HSCT centers in the USA [67]. The low 
prevalence of the virus, absence of functional immune evasion mechanisms or a strong response 
of the innate immune system to HAdV35 may provide an explanation for the low occurrence of 
disseminated HAdV35 infections in HSCT patients.
The phenomenon that these two adenovirus serotypes exhibit substantial differences in their 
capacity to evoke an innate immune response is relevant because HAdV35-derived vectors are 
recently being explored for the delivery of vaccines [66;68]. Most experience with adenovirus-
derived vectors has been acquired in experimental models or clinical trials using HAdV5-derived 
vectors. Based on the present findings, it may be anticipated that the HAdV35-derived vectors 
behave differently in their efficacy and/or their degree of side effects in clinical trials.    
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Osteosarcoma and Ewing sarcoma are the most common bone tumors in children and adolescents. 
Despite intensive chemotherapy, patients with advanced disease have a poor prognosis, illustrating 
the need for alternative therapies. Sarcoma cells are susceptible to the cytolytic activity of resting 
natural killer (NK) cells which can be improved by interleukin(IL)–15 stimulation. In this study, 
we explored whether the cytolytic function of resting NK cells can be augmented and specifically 
directed toward sarcoma cells by antibody-dependent cellular cytotoxicity (ADCC). 
Epidermal growth factor receptor (EGFR) expression was examined on osteosarcoma and Ewing 
sarcoma cell lines by flow cytometry and in osteosarcoma biopsy and resection specimens by 
immunohistochemistry. Cetuximab-mediated ADCC by NKcells from osteosarcoma patients 
and healthy controls was measured with 4-hour 51Cr release assays. 
EGFR surface expression was shown on chemotherapy-sensitive and chemotherapy-resistant 
osteosarcoma cells (12/12), most primary osteosarcoma cultures (4/5), and few Ewing sarcoma 
cell lines (2/7). In the presence of cetuximab, the cytolytic activity of resting NK cells against all 
EGFR-expressing sarcoma cells was substantially increased and comparable with that of IL-15–
activated NK cells. Surface EGFR expression on primary osteosarcoma cultures correlated with 
EGFR expression in the original tumor. The cytolytic activity of osteosarcoma patient-derived 
NK cells against autologous tumor cells was as efficient as that of NK cells from healthy donors. 
Our data show that the cytolytic potential of resting NK cells can be potentiated and directed 
toward osteosarcoma cells with cetuximab. Therefore, cetuximab-mediated immunotherapy may 
be considered a novel treatment modality in the management of advanced osteosarcoma.  
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INTRoDuCTIoN 
Osteosarcoma and Ewing sarcoma most frequently arise in adolescents and young adults and 
represents the majority of all malignant primary bone tumors in this patient group [1–3]. The 
current treatment consists of a combination of systemic multi-drug chemotherapy and complete 
surgical resection [3–5]. In cases with localized disease, up to 70% of the patients achieve persistent 
remission. In contrast, patients with advanced, metastasized, and recurrent disease experience a 
very poor prognosis, which has not improved during the last decades despite intensification of 
chemotherapy regimens. Therefore, novel treatment strategies with a favorable toxicity profile are 
warranted. In this perspective, we and others have recently reported on the potential exploitation 
of cellular immunotherapy against sarcomas by natural killer (NK) cells [6–8]. 
NK cells can respond to and kill cells undergoing cellular stress due to virus infection or malignant 
transformation. The cytotoxic activity of NK cells is regulated by the equilibrium of inhibiting 
and activating signals conveyed by target cells. On tumor cells, MHC class I expression (NK cell 
inhibitory signal) may be down-regulated to evade cytotoxic T-cell recognition. Conversely, the 
expression of stress ligands (NK cell–activating signal) may be upregulated on tumor cells. Both 
of these processes may lead to increased sensitivity of tumor cells to NK cells [9,10]. In addition, 
the interplay with other immune cells and the pro- or anti-inflammatory microenvironment may 
modulate the function and activity of NK cells [10,11]. Recently, we and others have shown that 
sarcoma cell lines are moderately susceptible to the cytolytic potential of resting NK cells [6–8]. 
The cytolytic activity of NK cells can be directly potentiated by activating cytokines, such as 
interleukin(IL)–15, leading to increased lysis of sarcoma cells [6–8]. 
In this study, we set out to explore whether the cytolytic activity of resting NK cells can be 
improved and directed specifically toward sarcoma cells. Therefore, we intended using a 
monoclonal antibody (mAb) of the human IgG1 subtype which recognizes an antigen expressed 
on sarcoma cells and is able to induce antibody-dependent cellular cytotoxicity (ADCC) by 
NK cells. Osteosarcoma has previously been shown to express the epidermal growth factor 
receptor (EGFR, erbB1/Her1 [12]), which is recognized by the clinically-approved, chimeric 
IgG1 type mAb cetuximab [13]. So far, the application of anti-EGFR mAb–targeted therapy in 
bone sarcomas has not been reported. We focused on exploring whether the cytotoxic potential 
of allogeneic and autologous NK cells can be specifically directed toward sarcoma cells with 
cetuximab.  
MATeRIAlS AND MeThoDS 
Patient samples 
Formalin-fixed, paraffin-embedded tumor samples were obtained from one biopsy (obtained 
at the time of diagnosis, prechemotherapy) and 4 resections of local recurrent or metastatic 
tumors (postchemotherapy) from 4 high-grade osteosarcoma patients (diagnosed between 2008 
and 2010) by the Department of Pathology, Leiden University Medical Center. Five short term 
grown primary osteosarcoma cell cultures (between passage 2 and 13) were generated from the 
tumor material as previously described [6, 14]. Clinicopathologic details of these patients and 




prior to the initiation of chemotherapy after written informed consent approved by the Review 
Board on Medical Ethics of the Leiden University Medical Center and used for cytotoxicity 
experiments (Table 1). Tumor specimens were obtained and analyzed according to the ethical 
guidelines of the national organization of scientific societies (FEDERA, http://www.federa. org/
gedragscodes-codes-conduct-en). 
Cell lines 
The following extensively characterized sarcoma cell lines were included in this study: osteosarcoma 
cell lines OHS, OSA (SJSA-1), SAOS-2, U2OS, ZK-58 [15] and the Ewing sarcoma cell lines 
A673, CADO-ES, SK-ES-1, SK-NMC, STA-ET2.1, TC71 [15] and L1062 [14]. All sarcoma 
cell lines were obtained from the EuroBoNeT cell line repository (by 2007) and were confirmed 
for their identity by short-tandem repeat DNA fingerprinting in 2011. The cell line TC71 was 
maintained in IMDM medium (Invitrogen). All other cell lines were grown in RPMI-1640 
medium (Invitrogen). Both media were supplemented with 10% fetal calf serum (FCS), 100 
U/ml penicillin, and 100 mg/ml streptomycin (all Invitrogen). All Ewing sarcoma cell lines 
were grown in 0.1% gelatin-coated tissue culture flasks. The chemotherapy-resistant variant cell 
lines of SAOS-2 and U2OS [16–18] were cultured in IMDM medium with 10% FCS and 
penicillin/streptomycin and maintained in chemotherapeutic drugs as follows: SAOS-2–DX580 
and U2OS–DX580 with 580 mg/ml of doxorubicin (DX); SAOS-2–MTX1000 and U2OS–
MTX300 with 1,000 and 300 ng/ml of methotrexate (MTX), respectively; SAOS-2–CDDP6 
(SAOS-2–CDDP6mg) and U2OS–CDDP4 (U2OS–CDDP4μg) with 6 and 4 mg/ml of 
cisplatin (cis-diamminedichloroplatinum, CDDP), respectively. Drug sensitivities of each cell line 
were calculated from the drug dose–response curves and expressed as IC50 (drug concentration 
resulting in 50% inhibition of cell growth after 96 hours of in vitro treatment). Fold increases 
in drug resistance, quantified as the ratio between IC50 of each drug-resistant variant to that of 
its corresponding parental cell line, were as follows: 315 for U2OS–DX580, 328 for SAOS-2–
DX580, 135 for U2OS–MTX300, 281 for SAOS-2–MTX1mg, 63 for U2OS–CDDP4mg, and 
112 for SAOS-2–CDDP6mg. All cell lines were negative for Mycoplasma infection as regularly 
checked by PCR. The primary osteosarcoma cultures were maintained in RPMI-1640 medium 
supplemented with 20% FCS and penicillin/streptomycin in gelatin-coated culture tissue culture 
flasks. 
Table 1: Clinicopathologic details of patient material
Osteosarcoma 
patient
Sex Age Tumor origin Tumor site Histologic subtype Primary cell 
line
369 Female 31 Local relapsed Proximal humerus Fibroblastic L2792 p3
398 Female 14 Prechemotherapy  diagnostic biopsy Distal femur Conventional L2635 p6
404 Male 46 Postchemotherapy resection Humerus Conventional L2826 p9
404 Male 46 Local relapse Humerus Conventional L3312 p13
407 Male 9 Postchemotherapy resection Proximal tibia Chondroblastic L2857 p7
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Cell isolations and stimulations
Peripheral blood mononuclear cells (PBMC) were isolated from osteosarcoma patients’ blood 
samples (autologous) or buffy coats of healthy adult donors (allogeneic; Sanquin Blood 
bank, Region Southwest, Rotterdam, the Netherlands) by Ficoll-Hypaque density gradient 
centrifugation. NK cells were purified by negative selection, depleting non-NK cells through 
a combination of biotin-conjugated monoclonal anti-human antibodies and MicroBeads using 
the “Human NK cell Isolation Kit” (Miltenyi Biotech); NK cell purity was more than 95% 
as determined by flow cytometry, analyzing NK cells as CD56+, CD3-, CD14- , and CD19- 
cells. NK cells were depleted from PBMC (NKD PBMC) by positive selection using anti-CD56 
MicroBeads (Miltenyi Biotech); NKD PBMC contained less than 0.1% of NK cells as analyzed 
by flow cytometry. IL-15–activated NK cells were obtained by incubating purified NK cells 
in AIM-V medium with 2 mM of glutamine (Invitrogen) supplemented with 10% of pooled 
human AB serum (Sanquin), penicillin/streptomycin and 10 ng/ml of IL-15 (Peprotech) for 
2 to 3 weeks in 24-well format tissue culture plates without feeder cells. To measure NK cell 
activation after cetuximab crosslinking, upregulation of CD69 expression on NK cells (300,000) 
was measured after coculture with STA-ET2.1 (150,000), L1062 (80,000), and OSA (75,000) 
cells for 48 hours in 24-well plates in the absence or presence of cetuximab (10 mg/ml). 
flow cytometry 
Determination of NK cell percentages in PBMC, validation of NK cell purity, and expression 
of the NK cell activation marker (CD69) was analyzed phenotypically by staining with 
fluorescently labeled antibodies followed by fluorescence-activated cell sorting (FACS). The 
following antibodies were applied according to the manufacturer’s instructions: CD3FITC (SK7), 
CD3PerCP-Cy5.5 (SK7), CD14PerCP-Cy5.5 (M5E2), CD19PE (4G7), CD69FITC (L78; Becton 
Dickinson); CD56APC (N901 NKH1), NKG2DPE (ON72; IOTEST Immunotech). Expression 
of EGFR on the surface of sarcoma cell lines and primary osteosarcoma cultures was measured 
using the anti-EGFR mAb cetuximab (Erbitux; Merck KGaA) followed by the Alexa Fluor 647 
goat anti-human IgG secondary antibody (A21445; Invitrogen). The anti-CD20 mAb rituximab 
(MabThera; Roche) was used as an IgG1 isotype-matched negative control for cetuximab. FACS 
measurements were carried out with the FACSCalibur (BD Biosciences) and analyzed with the 
"BD Cell Quest Pro" software (version 5.2.1). 
51chromium release assay 
The cytolytic activity of PBMC, NKD PBMC, and purified NK cells against sarcoma cell lines 
and primary osteosarcoma cultures was measured in 4-hour 51chromium (51Cr) release assays. 
Target cells were labeled with 100 ml Na-chromate (51Cr, 3.7 MBq) for 1 hour. After washing, 
2.5x103 target cells were added to the effector cells in duplicate or triplicate at the indicated 
effector–target (E:T) ratios and incubated in the presence or absence of cetuximab (10-7 to 10 
mg/ml as indicated) or the control mAb rituximab (10 mg/ml) for 4 hours at 37°C. Supernatants 
were collected, and the release of 51Cr was measured with a beta-counter (Wallac/PerkinElmer). 
Spontaneous and total release were obtained by incubation with medium and Triton X-100 




formula: percentage of specific lysis = 100 – (experimental release – spontaneous release/total 
release – spontaneous release). 
Immunohistochemistry 
Sections of 4 mm of representative tumor sections were deparaffinized and pepsin antigen 
retrieval was done. Expression of EGFR was assessed using a mouse monoclonal anti-EGFR 
antibody (31G7, 1:10; Zymed; Invitrogen) followed by a polyclonal goat anti-mouse/rabbit/
rat IgG HRP linker antibody conjugate (DPVO-110HRP; Immunologic) and DAB+Substrate 
Chromogen System (Dako) detection. The sections were examined with a Leica DM5000 
fluorescence microscope and LAS-AF acquisition program (Leica). 
Statistical analysis
Statistical analyses were carried out with GraphPad Prism version 5.04 or SPSS version 16.0 
(IBM) using paired student t tests, comparing means between groups of samples and linear 
regression analysis. Error bars represent the SEM. A P value less than 0.05 was considered 
statistically significant. ns, not statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Figure 1: EGFR is expressed on the surface of sarcoma cell lines
(A) Surface expression of EGFR on osteosarcoma and Ewing sarcoma cell lines was measured by flow cytometry using the 
anti-EGFR mAb cetuximab followed by the Alexa Fluor-647 goat anti-human IgG secondary antibody. A, representative 
FACS overlay plots, detecting EGFR by cetuximab (bold solid line) and CD20 by the isotype-matched, negative control 
mAb rituximab (solid line), both followed by secondary antibody and secondary antibody only (grey area). The indicated 
fold expression of EGFR was calculated by dividing the geometric mean fluorescence intensity of EGFR by the geometric 
mean fluorescence intensity of the control CD20. (B) combined data of the fold change of EGFR expression on all tested 
sarcoma cell lines of multiple experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Surface expression of EGFR on sarcoma cell lines
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ReSulTS  
egfR is expressed on the surface of osteosarcoma cell lines 
ADCC by NK cells requires antibody binding to an antigen expressed on the tumor cell surface. 
Therefore, surface expression of EGFR, as detected by cetuximab, was measured on a panel of 
osteosarcoma (n=12) cell lines by flow cytometry. All osteosarcoma cell lines expressed EGFR on 
the cell surface, with the highest expression on the cell lines HOS, OHS, and OSA (Figure 1). 
The chemoresistant variants of SAOS-2 and U2OS also expressed EGFR. Previously, EGFR has 
been reported undetectable in Ewing sarcoma cell lines (n=3; [19]). To extend these findings, 
surface EGFR expression was assessed on a panel of Ewing sarcoma cell lines (n=7). EGFR 
expression was not detectable on 5 of 7 Ewing sarcoma cell lines. Correspondingly, EGFR 
expression was not detectable in Ewing sarcoma biopsy and resection specimens, as determined 
by immunohistochemistry (data not shown). 
Figure 2: Cetuximab-enhanced killing of sarcoma cell lines by NK cells
Lysis of EGFR+ and EGFR- sarcoma cell lines by purified, resting NK cells and IL-15–activated NK cells was measured 
in triplicate in a 4-hour 51Cr release assay in the presence of cetuximab or the isotype-matched, negative control mAb 
rituximab. The specific lysis (%) of sarcoma cells in the presence of the control mAb was comparable with killing without 
mAb addition. (A) representative data of the specific lysis of sarcoma cell lines (ranked by increasing EGFR density) by 
resting NK cells (squares) and IL-15–activated NK cells (triangles) in the presence of cetuximab (filled symbols) and the 
control mAb (open symbols). (B) combined data of the specific lysis of sarcoma cells by resting NK cells (i, no pattern) 
and IL-15–activated NK cells (ii, horizontal pattern) calculated at a 10:1 E:T ratio. Data represent 3 independent 
experiments done in triplicate, showing lysis in the presence of the control mAb (open bars) and the respective extra 
lysis induced by the presence of cetuximab (filled bars,  SEM). Significance of cetuximab-induced lysis was calculated 
by comparing whether the total lysis in the presence of cetuximab (filled bar plus open bar) was statistically different to 
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Cetuximab enhanced cytolysis of egfR-expressing osteosarcoma cell lines by NK 
cells 
To investigate whether cetuximab can enhance cytolysis of EGFR-expressing osteosarcoma and 
Ewing sarcoma cell lines by NK cells, resting NK cells were incubated with one EGFR- and 
several EGFR* cell lines in the presence of cetuximab or the isotype-matched, nonbinding anti-
CD20 control mAb in a 4-hour 51Cr release assay. As compared with cytolysis in the absence 
of mAb, the negative control mAb did not alter killing of sarcoma cells by NK cells (data now 
shown). In contrast, the addition of cetuximab increased the lysis of EGFR-expressing sarcoma 
cells but not of EGFR-negative cell lines (Figure 2, panel A and B, i; data not shown). The lysis 
of the chemotherapy-resistant variant cell lines of SAOS-2 and U2OS was equally enhanced 
by cetuximab. Cetuximab-enhanced lysis by resting NK cells was comparable with the lysis by 
IL-15–activated NK cells (Figure 2, panel A and B, ii). The addition of cetuximab to IL-15–
activated NK cells hardly led to a further increase of the cytolytic activity. As an alternative 
parameter for NK cell activation, it was observed that the percentage of CD69- expressing NK 
cells increased after coculture of NK cells with EGFR-expressing sarcoma cells in the presence of 
cetuximab (Figure 3, panel A). 
Thus, the cytotoxic function of resting NK cells toward EGFR-expressing sarcoma cell lines as 
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Figure 3: Cetuximab-induced activation of NK cells
(A) EGFR-expressing (OSA and STA-ET2.1) and 
EGFR-negative cell lines (L1062) were cocultured 
with purified NK cells in the presence of cetuximab 
for 48 hours and CD69 expression on NK cells was 
assessed. The percentage of CD69-positive NK cells is 
indicated. (B) The extra lysis induced by cetuximab, 
as calculated by subtracting the lysis by the control 
mAb from the lysis by cetuximab, was correlated with 
EGFR expression levels on the cell lines. Lysis of EGFR+ 
sarcoma cell lines (n = 13) by resting NK cells at a 10:1 
E:T ratio was measured in the presence of cetuximab or 
the negative control mAb (Fig. 2). The extra lysis was 
calculated by subtracting the specific lysis in the presence 
of the control mAb from the total lysis in the presence 
of cetuximab, and plotted against the log of the fold 
change of EGFR expression (Figure 1). The regression 
coefficient (r2) between extra lysis and EGFR expression 
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Cetuximab-mediated lysis is independent of egfR expression intensity 
Despite different sensitivities to NK cell killing, the magnitude of cetuximab-enhanced lysis by 
resting NK cells was comparable among most EGFR-expressing cell lines (Figure 2, panel B, i). 
This increase did not correlate significantly with EGFR surface densities (Figure 3, panel B). 
Thus, even the minimal EGFR expression levels on some of the sarcoma cells were sufficient for 
the induction of ADCC. 
Cetuximab-mediated lysis is dependent on NK cells
In the absence of effector cells, cetuximab did not elicit cytolytic effects on EGFR-expressing 
cell lines during the 4-hour cytotoxicity assay (Figure 4). FcγRIIIa/CD16 expression is required 
to elicit ADCC by NK cells. Because FcγRIIIa/CD16 can also be expressed by monocytes, it 
was studied whether cetuximab-mediated ADCC by PBMC is dependent on NK cells. In the 
presence of cetuximab, lysis of EGFR-expressing sarcoma cells by PBMC was comparable with 
the cetuximab- enhanced lysis by purified NK cells (Figure 4, panel A). In contrast, NK cell 
depletion abolished killing by PBMC both in the absence and presence of cetuximab, indicating 
that in this in vitro system cetuximab-mediated killing was strictly dependent on NK cells present 
in the PBMC. 
Next, the dependence of cetuximab-mediated lysis on the concentration of cetuximab was 
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Figure 4: Cetuximab-mediated 
killing is dependent on NK 
cells
(A) The specific lysis of the 
osteosarcoma cell line OSA 
(i) and the Ewing's sarcoma 
cell line STA-ET2.1 (ii) in the 
presence of cetuximab or the 
control mAb by resting NK 
cells was compared with the 
lysis by total PBMCs, NKD 
PBMCs, and medium (absence 
of effector cells). Killing by 
PBMCs was analyzed at a 
150:1 E:T ratio. Killing by 
NKD PBMCs was analyzed 
at a 150:1 E:T ratio corrected 
for the absence of NK cells in 
accordance to the percentage of 
NK cells in the corresponding 
PBMCs. Killing by purified 
NK cells was extrapolated to a 
150:1 E:T ratio of PBMCs in 
accordance with the percentage 
of NK cells in the corresponding 
PBMCs. Combined data of 
2 experiments. (B) The extra 
lysis of the two EGFR+ cell 
lines OSA and STA-ET2.1 by 
resting NK cells was measured 
in the presence of increasing 
concentrations of cetuximab, 
from 10-7 to 10 mg/ml at a 10:1 
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between 10 and 1x10-2 mg/ml of cetuximab, but it was reduced by at least 50% at a concentration 
of 1x10-3 mg/ml (Figure 4, panel B). Lower cetuximab concentrations failed to enhance lysis. 
Hence, 0.01 mg/ml of cetuximab was the minimal concentration to substantially enhance 
cytolysis by NK cells. 
egfR+ primary cultures derived from egfR+ osteosarcoma tumors are highly 
susceptible to cetuximab-mediated lysis by autologous PBMC 
Primary tumor cell cultures (n=5) were generated from osteosarcoma biopsy (n=1) and resection 
(n=4) specimens derived from 4 different osteosarcoma patients (Table 1). EGFR expression 
in these osteosarcoma samples was membranous, as determined by immunohistochemistry, 
and correlated to the EGFR densities on the corresponding primary cultures, as determined by 
flow cytometry between passages (p) 3 and 13. Except for osteosarcoma patient 398, in which 
EGFR was not detectable in the biopsy and only weakly detectable on the corresponding primary 
culture L2635 p6, all osteosarcoma patients (369, 404, and 407) presented EGFR expression 
both in the original tumor material and the respective primary cultures (L2792 p3; L2826 p9, 
and L3312 p13; L2857 p7; Figure 5, panel A and B). 
The cytolytic activity of NK cells from patient-derived PBMC toward EGFR-expressing 
autologous osteosarcoma cultures was substantially enhanced by cetuximab (Figure 5, panel C). 
Notably, patient-derived NK cells lysed the osteosarcoma cultures as efficient as NK cells from 
healthy donors. Thus, when sarcoma cells are specifically targeted with cetuximab, their lysis by 
resting NK cells can be enhanced by ADCC.  
DISCuSSIoN
 The identification of antigens specifically expressed on tumor cells has fueled the development of 
tumor-specific, mAb-based targeted therapies. The introduction of anti- CD20 mAb (Rituximab, 
MabThera) and anti-Her2 mAb (Trastuzumab, Herceptin) against B cell malignancies and breast 
cancer, respectively, has improved patient prognosis [20,21]. Surface expression of EGFR has 
been shown in several tumors, such as colorectal cancer, head and neck squamous cell carcinoma, 
and is specifically recognized by the chimeric IgG1 mAb cetuximab [13,20]. In numerous clinical 
phase II and III studies, the addition of cetuximab to conventional multi-drug chemotherapy 
or radiotherapy has led to a significant improvement of clinical response rates, progression-free 
survival, and overall survival. Therefore, cetuximab therapy was approved for the treatment of 
recurrent, refractory, and metastatic colorectal cancer [22–25] as well as head and neck squamous 
cell carcinoma [26,27] by the U.S. Food and Drugs Administration (FDA). 
Previously, we and others have shown the cytolytic potential of NK cells against sarcoma cells 
[6–8]. In this study, we sought to explore whether this cytolytic activity can be more specifically 
targeted toward sarcoma cells using a sarcoma-reactive mAb, with a human Fc portion that can 
bind to FcγRIIIa/CD16 on human NK cells. As several studies have described surface EGFR 
expression in osteosarcoma tumors and on osteosarcoma cell lines [12,19,28–31], we explored 
the potential of the anti-EGFR mAb cetuximab to specifically direct NK cell–mediated killing 
to sarcoma cell lines. In agreement with previous studies on other tumor types, cetuximab 




studies [32–35], we show that 0.01 mg/ml of cetuximab was the minimal concentration to 
induce cetuximab-mediated lysis by NK cells. These concentrations have been reported in sera 
of patients treated with cetuximab and in the tumor environment in a xenograft model [36,37], 
indicating that cetuximab-mediated ADCC could be a functional anticancer mechanism in vivo. 
Although in other studies the magnitude of cetuximab-induced ADCC correlated with the level 
of EGFR expression [34,35,38], this correlation was not evident in osteosarcoma, despite the use 
of highly comparable methods to assess ADCC [32,39]. In fact, minimal EGFR densities were 
sufficient for the cetuximab-induced lysis of sarcoma cells [32,39]. Cetuximab-induced ADCC 
was comparable with the maximal killing achieved by IL-15–activated NK cells. In contrast to 
some other models [32,34,40,41], we did not observe an additive effect of cetuximab on the lysis 
by cytokine (IL-15)–activated NK cells. 
Multiple mechanisms may account for the antitumor effect of cetuximab in patients. Masking 
of the EGFR extracellular binding site from its natural ligand EGF inhibits the activation of 
the receptor tyrosine kinase and downstream signaling pathways [13,42]. EGFR blockage has 
been shown to arrest cell-cycle progression and lead to apoptosis [13}. Cetuximab can inhibit 
tumor angiogenesis, neovascularization and invasion, and sensitizes tumor cells to radiation and 
chemotherapy-induced growth inhibition and apoptosis in vivo [13}. Finally, cetuximab may 
induce complement-dependent cytotoxicity or cytolytic effects by immune cells via ADCC 
[13,32,38,39,43]. An advantage of cetuximab-mediated ADCC is that it would be independent 
of the EGFR mutation status [34,38] and persistently activated EGFR signaling pathways 
[13,40}.
The primary mode of action of cetuximab in vivo is difficult to determine. In a murine model, 
the anticancer effect of cetuximab was presumed to be mediated by NK cells [41]. Depletion of 
NK cells in murine osteosarcoma xenograft models or in mice with syngeneic mesenchymal stem 
cell–induced osteosarcoma could address whether an antitumor effect of cetuximab or murine 
anti-EGFR mAb relies on the presence of NK cells [44–46]. In humans, the relevance of ADCC 
has been suggested by the finding that FcγRIIIa/CD16 polymorphism of NK cells correlated 
with the survival of colorectal cancer patients [47,48], as well as with the efficacy of cetuximab-
mediated ADCC by NK cells in vitro [34}. Interestingly, the intratumoral NK cells have recently 
been associated with improved survival when colorectal cancer patients had been treated with 
cetuximab [49]. In this study, we used a unique combination of tumor specimens, primary tumor 
cultures, and PBMC from osteosarcoma patients. This allowed us to establish that cetuximab 
treatment can improve the lysis of EGFR-expressing, autologous primary osteosarcoma cells by 
patient-derived NK cells via cetuximab-mediated ADCC. 
Cetuximab treatment is associated with relatively mild adverse effects and has been approved 
for clinical usage by the FDA [37,50]. Therefore, in the treatment of osteosarcoma patients, 
cetuximab-mediated immunotherapy could be scheduled in the presence of endogenous or 
adoptively transferred NK cells. As  such, cetuximab may provide an interesting treatment 
modality for patients with chemotherapy-resistant or metastatic EGFR+ sarcomas. 
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Antibody-dependent cell lysis by NK cells is preserved after 
sarcoma-induced inhibition of NK cell cytotoxicity
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Osteosarcoma and Ewing sarcoma tumor cells are susceptible to IL-15–induced or antibody-
mediated cytolytic activity of NK cells in short-term cytotoxicity assays. When encountering 
the tumor environment in vivo, NK cells may be in contact with tumor cells for a prolonged 
time period. We explored whether a prolonged interaction with sarcoma cells can modulate the 
activation and cytotoxic activity of NK cells.
The 40-hour co-culture of NK cells with sarcoma cells reversibly interfered with the IL-15–
induced expression of NKG2D, DNAM-1 and NKp30 and inhibited the cytolytic activity of 
NK cells. The inhibitory effects on receptor expression required physical contact between NK 
cells and sarcoma cells and were independent of TGF-β. Five days pre-incubation of NK cells 
with IL-15 prevented the down-regulation of NKG2D and cytolytic activity in subsequent co-
cultures with sarcoma cells. NK cell FcγRIIIa/CD16 receptor expression and antibody-mediated 
cytotoxicity were not affected after the co-culture. Inhibition of NK cell cytotoxicity was directly 
linked to the down-regulation of the respective NK cell–activating receptors.
Our data demonstrate that the inhibitory effects of sarcoma cells on the cytolytic activity of NK 
cells do not affect the antibody-dependent cytotoxicity and can be prevented by pre-activation 
of NK cells with IL-15. Thus, the combination of cytokine-activated NK cells and monoclonal 
antibody therapy may be required to improve tumor targeting and NK cell functionality in the 
tumor environment.4
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INTRoDuCTIoN
Osteosarcoma and Ewing sarcoma represent the most frequent osseous, malignant tumors in 
adolescents and young adults. The current treatment consists of a combination of systemic 
multi-drug chemotherapy and surgical resection [1–3]. Up to 70% of patients with localized 
disease achieve persistent remission. In contrast, the prognosis of patients with metastasized 
and recurrent disease has remained dismal, despite advancements in surgical techniques and 
intensification of chemotherapy regimens during the last decades. In the quest for novel cytolytic 
therapies, we have previously reported the sensitivity of sarcoma cells to NK cell-based cellular 
immunotherapy [4–7]. 
Human NK cells express a broad repertoire of germ-line–encoded inhibitory and activating 
receptors [8–10]. The proportion of inhibiting and activating signals perceived from target 
cells tunes the cytotoxic activity of NK cells. The inhibitory ‘killer cell immunoglobulin-like 
receptors’ (KIR) recognize HLA-A, B, C alleles of the MHC class I complex [11], whereas the 
NKG2A/CD94 complex binds HLA-E [12]. The activating receptor NKG2D recognizes the 
stress ligands MHC class I chain-related protein (MIC) A, MICB and UL-binding proteins 
(ULBP) 1 to ULBP6 [13–17], and DNAM-1 binds to CD112 and CD155 [9,18]. B7-H6 has 
recently been identified as a ligand for the ‘natural cytotoxicity receptors’ (NCR) NKp30 [19], 
whereas ligands for NKp44 and NKp46 are insufficiently characterized on tumor cells. Loss of 
MHC class I expression and ligation of NK cell–activating receptors increase the sensitivity of 
tumor cells to NK cell-mediated lysis [8–10]. In addition to the properties of target cells, NK cell 
cytotoxicity can be ‘primed’ by cytokines such as IL-2 and IL-15 [20–22].      
Apart from killing tumor cell lines in vitro, NK cells have been shown to be involved in the 
rejection of transplanted hematopoietic tumors or chemically-induced tumors in mice, preventing 
tumor outgrowth and supporting tumor-specific T cell responses [23–26]. A role of NK cells in 
anti-cancer responses in humans has been emphasized by the observation that patients with 
leukemia have a better outcome when receiving KIR-ligand–mismatched allogeneic stem cell 
transplantations [27]. However, tumor cells may acquire diverse mechanisms to evade NK cell 
responses. Shedding of NKG2D ligands [28,29], down-regulation of NKG2D and DNAM-1 
surface expression [30–33] by sustained ligand–receptor interactions, and secretion of TGF-β 
[34,35] have been associated with defective NK cell functions, hampering tumor cell recognition 
and killing.
We and others have established that ligands for the NK cell–activating receptors NKG2D and 
DNAM-1 are differentially expressed in sarcoma tissue and on sarcoma cell lines. Sarcoma cell 
lysis by NK cells involves NKG2D and DNAM-1 as measured in short-term cytotoxicity assays 
[4,5,7]. In vivo, however, NK cells may be in contact with tumor cells over a long time period 
which may alter the cytotoxic function of NK cells. Indeed, we have previously observed that 
peripheral blood NK cells from Ewing sarcoma patients exerted low cytolytic activity [7]. In 
the present study we demonstrate that prolonged interactions with sarcoma cells can inhibit the 
cytotoxic activity of NK cells as well as NK cells receptor expression. Remarkably, IL-15–activated 
NK cells and antibody-dependent cytotoxicity by NK cells were resistant to this inhibition. 
Therefore, the combination of IL-15–activated NK cells and monoclonal antibodies may sustain 






The following previously characterized sarcoma cells were included in this study: Ewing sarcoma 
cell lines A673, CADO-ES, SK-ES-1, SK-N-MC, STA-ET2.1, TC71 and L1062; osteosarcoma 
cell lines HOS, OHS, OSA, SAOS-2 and U2OS. All sarcoma cell lines were obtained from 
the EuroBoNeT cell line repository (by 2007) and were confirmed for their identity by short 
tandem repeat DNA fingerprinting in 2011. The TC71 cell line was cultured in IMDM medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS, Invitrogen) 
and 100 U/ml penicillin and 100 ug/ml streptomycin (Invitrogen); all other sarcoma cell lines 
as well as the erythroleukemic cell line K562, the Burkitt’s lymphoma cell line Daudi and the 
murine mastocytoma cell line P815 (ATCC, Manassas, VA, USA) were maintained in RPMI 
1640 supplemented with 10% FCS and penicillin/streptomycin. All Ewing sarcoma cell lines 
were grown in 0.1% gelatin coated culture flasks. All cell lines were negative for mycoplasma 
infection as regularly tested by RT-PCR.
T cell depletion and NK cell isolation
PBMC were separated from buffy coats of healthy adult donors (Sanquin Blood bank, Region 
Southwest, Rotterdam, the Netherlands) by Ficoll-Hypaque density gradient centrifugation. T 
cells were depleted from PBMC (TCD PBMC) by positive selection using anti-CD3 MicroBeads 
(Miltenyi Biotech, Bergisch Gladbach, Germany) to exclude NK cell activation via T cell–
derived IL-2 due to potential alloreactivity toward sarcoma cells. TCD PBMC contained less 
than 0.5% of contaminating CD3+ T cells as analyzed by flow cytometry. NK cells were purified 
from PBMC by negative selection, depleting non-NK cells through a combination of biotin-
conjugated monoclonal anti-human antibodies and MicroBeads using the “Human NK cell 
Isolation Kit” (Miltenyi Biotech); NK cell purity was >95% as determined by flow cytometry, 
analyzing NK cells as CD56+, CD3-, CD14- and CD19- cells. IL-15–activated NK cells were 
obtained by incubating purified NK cells for five days with 10 ng/ml of IL-15 (Peprotech, Rocky 
Hill, NJ, USA) in RPMI medium (with 10% FCS and penicillin/streptomycin) in 24-well tissue 
culture plates. 
Co-cultures
Sarcoma cell lines were seeded in 24-well plates in 1 ml of RPMI medium and incubated for 
18  h. According to cell size and growth rate, the cell lines were seeded at the following cell 
numbers per well, allowing sub-confluent cell densities at the start of co-cultures: TC71 and 
HOS at 50,000; OHS, OSA, SAOS-2 and U2OS at 75,000; A673, CADO-ES and L1062 
at 80,000; SK-ES-1 and STA-ET2.1 at 150,000; SK-N-MC at 200,000. Co-cultures were 
assembled by carefully adding 1x106 TCD PBMC, 1.5x105 purified NK cells or 5-day IL-15–
activated NK cells to the attached sarcoma cells, achieving NK cell–tumor cell ratios of 1:1 
to 3:1 according to the tumor cell numbers seeded. In trans-well experiments, TCD PBMC 
(upper compartment) were separated from STA-ET2.1 or TC71 cells (lower compartment) by a 
porous membrane (0.4 µm pore size). Co-cultures were incubated for approximately 40 h with 
or without IL-15. The following TGF-β inhibitors were applied: TGF-β–neutralizing antibody 
(10 µg/ml; anti-TGFβ1/TGFβ2/TGFβ3; clone 1D11; R&D Systems, Minneapolis, MN, USA), 
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ALK (TGF-βRI kinase) small molecule inhibitor SB-431542 (10 µM; kindly provided by Dr. 
Luuk J.A.C. Hawinkels, Department of Molecular Cell Biology, Leiden University Medical 
Center, Leiden, Netherlands) or recombinant human latency-associated peptide (LAP; 250 ng/
ml; R&D Systems). As controls, TCD PBMC or purified NK cells were incubated in the absence 
of sarcoma cells with or without IL-15, recombinant TGF-β (1 ng/ml; R&D Systems) or TGF-β 
inhibitors. Subsequently, non-attached cell populations were harvested to analyze the expression 
of NK cell activation markers by flow cytometry and the cytolytic activity of NK cells in a 4 h 
51chromium (51Cr) release assay.
flow cytometry
Determination of NK cell percentages in TCD PBMC, validation of NK cell purity and T cell 
depletion, and the expression of NK cell activation markers were analyzed phenotypically with 
fluorescently labeled antibodies and flow cytometry. The following mouse anti-human monoclonal 
antibodies were applied according to the manufacturer’s instructions: HLA-GFITC (MEM-G/9) 
(Abcam, Cambridge, UK); CD3FITC (SK7), CD3PerCP-Cy5.5 (SK7), CD14PerCP-Cy5.5 (M5E2), 
CD69PE (L78), CD69FITC (L78), DNAM-1FITC (DX11), MICA/BPE (6D4), PD-1 (CD279, 
MIH4), goat anti-mouse IgAPC (550826) (BD Biosciences, Franklin Lakes, NJ, USA); HLA-EPE 
(3D12), PD-1LAPC (CD274, MIH1) (eBiosciences, San Diego, CA, USA); CD16FITC (3G8), 
CD56APC (N901 NKH1), CD112PE (R2.477.1), CD155 (PV404.10), NKG2APE (Z199), 
NKG2DPE (ON72), NKp30PE (Z25), NKp44PE (Z231), NKp46PE (BAB281) (IOTEST 
Immunotech, Marseille, France); MICA (159227), MICB (236511), ULBP1 (170818), ULBP2 
(165903), ULBP3 (166510) (R&D Systems); perforinFITC (deltaG9, Ancell, Bayport, MN, 
USA). To analyze ligands for NKG2D, NKp30 and NKp44 on sarcoma cells, freshly harvested 
tumor cells were incubated with the respective Fc fusion protein constructs for 2 h (2.5 µg/mL; 
R&D Systems, Minneapolis, MN, USA) followed by the Alexa Fluor 647 goat anti-human IgG 
secondary antibody (A21445; Invitrogen). The anti-CD20 mAb rituximab (MabThera; Roche, 
Basel, Switzerland) was used as an IgG1 isotype-matched negative control for fusion proteins. 
FACS measurements were performed with the FACSCalibur (BD Biosciences) and analyzed with 
the “BD Cell Quest ProTM” software (version 5.2.1). The indicated fold expression data were 
calculated by dividing the geometric mean fluorescence intensity after the 40 h co-cultures by 
the geometric mean fluorescence intensity after 40 h incubation in medium or IL-15 only (as 
set to 1.00). 
51Chromium release assay
The cytolytic activity of NK cells in TCD PBMC or purified NK cells against K562 (sensitive to 
unstimulated and activated NK cells), Daudi (sensitive to activated NK cells only) and sarcoma 
cell lines was measured in 4  h 51Cr release assays. Effector cells were unstimulated, non-co-
cultured TCD PBMC or purified NK cells, or the non-adherent cell fraction from the 40 h 
co-cultures. For blocking experiments, effector cells were incubated with 10 µg/ml of mouse 
anti-human NKG2D (149810, R&D Systems), DNAM-1 (DX11, BD Biosciences) and NKp30 
(P30-15, Biolegend, San Diego, CA, USA) for 30 min. Target cells were labeled with 100 µl 
Na-chromate (51Cr, 3.7 MBq) for 1 hr. To measure antibody-dependent cellular cytotoxicity 
(ADCC), sarcoma cells were incubated with the chimeric monoclonal antibody cetuximab (anti-




30 min. To measure redirected lysis, murine FcγR+ P815 cells were incubated with 1 µg/ml of 
mouse anti-human CD16FITC (3G8, 1/100, IOTEST Immunotech), DNAM-1 (DX11, BD 
Biosciences), NKG2D (149810, R&D Systems), NKp30 (P30-15, Biolegend) and NKp46 
(9E2, Biolegend) for 30 min. 2.5x103 target cells +/- antibodies were added to effector cells in 
triplicate or duplicate at the indicated effector-target (E:T) ratios and incubated for 4 h at 37°C. 
Supernatants were collected, and the release of 51Cr was measured with a β-counter (Wallac/
PerkinElmer, Waltham, MA, USA). Spontaneous and total release were obtained by incubation 
in medium and Triton X-100 (2.5%; Merck Chemicals, Darmstadt, Germany), respectively. 
The specific lysis was calculated by the following formula: percentage of specific lysis = 100 x 
(experimental release–spontaneous release / total release–spontaneous release).
Statistical analysis
Statistical analyses were performed with Graphpad Prism version 5.04 (La Jolla, CA, USA) or 
SPSS version 16.0 (IBM, Armonk, NJ, USA) using paired Student’s t-tests, comparing means 
between groups of samples. Error bars represent the standard error of the mean. A P-value 
of <0.05 was considered statistically significant. ns, not statistically significant; *, P<0.05; **, 
P<0.01; ***, P<0.001.
ReSulTS
Sarcoma cells can interfere with NK cell receptor expression and cytolysis
To explore whether sarcoma cell lines are able to influence NK cell function, T cell–depleted 
PBMC (TCD PBMC) were co-cultured with osteosarcoma and Ewing sarcoma cell lines for 
40 h. After the co-culture, NKG2D and DNAM-1 were down-regulated on resting NK cells 
by most of the cell lines (8/12 and 6/12 respectively) (Figure 1, panel A and B). Four cell lines 
significantly down-regulated both NKG2D and DNAM-1 expression. 
In addition to the phenotypical changes, it was investigated whether sarcoma cells can affect 
the cytolytic potential of resting NK cells. TCD PBMC were removed from co-cultures with 
STA-ET2.1, HOS (relatively strong inhibitors of NKG2D expression) and TC71 cells (relatively 
weak inhibitor of NKG2D). Afterwards, NK cell-mediated cytolytic activity was tested against 
non–co-cultured sarcoma and non-sarcoma target cells in 4 h 51Cr release assays. The 40 h co-
culture of TCD PBMC with STA-ET2.1 and HOS cells substantially reduced the cytolytic 
activity against (non–co-cultured) STA-ET2.1 and HOS target cells (Figure 1, panel C and 
D). Likewise, lysis of the NK cell target cell line K562 was decreased after these co-cultures 
(Supplementary Figure 1, panel A, page 87), indicating that there was no sarcoma cell-specific 
inhibitory effect. In contrast, co-culture with TC71 cells had little effect on NK cell cytolysis. 
Hence, sarcoma cell lines differed in their efficacy to down-regulate the cytolytic activity of NK 
cells as well as the expression of the NK cell–activating receptors NKG2D and DNAM-1.
Il-15–induced NK cell activation is impaired by sarcoma cells
IL-15 is a potent NK cell–activating cytokine which enhances the expression of NKG2D and 
DNAM-1 on NK cells and boosts their cytolytic activity against sarcoma cells [4,7]. It was 
investigated whether IL-15–induced activation of NK cells can also be inhibited by sarcoma cells. 
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When co-cultured with TCD PBMC in the presence of IL-15, sarcoma cell lines significantly 
interfered with the IL-15–induced up-regulation of NKG2D (12/12) and DNAM-1 (9/12) on 
NK cells (Figure 2, panel A and B; Figure 3, panel A). In addition, STA-ET2.1 cells inhibited 
the IL-15–induced expression of CD69, NKp30, NKp44 and NKp46, whereas HOS and TC71 
cells inhibited only NKp30 and NKp44 (Figure 3, panel B). 
Stimulation of TCD PBMC with IL-15 for 40  h enhanced the lysis of non–co-cultured 
STA-ET2.1 and HOS target cells (Figure 2, panel C and D). The IL-15–induced lysis of both 
cell lines was reduced after the co-culture with STA-ET2.1 cells, while the co-cultures with 
Figure 1: Down-regulation of NK cell NKG2D, DNAM-1 and cytolytic activity by sarcoma cells
Surface expression of NKG2D (A) and DNAM-1 (B) on NK cells was analyzed after 40 h co-cultures of TCD PBMC 
with the indicated Ewing sarcoma and osteosarcoma cell lines by flow cytometry. The indicated fold expression was 
calculated by dividing the geometric mean fluorescence intensity after 40 h co-cultures by the geometric mean fluorescence 
intensity after 40 h incubation in medium only (as set to 1.00). Within the lymphocyte population of life-gated TCD 
PBMC, NK cells were identified as CD56+ cells devoid of CD3 and CD14 expression. Diagonal and horizontal-lined 
patterns in bars indicate the co-cultures mainly focused on in the following experiments (relatively strong inhibitors of 
NKG2D, STA-ET2.1 and HOS; relatively weak inhibitor, TC71). Combined data of the fold expression of multiple 
experiments are depicted. Lysis of (non-co-cultured) STA-ET2.1 (C) and HOS cells (D) by NK cells after the 40 h co-
culture of TCD PBMC with STA-ET2.1, TC71 and HOS cells or 40 h incubation in medium only was measured in 4 
h 51Cr release assays. The specific lysis (%) is depicted as representative data of one experiment and as combined data 
of at least experiments analyzed at a 10:1 E:T ratio. ns, not statistically significant; *, P<0.05; **, P<0.01; ***, P<0.001. 

























































B NK cell DNAM-1 expression in TCD PBMC 
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HOS or TC71 had little or no effect. Furthermore, the IL-15–induced lysis of Daudi cells, 
which are only susceptible to activated NK cells, was greatly diminished after the co-culture with 
STA-ET2.1 cells (Supplementary Figure 1, panel B, page 87).  
These results indicate that sarcoma cells could also interfere with NK cell function in the presence 
of the activating cytokine IL-15.
B NK cell DNAM-1 expression in TCD PBMC 
after co-culture with IL-15
A NK cell NKG2D expression in TCD PBMC 
after co-culture with IL-15
C Lysis of STA-ET2.1 by TCD PBMC 










































































































































































































































Figure 2: Down-regulation of IL-15–induced NK cell cytolytic activity and NKG2D and DNAM-1 expression by 
sarcoma cells 
NKG2D (A) and DNAM-1 (B) on NK cells was analyzed after IL-15–stimulated co-cultures of TCD PBMC with 
Ewing sarcoma and osteosarcoma cell lines. The indicated fold expressions are combined data of multiple experiments, 
comparing expression levels of IL-15–stimulated 40 h co-cultures with expression levels after incubation with IL-15 
only. Gray bars depict TCD PBMC incubated with IL-15 only (no pattern) or IL-15–stimulated co-cultures (diagonal 
and horizontal-lined patterns with STA-ET2.1, HOS or TC71 cells), and white bars depict TCD PBMC incubated in 
medium only. The expression of NKG2D after IL-15 stimulation only was set to 1.00. Lysis of STA ET2.1 (C) and 
HOS cells (D) by NK cells after IL-15–stimulated co-culture of TCD PBMC with sarcoma cells or incubation in IL-15 
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NKg2D down-regulation on NK cells requires direct contact with sarcoma cells and is 
independent of TGF-β
The mechanism responsible for NK cell receptor down-regulation by certain sarcoma cells could 
be based on sustained ligand–receptor interactions. Although the STA-ET2.1 cell line had the 
strongest inhibitory effect on NK cell NKG2D and DNAM-1 expression, the NKG2D ligands 
MIC-A, ULBP1 and ULPB3 were hardly detected on STA-ET2.1 cells, while MIC-B, ULBP2, 
the NKG2D-Fc fusion construct and the DNAM-1 ligands CD112 and CD155 were detected 
at lower intensities as compared to other sarcoma cell lines (Supplementary Figure 2, page 88). 
Notably, the STA-ET2.1 cell line down-regulated NKp30 and NKp44 expression on NK cells but 
ligands for NKp30 and NKp44 were barely detected on STA-ET2.1 cells by Fc fusion constructs 
as compared to TC71 and HOS cells (Figure 3, panel C). Ligands for NKp30 and NKp44 
were only expressed on a few Ewing sarcoma and osteosarcoma cell lines (Supplementary Table, 
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Figure 3: NKp30 and NKp44 down-regulation on NK cells is not associated with NKp30 and NKp44 ligands 
expression on sarcoma cells
(A) Representative FACS overlay plots of the geometric mean fluorescent intensity of NKG2D expression on NK cells 
after 40 h incubation of TCD PBMC with medium (light gray area) and with IL-15 (dark gray area) and after 40 h 
co-culture (black solid line) with the sarcoma cell lines STA-ET2.1 (left panel), TC71 (middle panel) and HOS (right 
panel) in the presence or absence of IL-15. (B) Expression of the NK cell receptors NKG2D, DNAM 1, FcγRIIIa/CD16, 
NKG2A, NKp30, NKp44 and NKp46 and of the NK cell activation marker CD69 was investigated after the co-culture 
of TCD PBMC with STA ET2.1, TC71 or HOS cells in the presence of IL-15. Fold expression data were calculated from 
geometric mean fluorescence intensities and combined of multiple experiments. (C) Representative FACS overlay plots, 
detecting NKp30 ligands by NKp30-Fc fusion protein (black solid line), NKp44 ligand by NKp44-Fc fusion protein 
(grey solid line) and isotype-matched negative control by the anti-CD20 mAb rituximab (light grey area), all followed by 




page 89). Overall, when comparing surface densities of NKG2D, DNAM-1, NKp30 and 
NKp44 ligands on the various sarcoma cell lines, differences in surface densities and expression 
profiles did not appear to correspond to the level of NKG2D, DNAM-1, NKp30 or NKp44 
receptor down-regulation by the respective cell lines (Supplementary Table, page 89). Thus, 
variability in ligand surface densities alone did not explain the differences among sarcoma cell 
lines in down-regulating NK cell receptors. In addition, despite the strong inhibitory effect of 
STA-ET2.1 cells, expression levels of the known NK cell–inhibitory surface ligands HLA-E, 
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after co-culture
B, i iiTGF-β inhibits IL15-induced
NKG2D expression
TGF-β is not involved in NKG2D 





























































































Figure 4: Down-regulation of NKG2D on NK cells requires cell-cell contact and is independent of TGF-β
(A) TCD PBMC (upper compartment) were separated from sarcoma cells (lower compartment) by a porous membrane 
(0.4 μm) in trans-well experiments. NKG2D on NK cells was investigated after the unseparated co-culture and the 
trans-well co-culture, both in the presence of IL-15 and incubated for 40 h. (B) (i) NKG2D expression on NK cells was 
investigated after incubation of TCD PBMC with IL-15 in the presence or absence of recombinant TGF-β and TGF-β 
inhibitors (TGF-β neutralizing antibody, SB 431542 and recombinant LAP) and (ii) after the IL-15–stimulated co-
culture with sarcoma cells in the presence or absence of TGF-β inhibitors. (C) NKG2D on NK cells was measured after 
co-culture of purified NK cells with sarcoma cells in the presence of IL-15. All data were combined from at least two 
experiments. In all panels, IL-15–stimulated samples are indicated by gray bars, white bars depict control incubations in 
medium only. Expression of NKG2D after IL-15 stimulation was set to 1.00. 
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page 88). PD-1 expression was not specifically increased on NK cells after co-culture with 
STA-ET2.1 cells (Supplementary Figure 3, panel A, page 89).
To investigate the role of soluble factors and/or cell–cell contact in the down-regulation of 
the NKG2D receptor, it was tested whether cell-free supernatants of long-term, high-density 
cultures of STA-ET2.1, TC71 and HOS cells influenced NK cell NKG2D and DNAM-
1 expression. Incubation of NK cells with supernatant of sarcoma cell cultures did not alter 
NKG2D or DNAM-1 expression on NK cells (Supplementary Figure 1, panel C, page 87). 
When STA-ET2.1 or TC71 cells (lower compartment) were separated from TCD PBMC (upper 
compartment) in trans-well cultures, both cell lines failed to interfere with IL-15–induced 
NKG2D expression on NK cells (Figure 4, panel A). Thus, cell–cell contact was either required 
directly or because it resulted in the production of inhibitory soluble factors mediating NKG2D 
down-regulation. Incubation of TCD PBMC with supernatant of co-cultures of TCD PBMC 
and STA-ET2.1 or TC71 cells did also not down-regulate NKG2D expression on NK cells 
(Supplementary Figure 1, panel C, page 87). Altogether, these data indicate that the down-
regulation of NKG2D and DNAM-1 was mediated by close cell–cell contact between sarcoma 
cells and NK cells and not by soluble mediators derived from sarcoma cell lines or produced after 
cell–cell contact during the co-cultures.
In previous studies, membrane-associated TGF-β has been described to interfere with the 
activation of NK cells in a cell–cell contact dependent-manner [36-38]. Therefore, it was 
investigated whether neutralization of TGF-β can abolish the inhibitory effect of sarcoma cells. 
The inhibition of IL-15–induced up-regulation of NKG2D on NK cells by recombinant TGF-β 
could be prevented by the addition of a TGF-β–neutralizing antibody, the small molecule 
inhibitor SB-431542 (TGF-βRI kinase inhibitor) or recombinant LAP (inactivator of TGF-β). 
In contrast, addition of the TGF-β inhibitors to the co-cultures of TCD PBMC with STA-ET2.1 
or HOS cells did not prevent the interference with the IL-15–induced NKG2D expression on 
NK cells, suggesting that TGF-β did not play a role in the inhibitory effects of the sarcoma cell 
lines (Figure 4, panel B, ii).
Since until now all experiments have been performed using TCD PBMC, sarcoma cell–
dependent inhibition of NK cells could have been indirect and mediated by non-NK, non-T 
cell populations in PBMC. Therefore NK cells were purified and co-cultured with sarcoma cells. 
Similar to NK cells in TCD PBMC, also on purified NK cells the IL-15–induced up-regulation 
of NKG2D was inhibited after the co-culture with, in particular, STA-ET2.1 cells (Figure 4, 
panel C).  Consequently, sarcoma cells could influence NK cells by direct cell–cell interaction 
without requiring the presence of other PBMC populations.  
Pre-activation of NK cells with Il-15 prevents NK cell inhibition
To explore whether the inhibitory effect of sarcoma cells resulted in irreversible alterations 
in NK cells, TCD PBMC were removed from STA-ET2.1 cells after the 40 h co-culture and 
subsequently incubated with IL-15 alone. The down-regulated expression of NKG2D and 
DNAM-1 after the 40 h co-culture was restored when the TCD PBMC were incubated for three 
additional days with IL-15 in the absence of STA-ET2.1 cells (Figure 5, panel A and data not 
shown). NK cell NKG2D and DNAM-1 expression remained inhibited when STA-ET2.1 cells 




Next it was investigated whether NK cells activated with IL-15 prior to the co-culture are still 
susceptible to sarcoma cell-induced inhibition. Remarkably, when using five days pre-activated 
NK cells neither NKG2D expression nor the cytolytic activity of the NK cells was altered by 
subsequent 40 h co-cultures with sarcoma cells (Figure 5, panel B and C). 
Overall, the sarcoma cell-induced inhibitory effect on NK cell activation was reversible and could 
be prevented by pre-activation of NK cells with IL-15. 
Antibody-dependent cytotoxicity by NK cells is not affected by sarcoma cells
In the previous experiments, the co-culture with the STA-ET2.1 cell line significantly down-
regulated NKG2D, DNAM-1 and NKp30 expression as well as the cytolytic activity against 
sarcoma cell lines. These receptors play an important role in sarcoma cell lysis by NK cells as 
illustrated in 51Cr release assays performed in the presence of specific neutralizing antibodies 
against the respective receptors. Lysis of STA-ET2.1, TC71 and HOS cells by resting NK cells 
was significantly reduced by antibodies against DNAM-1 and fully inhibited by combined 
blocking of DNAM-1 and NKG2D while lysis was only partly dependent on NKG2D alone 
(Supplementary Figure 1, panel D, page 87). Lysis by IL-15–activated NK cells could only be 
A NKG2D down-regulation is 
reversible after co-culture  
B NKG2D on 5 d IL-15–
activated NK cells 
after 40 h co-culture
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Figure 5: NKG2D expression and 
cytotoxicactivity of 5-day IL-15–
activated NK cells is not inhibited 
by sarcoma cells
(A) After the IL-15–stimulated 
40 h co-culture (second bar), 
TCD PBMC were removed from 
STA-ET2.1 cells, as indicated 
by the arrows, and subsequently 
incubated with IL-15 for three 
additional days in the presence 
(fourth bar) or absence (fifth bar) 
of fresh STA-ET2.1 cells. NKG2D 
expression on NK cells was analyzed 
after the 40 h co-culture and after 
the 40 h plus 3 days co-culture. 
Data are combined of multiple 
experiments. (B) Purified NK cells 
were activated with IL-15 for 5 days 
and afterwards co-cultured with 
sarcoma cells for 40 h (gray bars, 
IL-15–stimulated samples). Data of 
NKG2D expression are combined 
of multiple experiments. (C) Lysis 
of non-co-cultured STA-ET2.1 and 
HOS cells after the co-culture of 
5-day IL-15–activated NK cells with 
sarcoma cells. Data are analyzed 
at a 10:1 E:T ratio and combined 
of three and two experiments, 
respectively. 4
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significantly reduced by the combination of DNAM-1 and NKG2D antibodies and was fully 
inhibited by the addition of NKp30 antibodies. 
Therefore, down-regulation of these NK cell receptors may be an explanation for the reduced 
cytolytic activity. To investigate whether down-regulation of a single receptor resulted in reduced 
lysis mediated by this receptor, NK cell cytotoxicity after co-culture was analyzed in redirected 
lysis assays against the murine FcγR+ P815 cell line. Lysis of P815 cells by two days IL-15–
stimulated NK cells was enhanced when P815 cells were coated with mouse anti-human FcγRIIIa/
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Figure 6: Lysis of antibody-coated tumor cells by NK cells is not affected after the co-culture
(A) Redirected lysis of P815 cells coated with FcγRIIIa/CD16, NKG2D, NKp30 and NKp46 antibodies by NK cells 
after for two days incubation of purified NK cells with IL-15 only (bars without pattern) and in the presence or absence 
of STA-ET2.1 or TC71 cells (bars with pattern), depicted as combined data of three experiments analyzed at a 8:1 
E:T ratio (lysis of P815 in the absence of antibodies was subtracted from the total lysis in the presence of antibodies). 
(B) Representative data of redirected lysis of P815 cells with or without antibody coating without (upper panel) or after 
co-culture with STA-ET2.1 cells (lower panel). (C) FcγRIIIa/CD16, NKG2D, NKp30 and NKp46 expression on NK 
cells after co-culture used in redirected lysis experiments above. Data are combined of three experiments. (D) Lysis of 
non-co-cultured, uncoated (white bar, no antibody addition) and cetuximab-coated (gray bar) STA-ET2.1 cells by NK 
cells after co-culture of purified NK cells with STA-ET2.1, TC71 or HOS cells in the presence or absence of IL-15. Data 




and data not shown). After the IL-15–stimulated co-culture with STA-ET2.1 cells, however, 
redirected lysis through NKG2D and NKp30 was severely diminished (Figure 6, panel A and 
B). Lysis through NKp46 was partly reduced, whereas FcγRIIIa/CD16–mediated lysis remained 
intact. These results were closely correlated with the down-regulation of NKG2D and NKp30 
expression and the partly reduced levels of NKp46 on these NK cells, whereas FcγRIIIa/CD16 
expression remained intact (Figure 6, panel C). In contrast, after co-culture with TC71 cells, 
redirected lysis via CD16, NKG2D, NKp30 and NKp46 as well as expression of the respective 
receptors was unaffected (Figure 6, panel A and C). These data demonstrate that the inhibition 
of NKG2D-, NKp30- and partly NKp46-dependent NK cell cytotoxicity were directly linked 
to the down-regulation of the respective NK cell receptors. As indicated by functional FcγRIIIa/
CD16–mediated redirected lysis, the components of the cytolytic machinery appeared to be 
intact after the co-culture. This was further corroborated by the fact that intracellular perforin 
expression in NK cells remained normal (Supplementary Figure 3, panel B, page 89). 
Since FcγRIIIa/CD16–mediated redirected lysis as well as FcγRIIIa/CD16 receptor expression 
was intact after the co-culture, this raised the question whether the FcγRIIIa/CD16–mediated 
antibody-dependent cytotoxic function of NK cells can be exploited to preserve sarcoma cell lysis 
after the co-culture. Coating of STA-ET2.1 cells with the anti-epidermal growth factor receptor 
antibody cetuximab substantially enhanced their lysis by resting NK cells and, moderately, by 
IL-15–stimulated NK cells (Figure 6, panel D) [6] (this thesis, chapter 3). Remarkably, lysis 
of antibody-coated STA-ET2.1 cells by NK cells was not inhibited after the co-culture with 
STA-ET2.1, TC71 or HOS cells in the absence or presence of IL-15. 
Thus, despite the inhibitory effects of certain sarcoma cells, the FcγRIIIa/CD16–mediated, 
antibody-dependent cytotoxicity of NK cells was preserved after the co-culture.
DISCuSSIoN
Tumor escape from NK cell immunosurveillance may occur by selection of tumor cells with no 
or low expression of ligands for NK cell activating receptors or increased expression of ligands 
for inhibitory receptors. Alternatively, tumor cells may produce factors which inhibit NK cell 
activity [39]. In our study, the prolonged, i.e., 40 hours, co-culture of sarcoma cells with NK 
cells resulted in a sarcoma cell line-specific modulation of NK cell activating receptors, in 
particular reducing (IL-15–induced) expression of NKG2D and DNAM-1. Most remarkably, 
the STA-ET2.1 cell line reduced the IL-15–induced expression of NKG2D even to lower levels 
than expressed on resting NK cells. In addition, the IL-15–induced cytolytic activity of NK 
cells was reduced against sarcoma and non-sarcoma cell targets after the co-culture. The down-
regulation of NK cell activating receptors such as NKG2D, NKp30 and NKp46 was directly 
linked to the reduction in cytotoxicity mediated through these receptors as shown in redirected 
lysis experiments. This may offer an explanation for the inhibited sarcoma cell lysis which was 
dependent on NKG2D, DNAM-1 and NKp30.
It was notable that the different sarcoma cell lines were differentially able to down-regulate NK 
cell phenotype and function. We attempted to define whether one or more of the described 
mechanisms were responsible for this effect. Sustained interactions of NKG2D with its ligands 
expressed on tumor cells have been described to induce receptor internalization and degradation, 
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resulting in NK cell hyporesponsiveness [33,40–43]. However in our study, the degree of 
down-regulation of NK cell receptors by different sarcoma cell lines did not correlate with 
the expression of the cognate ligands or known NK cell inhibitory molecules, such as HLA-E, 
HLA-G and PD-1L on these tumor cells. In particular, the sarcoma cell line with the strongest 
inhibitory potential (STA-ET2.1) exhibited only few NKG2D ligands (MICB and ULBP2), 
had relatively low intensities of NKG2D and DNAM-1 ligands and had undetectable expression 
of NKp30 and NKp44 ligands. Thus, the differences in ligand on the sarcoma cell lines do 
not sufficiently explain the differences in down-regulation of NK cell receptors. This suggests 
that other inhibiting factors than sustained ligand–receptor interactions are involved. Another 
potential mechanism of NK cell receptor down-regulation could be through soluble mediators 
as has been demonstrated for melanoma cells [44,45]. However, NKG2D and DNAM-1 down-
regulation after co-culture with sarcoma cells was not mediated by soluble factors. Instead, direct 
cell–cell contact between sarcoma cells and NK cells was required as similarly shown for other 
tumor cell types [30,38,45,46]. This requirement for cell–cell contact could be mediated by 
membrane-associated TGF-β as has been shown for various other tumor cells perturbing NK cell 
NKG2D expression [36–38]. However, in our experiments TGF-β, either membrane-associated 
or soluble, was not involved since blockage of TGF-β or its signaling pathway during the co-
culture did not prevent NKG2D down-regulation on NK cells. Hence, we have determined that 
the inhibition of NK cell cytotoxicity was linked to the down-regulation of the respective NK 
cell activating receptors. However, the mechanism of NKG2D and DNAM-1 down-regulation 
by some of the sarcoma cell lines remains to be further explored. It is tempting to speculate 
that certain sarcoma cells express a membrane-bound, inhibiting factor other than TGF-β that 
can globally impair NK cell receptor expression and thus NK cell cytolytic activity but leaving 
FcγRIIIa/CD16–mediated lysis intact.
Several studies have reported on defective cytotoxic functions of tumor-associated and peripheral 
blood NK cells from patients with cancer (prior to the start of anti-cancer therapies) in 
association with reduced expression of NK cell–activating receptors [30,47–50]. As an exception 
to these studies, we have previously shown that peripheral blood NK cells from patients with 
Ewing sarcoma exerted low cytolytic activity despite higher levels of NKG2D, suggesting that 
another mechanism may be responsible for the in vivo down-regulation of NK cell reactivity [7]. 
Interestingly, when the NK cells were activated with IL-15 for five days prior to the co-culture, 
NKG2D expression and cytolytic activity were no longer affected by sarcoma cells. Conversely, 
the impaired expression of NKG2D and DNAM-1 could be reversed when the NK cells were 
removed from the co-culture and subsequently stimulated with IL-15 [32,38,40,42]. Thus, the 
reduction of NK cell receptor expression requires the permanent presence of tumor cells. Ex 
vivo stimulation with IL-15 of NK cells from patients with Ewing sarcoma restored the cytolytic 
activity [7], indicating that the inhibited cytolytic function of patient’s NK cells can also be 
reversed. Similarly, it has been shown that the decreased cytolytic activity of NK cells from 
patients with leukemia normalizes when patients have achieved complete remission [48]. 
In vivo, the excess of tumor cells, imperfect NK cell activation and incomplete tumor cell 
elimination may result in prolonged tumor–NK cell interactions, rendering NK cells non-
functional over time. In this perspective, adoptively transferred NK cells have been shown to lose 




antibody-dependent cytotoxic activity in patients [51,52]. Importantly, in our experiments 
antibody-dependent target cell lysis remained functional after the interaction with sarcoma cells, 
whereas FcγRIIIa/CD16–independent cytotoxicity of NK cells was inhibited. In several other 
studies, defective antibody-dependent cytotoxicity of NK cells from patients with cancer was 
associated with reduced expression of FcγRIIIa/CD16 on NK cells, whereas in our experiments 
FcγRIIIa/CD16 expression was unaffected and mediated antibody-dependent target cell lysis. 
Different tumors apparently employ different mechanisms to interfere with cytolytic pathways 
of NK cells [30,41,53]. Hence, the co-culture with sarcoma cells neither exhausted the cytolytic 
potential nor caused overall NK cell hyporesponsiveness. The inhibition of both ITAM-
dependent (NKp30 and NKp46) and ITAM-independent (NKG2D) NK cell cytotoxicity 
appeared to be directly linked to the down-regulation of the respective NK cell receptors. Thus, 
target cell recognition was presumably impaired while other prerequisites for target cell lysis, 
such as perforin expression, remained intact.
In our study, neither the cytotoxicity of five-day IL-15–activated NK cells nor the antibody-
dependent cytolytic function of resting and IL-15–stimulated NK cells was affected by the 
inhibitory effects of sarcoma cells. Thus, a combination of adoptively transferred, IL-15–activated 
NK cells with infusion of tumor-reactive antibodies may improve tumor targeting and conserve 
NK cell functionality in vivo in a potentially NK cell–inhibiting tumor environment. 
ACKNowleDgMeNTS
The authors thank F. Schaper, M. Verheul and L. Oudejans for technical contributions. We thank 
T. van Hall, G. de Groot-Swings, J. Suurmond and S. de Jong for kindly providing antibodies 
against HLA-E, HLA-G, PD-1 and PD-1L, respectively. This work was financially supported by a 
grant from the foundation ‘’Quality of Life Gala 2007”, the European Commission (EuroBoNeT, 
grant No 018814) and the Dutch Foundation Children Cancer Free (grant 2009-052). 
RefeReNCeS
1. Bernstein M, Kovar H, Paulussen M, Randall 
RL, Schuck A, Teot LA, Juergens H (2006) Ewing 
sarcoma family of tumors: current management. 
Oncologist 11:503-519
2. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M 
(2010) Emerging drugs for high-grade osteosarcoma. 
Expert Opin Emerg Drugs 15:615-634
3. van den Berg H, Kroon HM, Slaar A, Hogendoorn 
PCW (2008) Incidence of biopsy-proven bone 
tumors in children: a report based on the Dutch 
pathology registration “PALGA”. J Pediatr Orthop 
28:29-35
4. Berghuis D, Schilham M.W., Voss HI, Santos SJ, 
Kloess S, Buddingh EP, Egeler RM, Hogendoorn 
PCW, Lankester AC (2012) Histone Deacetylase 
Inhibitors Enhance Expression of NKG2D Ligands 
in Ewing Sarcoma and Sensitize for Natural Killer 
Cell-Mediated Cytolysis. Clinical Sarcoma Research 
2:8:
5. Buddingh EP, Schilham MW, Ruslan SE, Berghuis 
D, Szuhai K, Suurmond J, Taminiau AH, 
Gelderblom H, Egeler RM, Serra M, Hogendoorn 
PCW, Lankester AC (2011) Chemotherapy-resistant 
osteosarcoma is highly susceptible to IL-15–activated 
allogeneic and autologous NK cells. Cancer Immunol 
Immunother 60:575-586
6. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai 
K, Serra M, Gelderblom H, Hogendoorn PC, Egeler 
RM, Schilham MW, Lankester AC (2012) Anti-
EGFR antibody cetuximab enhances the cytolytic 
activity of natural killer cells toward osteosarcoma. 
Clin Cancer Res 18:432-441
7. Verhoeven DHJ, de Hooge AS, Mooiman EC, 
Santos SJ, ten Dam MM, Gelderblom H, Melief 
CJ, Hogendoorn PCW, Egeler RM, van Tol MJD, 
Schilham MW, Lankester AC (2008) NK cells 
recognize and lyse Ewing sarcoma cells through 
4
85
Intact ADCC after sarcoma-induced NK cell hyporesponsiveness 
NKG2D and DNAM-1 receptor dependent 
pathways. Mol Immunol 45:3917-3925
8. Bryceson YT, and Long EO (2008) Line of attack: 
NK cell specificity and integration of signals. Curr 
Opin Immunol 20:344-352
9.  Moretta L, Bottino C, Pende D, Castriconi R, 
Mingari MC, Moretta A (2006) Surface NK 
receptors and their ligands on tumor cells. Semin 
Immunol 18:151-158
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini 
S (2008) Functions of natural killer cells. Nat 
Immunol 9:503-510
11. Thielens A, Vivier E, Romagne F (2012) NK cell 
MHC class I specific receptors (KIR): from biology 
to clinical intervention. Curr Opin Immunol 
24:239-245
12. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks 
AG (1998) Recognition of human histocompatibility 
leukocyte antigen (HLA)-E complexed with HLA 
class I signal sequence-derived peptides by CD94/
NKG2 confers protection from natural killer cell-
mediated lysis. J Exp Med 187:813-818
13.  Bacon L, Eagle RA, Meyer M, Easom N, Young 
NT, Trowsdale J (2004) Two human ULBP/RAET1 
molecules with transmembrane regions are ligands 
for NKG2D. J Immunol 173:1078-1084
14.  Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier 
LL, Spies T (1999) Activation of NK cells and T cells 
by NKG2D, a receptor for stress-inducible MICA. 
Science 285:727-729
15. Chalupny NJ, Sutherland CL, Lawrence WA, Rein-
Weston A, Cosman D (2003) ULBP4 is a novel 
ligand for human NKG2D. Biochem Biophys Res 
Commun 305:129-135
16.  Cosman D, Mullberg J, Sutherland CL, Chin W, 
Armitage R, Fanslow W, Kubin M, Chalupny NJ 
(2001) ULBPs, novel MHC class I-related molecules, 
bind to CMV glycoprotein UL16 and stimulate 
NK cytotoxicity through the NKG2D receptor. 
Immunity 14:123-133
17. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale 
J (2009) ULBP6/RAET1L is an additional human 
NKG2D ligand. Eur J Immunol 39:3207-3216
18.  Bottino C, Castriconi R, Pende D, Rivera P, Nanni 
M, Carnemolla B, Cantoni C, Grassi J, Marcenaro 
S, Reymond N, Vitale M, Moretta L, Lopez M, 
Moretta A (2003) Identification of PVR (CD155) 
and Nectin-2 (CD112) as cell surface ligands for the 
human DNAM-1 (CD226) activating molecule. J 
Exp Med 198:557-567
19. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox 
B, Haldeman B, Ostrander CD, Kaifu T, Chabannon 
C, Moretta A, West R, Xu W, Vivier E, Levin SD 
(2009) The B7 family member B7-H6 is a tumor cell 
ligand for the activating natural killer cell receptor 
NKp30 in humans. J Exp Med 206:1495-1503
20. Bryceson YT, March ME, Ljunggren HG, Long EO 
(2006) Synergy among receptors on resting NK cells 
for the activation of natural cytotoxicity and cytokine 
secretion. Blood 107:159-166
21.  Horng T, Bezbradica JS, Medzhitov R (2007) 
NKG2D signaling is coupled to the interleukin 15 
receptor signaling pathway. Nat Immunol 8:1345-
1352
22. Lucas M, Schachterle W, Oberle K, Aichele P, 
Diefenbach A (2007) Dendritic cells prime natural 
killer cells by trans-presenting interleukin 15. 
Immunity 26:503-517
23.  Cerwenka A, Baron JL, Lanier LL (2001) Ectopic 
expression of retinoic acid early inducible-1 gene 
(RAE-1) permits natural killer cell-mediated rejection 
of a MHC class I-bearing tumor in vivo. Proc Natl 
Acad Sci USA 98:11521-11526
24. Diefenbach A, Jensen ER, Jamieson AM, Raulet 
DH (2001) Rae1 and H60 ligands of the NKG2D 
receptor stimulate tumour immunity. Nature 
413:165-171
25. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda 
K, Yagita H, Smyth MJ (2002) Induction of tumor-
specific T cell memory by NK cell-mediated tumor 
rejection. Nat Immunol 3:83-90
26. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama 
WM, Hayakawa Y (2005) NKG2D function protects 
the host from tumor initiation. J Exp Med 202:583-
588
27.  Ruggeri L, Capanni M, Urbani E, Perruccio K, 
Shlomchik WD, Tosti A, Posati S, Rogaia D, 
Frassoni F, Aversa F, Martelli MF, Velardi A (2002) 
Effectiveness of donor natural killer cell alloreactivity 
in mismatched hematopoietic transplants. Science 
295:2097-2100
28. Doubrovina ES, Doubrovin MM, Vider E, Sisson 
RB, O’Reilly RJ, Dupont B, Vyas YM (2003) Evasion 
from NK cell immunity by MHC class I chain-
related molecules expressing colon adenocarcinoma. 
J Immunol 171:6891-6899
29. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele 
C, Nuebling T, Raum T, Steinle A, Salih HR 
(2012) Comprehensive Analysis of NKG2D Ligand 
Expression and Release in Leukemia: Implications for 
NKG2D-Mediated NK Cell Responses. J Immunol 
189:1360-1371
30. Carlsten M, Norell H, Bryceson YT, Poschke I, 
Schedvins K, Ljunggren HG, Kiessling R, Malmberg 
KJ (2009) Primary human tumor cells expressing 
CD155 impair tumor targeting by down-regulating 
DNAM-1 on NK cells. J Immunol 183:4921-4930
31. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived 
soluble MIC ligands impair expression of NKG2D 
and T-cell activation. Nature 419:734-738
32. Ogasawara K, Hamerman JA, Hsin H, Chikuma 
S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, 
Bluestone JA, Lanier LL (2003) Impairment of NK 
cell function by NKG2D modulation in NOD mice. 
Immunity 18:41-51
33. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, 




(2005) Sustained localized expression of ligand 
for the activating NKG2D receptor impairs 
natural cytotoxicity in vivo and reduces tumor 
immunosurveillance. Nat Immunol 6:928-937
34. Castriconi R, Cantoni C, Della CM, Vitale M, 
Marcenaro E, Conte R, Biassoni R, Bottino C, 
Moretta L, Moretta A (2003) Transforming growth 
factor beta 1 inhibits expression of NKp30 and 
NKG2D receptors: consequences for the NK-
mediated killing of dendritic cells. Proc Natl Acad Sci 
USA 100:4120-4125
35. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, 
Sporn MB, Burlington DB, Lane HC, Fauci AS 
(1986) Effects of transforming growth factor beta on 
the functions of natural killer cells: depressed cytolytic 
activity and blunting of interferon responsiveness. J 
Immunol 136:3916-3920
36. Clayton A, Mitchell JP, Court J, Mason MD, Tabi 
Z (2007) Human tumor-derived exosomes selectively 
impair lymphocyte responses to interleukin-2. 
Cancer Res 67:7458-7466
37. Clayton A, Mitchell JP, Court J, Linnane S, Mason 
MD, Tabi Z (2008) Human tumor-derived exosomes 
down-modulate NKG2D expression. J Immunol 
180:7249-7258
38. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, 
Melcher AA, Meade JL, Cook GP (2011) Human 
Tumour Immune Evasion via TGF-beta Blocks 
NK Cell Activation but Not Survival Allowing 
Therapeutic Restoration of Anti-Tumour Activity. 
PLoS One 6:e22842
39. Waldhauer I, and Steinle A (2008) NK cells and 
cancer immunosurveillance. Oncogene 27:5932-
5943
40. Coudert JD, Zimmer J, Tomasello E, Cebecauer 
M, Colonna M, Vivier E, Held W (2005) Altered 
NKG2D function in NK cells induced by chronic 
exposure to NKG2D ligand-expressing tumor cells. 
Blood 106:1711-1717
41.  Coudert JD, Scarpellino L, Gros F, Vivier E, Held 
W (2008) Sustained NKG2D engagement induces 
cross-tolerance of multiple distinct NK cell activation 
pathways. Blood 111:3571-3578
42. Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens 
AM, Yee C, Nakakuma H, Spies T, Groh V (2010) 
NKG2D Initiates Caspase-Mediated CD3{zeta} 
Degradation and Lymphocyte Receptor Impairments 
Associated with Human Cancer and Autoimmune 
Disease. J Immunol 185:5732-5742
43. Roda-Navarro P, and Reyburn HT (2009) The traffic 
of the NKG2D/Dap10 receptor complex during 
natural killer (NK) cell activation. J Biol Chem 
284:16463-16472
44. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, 
Petretto A, Balsamo M, Conte R, Benelli R, Minghelli 
S, Solari N, Gualco M, Queirolo P, Moretta L, 
Mingari MC (2012) Melanoma cells inhibit natural 
killer cell function by modulating the expression of 
activating receptors and cytolytic activity. Cancer Res 
72:1407-1415
45.  Balsamo M, Scordamaglia F, Pietra G, Manzini 
C, Cantoni C, Boitano M, Queirolo P, Vermi W, 
Facchetti F, Moretta A, Moretta L, Mingari MC, 
Vitale M (2009) Melanoma-associated fibroblasts 
modulate NK cell phenotype and antitumor 
cytotoxicity. Proc Natl Acad Sci USA 106:20847-
20852
46. von Lilienfeld-Toal M, Frank S, Leyendecker C, 
Feyler S, Jarmin S, Morgan R, Glasmacher A, Marten 
A, Schmidt-Wolf IG, Brossart P, Cook G (2009) 
Reduced immune effector cell NKG2D expression 
and increased levels of soluble NKG2D ligands 
in multiple myeloma may not be causally linked. 
Cancer Immunol Immunother 59:829-839
47. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff 
M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende 
D, Olive D, Moretta A (2002) Defective expression 
and function of natural killer cell-triggering receptors 
in patients with acute myeloid leukemia. Blood 
99:3661-3667
48. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty 
D, Olive D, Costello RT (2007) Deficient expression 
of NCR in NK cells from acute myeloid leukemia: 
Evolution during leukemia treatment and impact 
of leukemia cells in NCRdull phenotype induction. 
Blood 109:323-330
49. Le Maux CB, Moretta A, Vergnon I, Opolon P, Lecluse 
Y, Grunenwald D, Kubin M, Soria JC, Chouaib 
S, Mami-Chouaib F (2005) NK cells infiltrating a 
MHC class I-deficient lung adenocarcinoma display 
impaired cytotoxic activity toward autologous tumor 
cells associated with altered NK cell-triggering 
receptors. J Immunol 175:5790-5798
50.  Lee JC, Lee KM, Kim DW, Heo DS (2004) Elevated 
TGF-beta1 secretion and down-modulation of 
NKG2D underlies impaired NK cytotoxicity in 
cancer patients. J Immunol 172:7335-7340
51.  Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA 
(2011) Adoptive transfer of autologous natural killer 
cells leads to high levels of circulating natural killer 
cells but does not mediate tumor regression. Clin 
Cancer Res 17:6287-6297
52. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A 
(2012) Sustained effector function of IL-12/15/18-
preactivated NK cells against established tumors. J 
Exp Med 209:2351-2365
53.  Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, 
Matsumoto Y (2002) Impaired antibody-dependent 
cellular cytotoxicity mediated by herceptin in patients 
with gastric cancer. Cancer Res 62:5813-5817
4
87
Intact ADCC after sarcoma-induced NK cell hyporesponsiveness 
A
































































































































































































































































































































































































































































































































































































































































































































































































































































STA-ET2.1 TC71 HOS L1062
4
89






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































% of PD-1+ NK cells
Perforin expression







































Jens H.W. Pahl, Kitty M.C. Kwappenberg, Eleni M. Varypataki, Susy J.  
Santos, Susan Mohamed, Juul T. Wijnen, Maarten J.D. van Tol,  
Anne-Marie Cleton-Jansen, R. Maarten Egeler, Wim Jiskoot,  
Arjan C. Lankester, and Marco W. Schilham 
Macrophages inhibit human osteosarcoma cell growth after 
activation with the bacterial cell wall derivative liposomal 






In osteosarcoma, the presence of tumor-infiltrating macrophages positively correlates with patient 
survival in contrast to the negative effect of tumor-associated macrophages in patients with other 
tumors. Liposome-encapsulated muramyl tripeptide (L-MTP-PE) has been introduced in the 
treatment of osteosarcoma patients, which may enhance the potential anti-tumor activity of 
macrophages. Direct anti-tumor activity of human macrophages against human osteosarcoma 
cells has not been described so far. Hence, we assessed osteosarcoma cell growth after co-culture 
with human macrophages.
Monocyte-derived M1-like macrophages inhibited osteosarcoma cell growth after two-day 
co-culture when activated with LPS+IFN-γ. Likewise, stimulation of M1-like macrophages with 
liposomal muramyl tripeptide (L-MTP-PE) inhibited tumor growth, but only when combined 
with IFN-γ. Addition of the tumor-reactive anti-EGFR antibody cetuximab did not further 
improve the anti-tumor activity of activated M1-like macrophages. The inhibition was mediated 
by supernatants of activated M1-like macrophages, containing TNF-α and IL-1β. However, 
specific blockage of these cytokines, nitric oxide or reactive oxygen species did not inhibit the 
anti-tumor effect, suggesting the involvement of other soluble factors released upon macrophage 
activation. While LPS+IFN-γ–activated M2-like macrophages had low anti-tumor activity, 
IL-10–polarized M2-like macrophages were able to reduce osteosarcoma cell growth in the 
presence of the anti-EGFR cetuximab involving antibody-dependent tumor cell phagocytosis. 
This study demonstrates that human macrophages can be induced to exert direct anti-tumor 
activity against osteosarcoma cells. Our observation that the induction of macrophage anti-tumor 
activity by L-MTP-PE required IFN-γ may be of relevance for the optimization of L-MTP-PE 
therapy in osteosarcoma patients. 
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INTRoDuCTIoN
Osteosarcoma is the most frequent malignant bone tumor in adolescents and young adults. Of 
patients with localized, non-metastatic disease, up to 70% achieve persistent remission [1]. In 
contrast, prognosis of patients with advanced, metastatic and recurrent disease is as low as 20% 
despite intensive chemotherapy and surgery. Recently, we have demonstrated that the presence of 
tumor-infiltrating macrophages at the time of diagnosis is positively correlated with a favorable 
outcome of patients with osteosarcoma [2]. Hence, targeting tumor-associated macrophages in 
osteosarcoma with macrophage-activating agents is an attractive option to complement current 
anti-tumor treatments. 
Macrophages are mononuclear phagocytic cells that are involved in homeostatic, pro-
inflammatory and immune regulatory responses in the tissue [3, 4]. While macrophages can 
originate from blood monocytes under inflammatory conditions, as in the classical model for 
macrophage development, it has recently been revealed that under non-inflammatory conditions 
tissue macrophages primarily originate from the yolk sac and fetal liver and are maintained 
independently of hematopoietic precursors [5]. Macrophages possess great functional and 
phenotypic plasticity which is often simplified by classification in M1 and M2 phenotypes [6]. 
M1 macrophages are involved in host defense through their bactericidal and tumoricidal activity 
and pro-inflammatory cytokine production if ‘classically-activated’ by interferon-γ (IFN-γ) and 
Toll-like receptor ligands such as bacterial lipopolysaccharide (LPS) [7, 8]. M2 macrophages 
can exhibit many different phenotypes in response to diverse stimuli such as polarization with 
interleukin-10 (IL-10) or LPS. M2 macrophages are involved in scavenging cell debris and 
bacteria, antibody-dependent phagocytosis, tissue remodeling, angiogenesis, wound healing and 
immune regulation. In contrast to ‘classically-activated’ M1 macrophages, macrophages with 
an M2-like phenotype are often detected in solid tumors and considered to promote tumor 
progression [6-9]. 
Macrophages constitute the majority of tumor-infiltrating immune cells in solid tumors including 
osteosarcoma [2, 10]. In most tumors, the presence of macrophages represents an unfavorable 
prognostic factor [11]. In contrast, in osteosarcoma as well as colorectal cancer higher numbers of 
tumor-infiltrating macrophages correlate with better survival [2, 12, 13]. In osteosarcoma, there 
was no clear association of good survival with an M1-like or M2-like phenotypic polarization of 
macrophages [2].
Monocytes and macrophages activated with LPS have been implicated in anti-tumor responses 
for a long time [14-19]. But while canine macrophages have been reported to have anti-tumor 
activity against canine osteosarcoma cells, comparable evidence for anti-tumor activity of human 
macrophages against human osteosarcoma cells is not available. The anti-tumor activity of 
canine macrophages was shown to be dependent on stimulation with LPS or another bacterial 
cell wall constituent, i.e. muramyl dipeptide (MDP) or the lipophilic derivative muramyl 
tripeptide phoshatidylethanolamine (MTP-PE) [20]. Application of liposome-encapsulated 
MTP-PE (L-MTP-PE) in vivo improved survival of dogs with osteosarcoma [21]. This 
observation encouraged the addition of L-MTP-PE to the treatment of osteosarcoma patients 
as a macrophage-activating agent but did not increase event-free survival of non-metastatic or 




Therefore, we set out to investigate the anti-tumor activity of human macrophages against human 
osteosarcoma cells and determine whether this activity can be manipulated. We set up an in vitro 
model in which the effect of human macrophages on the growth of osteosarcoma cells can be 
directly assessed by counting residual tumor cells after a two-day co-culture with macrophages. 
Using this model we demonstrate how anti-tumor activity of M1-like macrophages and M2-like 




The osteosarcoma cell lines HOS, HOS-143b, OHS, OSA, SAOS-2 and U2OS were obtained 
from the EuroBoNeT cell line repository (2007) [23]. Cell line identity was confirmed by short 
tandem repeat DNA fingerprinting in 2012. All cell lines were maintained in RPMI 1640 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Invitrogen) and 
100 U/ml penicillin and 100 ug/ml streptomycin (Invitrogen). All cell lines were negative for 
mycoplasma infection as regularly tested by RT-PCR.
Preparation of liposomal MTP-Pe
Liposomes (multi-lamellar vesicles) were prepared from a mixture of the synthetic phospholipids 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, 850457P) and 1,2-dioleoyl-sn-
glycero-3-phospho-L-serine (DOPS, 840035P) (both from Avanti Polar Lipids, Alabaster, Al, 
USA) at a 7:3 molar ratio in chloroform by mechanical agitation on a vortex mixer. MTP-PE 
(Mr 1237.5 g/mol; Mifamurtide; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
chloroform:methanol:water 60:36:4 (v/v/v). 5 mg of liposomes (Mr 775 g/mol) were loaded 
with 0.02 mg of MTP-PE (1:250 ratio).  The organic solution was dried in a rotary evaporator 
under reduced pressure for one hour to obtain a dry lipid film. Afterwards, the lipid film was 
rehydrated in 2.5 ml sterile PBS, resulting in a final concentration of 6.45 nmol MTP-PE per 
2 µmol/ml liposome preparation (L-MTP-PE). The liposomes were passed four times through 
a 1 µm unipore polycarbonate filter (Nuleopore). Control liposomes (L-PBS) were prepared by 
the same procedure except without MTP-PE addition. The z-average diameter of the liposomes 
was ~350 nm with a mean zeta potential of -97 mV as measured on a Zetasizer (version 6.01) 
(Malvern Instruments, Worcestershire, UK). 
Monocyte Isolation and differentiation to macrophages
PBMC were separated from buffy coats of healthy adult donors (Sanquin Blood bank, Region 
Southwest, Rotterdam, the Netherlands) by Ficoll-Hypaque density gradient centrifugation. 
Monocytes were isolated from PBMC by positive selection using anti-CD14 MicroBeads 
(Miltenyi Biotech, Bergisch Gladbach, Germany). For M1-like and M2-like macrophage 
differentiation, monocytes (1,5x106 per well per 3 ml of a 6-well tissue culture plate) were 
incubated with GM-CSF (80 ng/ml; Peprotech, Rocky Hill, NJ, USA) and M-CSF (20 ng/
ml, R&D Systems, Minneapolis, MN, USA) for seven days as previously described [9;27]. In 
some conditions, M1-like and M2-like macrophages were additionally stimulated during the 
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last day of differentiation with combinations of LPS (10 ng/ml; E. coli strain 0111:B4; Sigma-
Aldrich), IFN-γ (100 U/ml; Boehringer, Mannheim, Germany), empty control liposomes (250 
nmol) (L-PBS) or liposomes (250 nmol) containing MTP-PE (0.8 nmol, i.e., 1 µg) (L-MTP-
PE) per 3 ml culture medium. M2-like macrophages were alternatively stimulated with IL-10 
(10 ng/ml; Peprotech) during the last two days of differentiation. The phenotype of macrophage 
populations was tested in each experiment. Macrophages were devoid of the monocyte-derived 
dendritic cell marker CD1a (data not shown). 
Macrophage-tumor cell co-cultures
After differentiation, culture supernatants of macrophages were collected. Adherent macrophages 
were washed in cold PBS, detached by incubation in accutase (Sigma-Aldrich) for 30 min at 
37 °C and combined with the non-adherent cell fraction. Cell scraping of firmly adherent 
macrophages was avoided to maximize macrophage viability. Macrophages were seeded in 96-
well flat-bottom plates in RPMI medium at 3,000 (cell conjugate formation assay) or 30,000 cells 
(tumor cell survival assay) per well (four wells per condition) and incubated for cell attachment. 
After two hours 3,000 osteosarcoma cells were added and macrophage-tumor cell co-cultures 
were incubated for two hours in cell conjugate formation assays at a 1:1 ratio in 50 µl medium 
and for two hours, one day and two days in tumor cell survival assays at a 10:1 ratio in 100 µl 
medium. In some experiments, tumor cells were coated with the chimeric monoclonal antibody 
cetuximab (anti-epidermal growth factor receptor, 1 µg/ml final concentration in co-cultures; 
Erbitux; Merck KGaA, Darmstadt, Germany) or with the non-binding anti-CD20 antibody 
rituximab (1 µg/ml; MabThera; Roche, Basel, Switzerland) prior to the co-culture. In blocking 
experiments, co-cultures were performed in the presence of the soluble tumor-necrosis factor–α 
(TNF-α) receptor etanercept (10 µg/ml; Enbrel; Wyeth; Madison, NJ, USA) and TNF-α–
neutralizing antibody adalimumab (10 µg/ml; Humira; Abbot; North Chicago, IL, USA), the 
IL-1 receptor antagonist anakinra (10 µg/ml; Kineret; Amgen; Thousand Oaks, CA, USA), nitric 
oxide species inhibitor Nω-Nitro-L-arginine methyl ester (10 µM; L-NAME; Sigma-Aldrich), 
reactive oxygen species inhibitors catalase (186 µg/ml; Sigma-Aldrich) and superoxide dismutase 
(4.2 µg/ml; Sigma-Aldrich).
Anti-Tumor Activity Assay
The effect of macrophages on tumor cell survival was assessed by enumerating tumor cells by 
flow cytometry [13, 25]. Adherent and non-adherent cells were harvested after co-culture using 
accutase (if necessary supported by cell scraping) and stained with anti-CD56 and anti-CD32 
to distinguish tumor cells and macrophages, respectively. The complete tumor cell-macrophage 
suspension was analyzed by flow cytometry. Live-gated tumor cells present at the end of the co-
culture were quantified and in each experiment compared to the number of tumor cells grown in 
the absence of macrophages. In some experiments viable tumor cell numbers were measured after 
their incubation in medium with 50% (v/v) of macrophage cell-free supernatant or after their 
incubation with inhibitors in the presence of macrophages. Single measurements from multiple 





Tumor cell lines were labeled with CFSE (1 µM; Invitrogen) and incubated overnight to allow 
leakage of excess CFSE. IL-10–stimulated M2-like Macrophages were co-cultured with CFSE-
labeled HOS-143b cells for two hours at 1:1 ratio. All cells were harvested from the culture by cell 
scraping and macrophages were labeled with APC-labeled anti-CD32 antibodies. Cell conjugate 
formation between macrophages and tumor cells was analyzed by flow cytometry, assessing the 
percentage of CD32+ macrophages acquiring high CFSE fluorescence from tumor cells. 
For an indication of phagocytosis, after the cell conjugate formation assay, CD32+ macrophages 
which have acquired the fluorescent signal of CFSE+ tumor cells were sorted by flow cytometry 
in one experiment. The cells were stained with mouse anti-human HLA-DR (TAL.1B5; Dako, 
Glostrup, Denmark) followed by the Alexa-Fluor-594 goat anti-mouse IgG1 secondary antibody 
(Invitrogen) and embedded in Vectashield mounting medium containing DAPI (Vectorlabs, 
Burlingame, CA, USA). Cell conjugates were examined with a Leica DM5000 fluorescence 
microscope and LAS-AF acquisition program (Leica, Solms, Germany), detecting nuclei in blue, 
HLA-DR+ macrophages in red and CFSE+ tumor cells in green. 
flow cytometry
The following fluorochrome-labeled mouse anti-human monoclonal antibodies were used: 
CD32APC (clone FLI8.26), CD86PE (FUN-1), CD163PE (GHI/61), HLA-DRFITC (L243) (BD 
Biosciences, Franklin Lakes, NJ, USA); CD56PE (NKH-1) (Beckman Coulter, Brea, CA, USA); 
CD16FITC (3G8), CD64FITC (22) (IOTEST Immunotech, Marseille, France). Measurements 
were performed with the FACSCalibur (BD Biosciences) and analyzed with the BD Cell 
Quest ProTM software (version 5.2.1). Fold-expression data indicated in histogram plots were 
calculated by dividing the geometric mean fluorescence intensity (geoMFI) of antibodies by the 
geoMFI of the PBS control. 
luminex assay
Cytokine production in cell-free supernatants of macrophage cultures was measured using the 
Bio-Plex Pro Human Cytokine 27-plex group 1 panel according to the manufacturer’s description 
(Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Paired student t-tests were performed to compare the means two samples. One-way analysis of 
variance (ANOVA) was performed to compare the means of three or more samples followed by 
Dunnett’s or Bonferroni’s multiple comparison post test to compare samples of interest with a 
control sample as described in the figure legends. Error bars represent the standard error of the 
mean. A P-value of <0.05 was considered statistically significant. All statistical analyses were 
performed using Graphpad Prism version 5.04 (La Jolla, CA, USA).
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ReSulTS
M1-like macrophages inhibit osteosarcoma cell growth if activated with LPS+IFN-γ 
The potential of human macrophages to inhibit osteosarcoma cell growth in vitro was investigated. 
M1-like and M2-like macrophages were differentiated from blood monocytes with or without 
the polarization stimuli LPS+IFN-γ (for M1 and M2) or IL-10 (for M2) as previously established 
[8, 24, 26]. The various macrophage subtypes were co-cultured with osteosarcoma cell lines and 
after two days the residual number of viable tumor cells was assessed by flow cytometry [13, 25]. 
In particular M1-like macrophages pre-stimulated with LPS+IFN-γ were able to significantly 
reduce tumor cell numbers of HOS-143b and OHS cells to as low as 50% as well as of four 
other osteosarcoma cell lines (Figure 1, panel A-C). This inhibition of tumor cell growth as a 
consequence of macrophage addition was not yet apparent after 2 and 24 hours of co-culture 
but became pronounced after two days of co-culture (Figure 1, panel D). M2-like macrophages 
stimulated with LPS+IFN-γ showed less anti-tumor activity than LPS+IFN-γ–stimulated 
Figure 1: Inhibition of osteosarcoma cell growth by LPS+IFN-γ–activated M1-like macrophages
Human M1-like macrophages (dark shade) and M2-like macrophages (light shade) were pre-activated with or without 
LPS+IFN-γ (M1 and M2) or IL-10 (M2) and afterwards incubated with (A) HOS-143b cells (n= 4–11) and (B) OHS 
cells (n= 5–12) and (C) four other osteosarcoma cell lines (n= 2–12). After two days of co-culture, tumor cell numbers 
were counted by flow cytometry. Differences between one macrophage–tumor co-culture and the control, i.e. tumor 
cell recovery after incubation in the absence of macrophages (white bar, set to 100%), as in panel C were statistically 
analyzed by paired student t-tests, *** is P<0.001, ** is P<0.01, * is P<0.05, ns is not statistical significant. Differences 
between multiple groups as in panel A and B were statistically analyzed by ANOVA as indicated followed by Dunnett’s 
post test for differences (p<0.05) between individual co-cultures and the control as indicated by asterisks. (D) HOS-143b 
cell counts after 2, 24 and 48 hours co-culture with M1-like macrophages +/- LPS+IFN-γ (n=5). All data are means of 
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M1-like macrophages, while IL-10–polarized M2-like macrophages were not able to inhibit 
tumor cell growth (Figure 1, panel A and B). Incubation of tumor cells with LPS+IFN-γ alone 
had no inhibiting effect (data not shown).
Induction of anti-tumor activity by M1-like macrophages after stimulation with LPS+IFN-γ 
was associated with a more activated phenotype as indicated by the up-regulation of CD86 
and HLA-DR expression (Figure 2). In contrast to M1-like macrophages, M2-like macrophages 
expressed CD163, a marker frequently described for tumor-associated M2-like macrophages. 
LPS+IFN-γ–stimulated M2-like macrophages showed phenotypic similarities to LPS+IFN-γ–
stimulated M1-like macrophages, exhibiting reduced levels of CD163 and increased levels of 
CD86 and HLA-DR expression. Notably, in particular when stimulated with IL-10, M2-like 
macrophages displayed high levels of FcγRII (CD32) in addition to FcγRI (CD64) and FcγRIIIa 
(CD16), suggesting that IL-10–polarized M2-like macrophages could exert antibody-dependent 
functions as described below. 
Overall, of the different macrophage populations tested, LPS+IFN-γ–activated M1-like 
macrophages, resembling ‘classically-activated’ M1-like macrophages [6-8], were the most 























CD16 CD32 CD64 CD86 CD163 HLA-DR
2.0 13.0 6.8 8.3 2.2 16.1
1.1 10.2 4.2 36.3 1.9 24.2
2.4 25.7 2.0 3.5 6.2 28.7
1.2 17.4 2.0 13.6 2.9 54.7
4.7 40.2 3.5 2.1 7.1 15.0
Figure 2: Phenotypes of M1-like and M2-like macrophages
Surface expression of Fcγ receptors (CD16, CD32 and CD64), HLA-DR, CD86 and CD163 on the various M1-like 
and M2-like macrophage populations was analyzed by flow cytometry. Fold change of geoMFI of specific antibody 
stainings (bold solid line) compared to PBS control (light shade) is indicated in the FACS histogram plots. Representative 
data of three experiments are depicted.
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liposomal muramyl tripeptide only induces anti-tumor activity of M1-like macrophages 
in the presence of IfN-γ
In clinical applications, infusion of macrophage-activating bacterial products can cause severe, 
detrimental toxic reactions. This can be circumvented by incorporation of very lipophilic, 
synthetic MTP-PE into liposomes (L-MTP-PE), which results in rapid uptake by myeloid cells 
and low toxicity [19]. In spite of the inclusion of L-MTP-PE in clinical trials of osteosarcoma 
patients, direct evidence of L-MTP-PE to induce anti-tumor activity by human macrophages 
against human osteosarcoma cells is lacking. Therefore, it was investigated whether M1-like 
macrophages can be activated by L-MTP-PE to reduce tumor cell growth. Remarkably, only if 
co-stimulated with IFN-γ, L-MTP-PE–stimulated M1-like macrophages significantly inhibited 
tumor cell growth such as of HOS-143b cells and OHS cells to as low as 45% (Figure 3, panel A and 
B). The inhibition by L -MTP-PE+IFN-γ–stimulated M1-like macrophages was as potent as by 
LPS+IFN-γ–activated M1-like macrophages. In contrast, M1-like macrophages stimulated with 
MTP-PE-loaded liposomes alone, empty liposomes (L-PBS) or empty liposomes in combination 
with IFN-γ failed to inhibit tumor cell growth. Moreover, only if co-stimulated with IFN-γ, 
Figure 3: Anti-tumor activity 
by M1-like macrophages 
stimulated with L-MTP-PE 
requires IFN-γ
M1-like macrophages were 
stimulated with LPS+IFN-γ, 
L-MTP-PE+IFN-γ, L-MTP-
PE alone, L-PBS+IFN-γ or 
L-PBS alone. Macrophages 
were incubated with (A) HOS-
143b (n= 3–5) and (B) OHS 
(n= 2–4) tumor cells. After 
two-day co-culture,  tumor 
cell numbers were assessed and 
statistically analyzed relative to 
the control by ANOVA and 
Dunnett’s post test as indicated. 
(C) Surface expression of Fcγ 
receptors (CD64, CD32 and 
CD16), HLA-DR and CD86 
was analyzed on M1-like 
macrophages after activation 
with LPS+IFN-γ, L-MTP-
PE+IFN-γ, L-MTP-PE alone, 
L-PBS+IFN-γ or L-PBS alone. 
Representative data of two 
experiments are depicted. 
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L-MTP-PE–stimulated M1-like macrophages exhibited an activated phenotype by CD86 and 
HLA-DR up-regulation similar to LPS+IFN-γ–activated M1-like macrophages (Figure 3, panel 
C). In conclusion, L-MTP-PE stimulation induced substantial anti-tumor activity of M1-like 
macrophages but only after co-stimulation with the pro-inflammatory cytokine IFN-γ. 
Soluble factors produced by M1-like macrophages after LPS+IFN-γ and L MTP PE+IFN-γ 
activation inhibit tumor cell growth
Next, the mechanisms involved in the strong anti-tumor effect of LPS+IFN-γ–activated 
and L-MTP-PE+IFN-γ–activated M1-like macrophages were investigated. Incubation of 
osteosarcoma cells in medium with cell-free supernatant of activated M1-like macrophages 
reduced tumor cell growth to similar levels as activated M1-like macrophages themselves (Figure 
4, panel A). In contrast, supernatant from non-activated M1-like macrophages did not reduce 
tumor cell growth. Thus, both LPS+IFN-γ–activated and L-MTP-PE+IFN-γ–activated M1-like 
macrophages produced soluble factors that inhibited osteosarcoma cell growth. Therefore we 
measured the levels of soluble factors produced by activated macrophages alone and after two-day 
co-culture with the tumor cells. Activation of M1-like macrophages with LPS+IFN-γ enhanced 
the production of the pro-inflammatory cytokines IL-1β, IL-6, IL-12p70, TNF-α, CXCL10 
(IP-10) and CCL5 (Rantes), while CCL2 (MCP-1), CCL3 (MIP-1α) and CCL4 (MIP-1β) 
remained unchanged (Figure 4, panel B). L-MTP-PE+IFN-γ–activated M1-like macrophages 
displayed a similar cytokine profile except for lower levels of IL-12p70. 
Since TNF-α was reported to be able to confer anti-tumor effects [27] and was also produced by 
both LPS+IFN-α–activated and L-MTP-PE+IFN-α–activated M1-like macrophages during the 
co-culture (Figure 4, panel C), a role for TNF-α in the inhibition of osteosarcoma cell growth 
was examined. Blocking of TNF-α during the co-culture of macrophages and tumor cells by the 
soluble TNF receptor etanercept combined with the TNF-α neutralizing antibody adalimumab 
did not prevent the inhibiting effects of LPS+IFN-γ–activated M1-like macrophages or 
supernatants derived from these macrophages (Figure 4, panel D and data not shown). Blocking 
of TNF-α did also not prevent the inhibiting effects of L-MTP-PE+IFN-γ–activated M1-
like macrophages (data not shown). Moreover, blocking of IL-1 receptor, combined blocking 
of TNF-α and IL-1 receptor, or inhibition of nitric oxide and reactive oxygen species did not 
significantly interfere with the inhibition of tumor cell growth by activated macrophages (Figure 
4, panel D). None of the tested inhibitors affected tumor cell growth as compared to tumor cells 
incubated in the absence of inhibitors.
These results indicate that the inhibition of osteosarcoma cell growth by activated M1-like 
macrophages was mediated by soluble factors induced by macrophage activation in a TNF-α/
IL-1–independent manner.  
Il-10–stimulated M2-like macrophages can inhibit growth of osteosarcoma cells in an 
antibody-dependent manner
Both M1-like and M2-like macrophages have been detected in osteosarcoma lesions [2]. 
Hitherto, IL-10–stimulated M2-like macrophages were unable to inhibit osteosarcoma cell 
growth. In a previous study it has been shown that IL-10-polarized M2-like macrophages 
internalized antibody-coated B cell lymphoma cells [26]. Since IL-10–stimulated M2-like 
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Figure 4: Tumor cell growth inhibition by activated M1-like macrophages is mediated by soluble factors
(A) HOS-143b cells were incubated with M1-like macrophages (pre-activated +/- LPS+IFN-γ or L-MTP-PE+IFN-γ) 
(no pattern) or with cell culture supernatant from these macrophages (hatched pattern) for two days and tumor cell 
numbers were analyzed relative to the control by ANOVA and Dunnett’s post test as indicated (n= 3–8). (B)  The 
cytokine and chemokine profile of M1-like macrophages was assessed in cell-free supernatants obtained after macrophage 
activation +/- LPS+IFN-γ or L-MTP-PE+IFN-γ or (C) after two-day co-culture with HOS-143b cells (subsequent to 
macrophage activation and washing). Data of IL-1β, IL6, IL-12p70, TNF-α, CXCL10 (IP-10), CCL2 (MCP-1), CCL3 
(MIP-1α), CCL4 (MIP-1β) and CCL5 (Rantes) were acquired by Luminex assays (n= 2–3). There was no cytokine/
chemokine production by tumor cells alone. Compared to activated macrophages alone the co-culture with tumor 
cells did not enhance cytokine/chemokine production (data not shown). (D) HOS-143b cells were incubated with or 
without LPS+IFN-γ-activated M1-like macrophages in the presence or absence of inhibitors against TNF-α (neutralizing 
antibody and soluble TNF receptor), IL-1 receptor (i.e., IL-1Ra), TNF-α and IL-1 receptor, nitric oxide (i.e., L-NAME) 
or reactive oxygen species (i.e., catalase and SOD). In each set of inhibitor experiments (n= 3–6), HOS-143b cell 
numbers of activated M1-like macrophage co-culture (filled bar without pattern), tumor cells only with inhibitors (white 
bar with hatched pattern) and activated M1-like macrophage co-culture with inhibitors (filled bar with hatched pattern) 
are depicted and analyzed relative to the control (tumor cells only without inhibitors set to 100%, white bar without 
pattern). There was no statistical significant difference between co-cultures without inhibitors and co-cultures with 
inhibitors, or between tumor cells only with inhibitors and co-cultures with inhibitors, whereas differences between 
tumor cells only without inhibitors and co-cultures with/without inhibitors were statistical significant (P<0.05) as 
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macrophages exhibited the highest expression of FcγR in our experiments, we investigated 
whether these macrophages are able to form cell conjugates with and internalize osteosarcoma 
cells in an antibody-dependent manner as a potential anti-tumor mechanism. After two-hour co-
culture of IL-10–stimulated M2-like macrophages and CFSE-labeled HOS-143b cells, CD32+ 
M2-like macrophages acquiring the fluorescent signal of HOS-143b cells were analyzed by 
flow cytometry, as similarly described before [26, 28]. If HOS-143b cells were coated with the 
anti-EGFR antibody cetuximab, the percentage of CD32+CFSE+ macrophages was increased, 
indicative for cell conjugate formation between macrophages and tumor cells (Figure 5, panel A). 
Furthermore, FACS-sorted CD32+CFSE+ macrophages (upper right quadrant) were analyzed 
by immunofluorescence microscopy and contained tumor cells bound to macrophages as well as 

































































































Figure 5: Antibody-dependent tumor cell growth inhibition by IL-10–polarized M2-like macrophages
(A) CFSE-labeled HOS-143b cells coated with anti-EGFR cetuximab or non-binding anti-CD20 rituximab were 
incubated with IL-10–stimulated M2-like macrophages for two hours. Cell conjugate formation was evaluated by flow 
cytometry, assessing CD32+ macrophages acquiring high CFSE fluorescence of the tumor cells. Representative data of 
two experiments are depicted. (B) In one experiment, CD32+CFSE+ cells (upper right quadrant in lower panel A) were 
sorted by flow cytometry and examined by Immunofluorescence microscopy, detecting HLA-DR-stained macrophages 
in red (lower left), CFSE+ tumor cells in green (lower right) and DAPI-stained cell nuclei in blue (upper right) and 
composites (upper left). (C) HOS-143b (n= 4–7) and (D) OHS (n= 5–8) cells were coated with cetuximab (hatched 
pattern) or rituximab (control, no pattern) and incubated with M2-like macrophages pre-stimulated with or without 
IL-10. After two days tumor cell numbers were analyzed by ANOVA and Dunnett’s post test.
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Next, it was examined whether the antibody-dependent interaction between tumor cells and 
macrophages can result in inhibition of tumor cell growth. Indeed, IL-10–stimulated M2-like 
macrophages substantially inhibited growth of half of the osteosarcoma cell lines (3/6) such as 
HOS-143b to as low as 50% if coated with cetuximab (Figure 5 panel C and data not shown). 
There was not such an inhibiting effect when HOS-143b cells were treated with the isotype-
matched, non-tumor-binding anti-CD20 antibody rituximab. In contrast, IL-10–stimulated 
M2-like macrophages failed to inhibit cell growth of (or form cell conjugates with) cetuximab-
coated OHS cells despite high levels of EGFR expression [29], indicating that additional cell 
characteristics play a role in determining the sensitivity to antibody-dependent anti-tumor 
activity (Figure 5, panel D and data not shown). In the absence of macrophages, there was no 
inhibitory effect by cetuximab on osteosarcoma cells (Figure 5, panel C and D) [29]. Inhibition 
of tumor cell growth by LPS+IFN-γ–stimulated M1-like macrophages was not further increased 
by cetuximab (data not shown). 
Hence, IL-10–stimulated M2-like macrophages have the potential to inhibit osteosarcoma 
cell growth in an antibody-dependent manner with similar efficacy as antibody-independent 
inhibition by activated M1-like macrophages.  
DISCuSSIoN
In this report, we describe for the first time that human macrophages can interfere with the growth 
of human osteosarcoma cells. Significant induction of anti-tumor activity of human M1-like 
macrophages by liposomal muramyl tripeptide required co-stimulation with pro-inflammatory 
IFN-γ. Inhibition of osteosarcoma cell growth by activated M1-like macrophages was mediated 
by soluble factors which were induced upon macrophage activation before interaction with 
tumor cells. In addition, we report that IL-10–polarized M2-like macrophages could exert anti-
tumor activity against some osteosarcoma cell lines in an antibody-dependent manner. 
More than 100 years ago it has been observed by Busch, Fehleisen, Bruns and others that 
bacterial infections can result in tumor regression accompanied by febrile inflammatory responses 
which presumably mediated the anti-tumor effects [30, 31]. These findings pioneered the first 
extensive immunotherapy of bone sarcoma patients by Coley, administering heat-inactivated 
bacterial preparations with considerable but disputed remission rates. The anti-tumor effect was 
probably, at least in part, linked to the pro-inflammatory response of innate immune cells such as 
macrophages to bacterial constituents like LPS [31, 32]. Another bacterial cell wall component, 
muramyl dipeptdide (MDP) has originally been discovered as the minimal (synthetically-
derived) moiety of peptidoglycan which can substitute for mycobacteria in Freund’s complete 
adjuvant [33]. MTP-PE is a lipophilic, synthetic derivate of MDP which has low toxicity and 
enhanced macrophage-activating properties if incorporated in liposomes (L-MTP-PE) [19]. To 
mimic bacterial infections and trigger macrophage activation, L-MTP-PE has been included 
in the treatment of osteosarcoma patients [1]. Our observation that the anti-tumor effect of 
L-MTP-PE–stimulated macrophages was dependent on IFN-γ is noteworthy in this respect. 
IFN-γ was originally described as macrophage-activating factor [34]. ‘Priming’ of macrophages 
by IFN-γ may enhance liposome uptake and improve the response to bacterial components by, 




35-37]. The significance of IFN-γ observed in our experiments reproduces previous studies using 
different tumor cells which showed that activation of human/murine monocytes/macrophages 
by L-MTP-PE was enhanced by simultaneous or preceding stimulation with IFN-γ [15, 19, 36]. 
Furthermore, addition of IFN-γ to L-MTP-PE was reported to improve survival and inhibit 
metastases in murine renal adenocarcinoma [38]. Altogether, the clinical efficacy of L-MTP-PE 
addition in the treatment of osteosarcoma patients may be improved by the inclusion of a 
macrophage-priming signal like IFN-γ. 
This raises the question how such a macrophage-priming factor could be safely introduced in 
the osteosarcoma microenvironment. IFN-γ levels could be increased by local or systemic IFN-γ 
therapy as applied in patients with cancers or mycobacterial infections [39, 40]. To target the 
same macrophages with IFN-γ as with L-MTP-PE, IFN-γ could be incorporated in MTP-PE–
containing liposomes which are then both efficiently internalized by phagocytic cells such as 
tumor-resident or tumor-infiltrating macrophages. This approach is supported by murine 
studies in which the incorporation of IFN-γ into MTP-PE–containing liposomes enhanced 
the tumoricidal activity of macrophages as compared to liposomal MTP-PE alone [19, 41]. 
Alternatively, lymphocytes such as NK cells activated to secrete IFN-γ and recruited to tumor 
sites might enhance local IFN-γ production [42].
In our experiments, bacterial and pro-inflammatory stimuli induced the strongest inhibition 
of tumor cell growth by M1-like macrophages. Therefore, such macrophage-activating 
therapies may primarily be effective in tumor types that contain M1-like macrophages [12, 
13]. Most tumors contain high numbers of potentially ‘pro-tumor’ immune regulatory M2-
like macrophages. Therefore, several studies have considered depleting macrophage numbers 
or inhibiting macrophage recruitment to the tumor [9, 43, 44]. Instead, in our experiments, 
IL-10–polarized M2-like macrophages could be induced to inhibit osteosarcoma cell growth 
if the tumor cells were coated with the therapeutic anti-EGFR antibody cetuximab. Antibody-
dependent cell conjugate formation and inhibition of tumor cell growth were only observed 
for half of the osteosarcoma cell lines despite significant EGFR expression [29]. Hence, to 
improve antibody-dependent anti-tumor activity by M2-like macrophages, it would be required 
to elucidate additional parameters besides surface antigen expression that determine inhibition 
of tumor cell growth by macrophages. The potential of antibody-dependent anti-tumor activity 
by macrophages has been shown to mediate anti-tumor responses in murine lymphoma models 
[45, 46]. In humans, the addition of rituximab therapy to patients with follicular lymphoma can 
counteract the non-favorable prognostic factor of high macrophage counts in the tumor [47]. 
We have previously demonstrated that the cytotoxic activity of NK cells can be enhanced and 
directed to osteosarcoma cells by anti-EGFR cetuximab [29]. Since macrophages abundantly 
infiltrate osteosarcoma lesions, antibody-dependent inhibition of osteosarcoma cell growth by 
macrophages may be an additional anti-tumor mechanism of cetuximab.   
The recent finding that anti-CD40 therapy can induce anti-tumor activity in mice and humans 
independently of T cells but presumably via activating macrophages has revived the role of 
macrophages in anti-tumor responses [48]. Overall, activation of macrophages by e.g. L-MTP-PE 
in the presence of IFN-γ, and/or treatment with tumor-reactive antibodies may in particular be 
advantageous in tumors like osteosarcoma that have a high content of infiltrating macrophages.
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Osteosarcoma is the most frequent bone cancer in children and young adults. The outcome 
of patients with advanced disease is dismal. Exploitation of tumor–immune cell interactions 
may provide novel therapeutic approaches. CD70–CD27 interactions are important for the 
regulation of adaptive immunity. CD70 expression has been reported in some solid cancers and 
implicated in tumor escape from immunosurveillance. In this study, expression of CD70 and 
CD27 was analyzed in osteosarcoma cell lines and tumor specimens. 
CD70 protein was expressed on most osteosarcoma cell lines (5/7) and patient-derived primary 
osteosarcoma cultures (4/6) as measured by flow cytometry. In contrast, CD70 was detected 
on few Ewing sarcoma cell lines (5/15) and was virtually absent from neuroblastoma (1/7) 
and rhabdomyosarcoma cell lines (0/5). CD70+ primary cultures were derived from CD70+ 
osteosarcoma lesions. CD70 expression in osteosarcoma cryosections was heterogeneous, 
restricted to tumor cells and not attributed to infiltrating CD3+ T cells as assessed by 
immunohistochemistry/immunofluorescence. CD70 was detected in primary (1/5) but also 
recurrent (2/4) and metastatic (1/3) tumors. CD27, the receptor for CD70, was neither detected 
on tumor cells nor on T cells in CD70+ or CD70- tumors, suggesting that CD70 on tumor 
cells is not involved in CD27-dependent tumor–immune cell interactions in osteosarcoma. 
CD70 gene expression in diagnostic biopsies of osteosarcoma patients did not correlate with the 
occurrence of metastasis and survival (n=70). 
Our data illustrate that CD70 is expressed in a subset of osteosarcoma patients. In patients 
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INTRoDuCTIoN
Osteosarcoma is the most frequent bone cancer in children and adolescents. Despite intensive 
chemotherapy, patients with recurrent, metastatic and chemotherapy-refractory osteosarcoma 
have a poor prognosis [1]. Osteosarcoma is frequently infiltrated by immune cells such as 
macrophages and T cells [2–4]. Insight in tumor–immune cell interactions may be instrumental 
to develop novel treatment approaches like targeted immunotherapy. Aside from its role in 
adaptive immunity, CD70 is expressed on certain solid tumors and reported to be involved in 
tumor cell escape from immunosurveillance [5]. 
CD70 is the natural ligand for the tumor necrosis factor (TNF) superfamily member CD27 and 
has originally been described as a co-stimulatory molecule for B cell and T cell activation [5,6]. 
Expression of CD70 in non-malignant tissue is primarily confined to cells of the hematopoietic 
system, yet mostly transient and tightly regulated [6–9]. CD70 is absent from human and 
murine naïve T cells, immature B cells and Natural Killer (NK) cells, but induced by T cell and 
B cell receptor triggering, B cell transformation or NK cell activation by interleukin-15 (IL-15) 
[10–14]. While absent from immature dendritic cells and neutrophils [13], CD70 expression 
can be induced on myeloid and plasmacytoid dendritic cells as well as Langerhans cells by e.g. 
toll-like receptor ligands in combination with CD40 ligation [9,15–17]. Constitutive CD70 
expression has only been described on a population of antigen-presenting cells in the gut [18]. 
Interaction of CD70 with its receptor CD27 has originally been demonstrated to enhance the 
expansion, interferon-γ (IFN-γ) and IL-2 production and alloreactive cytotoxicity of T cells 
[11,12,19–21]. In addition, CD70 promotes survival of T cells responding to low-affinity or 
low-dose antigens [22,23]. 
Accordingly, CD27 is expressed on naïve and central memory CD4 and CD8 T cells as well 
as on thymocytes [5,21,24]. In addition, CD27 is expressed on mature B cells and CD70–
CD27 signaling results in B cell expansion, differentiation into plasma cells and IgG synthesis 
[6,10,17,25,26]. In innate immunity, CD70–CD27 interactions induce proliferation and 
IFN-γ production (but not direct cytotoxicity) of human and murine NK cells in vitro and 
have been shown to mediate NK cell-dependent tumor rejection in mice [27–29]. CD27 is 
expressed on nearly all murine NK cells [27]. On human NK cells, CD27 is acquired during 
maturation in lymphoid organs but down-regulated in terminal maturation stages as for effector 
memory CD45RA+ T cells and plasma cells [24,25,30]. In peripheral blood, CD27+ NK cells 
are functionally closely related to CD56bright NK cells [14].
In addition to its function and transient expression limited to innate and adaptive immune cells, 
abundant CD70 expression has been documented in B cell malignancies, chronic myelogenous 
leukemic stem and progenitor cells, and renal cell carcinoma [7,31–33]. Hence, CD70–CD27 
interactions may possess additional functions in cancer cells such as triggering tumor progression 
or escape from immunosurveillance [34,35]. In addition, CD70 on cancer cells is an attractive 
candidate for targeted immunotherapy due to its restricted expression on non-malignant cells.
In this study, we sought to determine the expression of CD70 and CD27 in osteosarcoma as well 






Tumor samples derived from biopsies (obtained at the time of diagnosis, pre-chemotherapy) 
and resections of primary, local recurrent and metastatic tumors (all post-chemotherapy) from 
ten high-grade osteosarcoma patients were freshly frozen in 2-methylbutane at the Department 
of Pathology, Leiden University Medical Center. From five of these patients, six primary 
osteosarcoma cell cultures were generated from the tumor material as previously described 
[36,37]. An overview of tumor samples and primary cultures as well as clinicopathological details 
of osteosarcoma patients is summarized in Table 1. Tumor specimens were obtained and analyzed 
according to the ethical guidelines of the national organization of scientific societies (FEDERA, 
http://www.federa.org/gedragscodes-codes-conduct-en). CD70 gene expression was analyzed 
from a genome-wide gene profiling data base consisting of diagnostic biopsies of 83 high-grade 
osteosarcoma patients as previously published [2] (accessible online at http://hgserver1.amc.nl/
cgi-bin/r2/main.cgi). 
Cell lines
Established osteosarcoma cell lines HOS, HOS-143b, OHS, OSA (SJSA-1), SAOS-2, U2OS, 
ZK-58 and Ewing sarcoma cell lines A673, CADO-ES, ET10, EW3, RD-ES, SK-ES-1, 
SK-N-MC, STA-ET1, STA-ET2.1, TC32, TC71, VH64 and WE68 were obtained from the 
EuroBoNeT cell line repository [38]. The Ewing sarcoma cell line IOR/BER was kindly provided 
by K. Scotlandi (Rizzoli Orthopaedic Institute, Bologna, Italy), L1062 was derived as previously 
described [37] and TC32 was obtained from the American Type Culture Collection (ATCC; 
Manassas, VA, USA).  TC71 cells were cultured in IMDM medium (Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% heat-inactivated fetal calf serum (FSC), 100 U/ml penicillin and 
100 ug/ml streptomycin (P&S) (all Invitrogen). All other osteosarcoma and Ewing sarcoma cell 
lines as well as the EBV-transformed B-LCL cell line 107 (established in our laboratory) were 
cultured in RPMI-1640 medium (Invitrogen) supplemented with FCS and P&S. Ewing sarcoma 
cell lines were grown in 0.1% gelatin coated tissue culture flasks. The neuroblastoma cell lines 
SJNB8, SKNFI, SKNBE, IMR32 (obtained from ATCC) were cultured in DMEM Glutamax I 
medium (high glucose) supplemented with FCS, P&S and 1% MEM-non-essential amino acids 
(Invitrogen); UKF NBL1 and UKF NBL4 (kindly provided by U. Koehl, Medical University 
of Hannover, Germany) in IMDM medium with FCS and P&S; and CHP126 (obtained from 
ATCC) in RPMI medium with FCS and P&S. The rhabdomyosarcoma cell lines RD (obtained 
from ATCC) and A204, TE671, RH30 and RH41 (obtained from DSMZ, Braunschweig, 
Germany) were cultured in DMEM medium with the above indicated supplements). All cell 
lines were negative for mycoplasma infection. 
CD70 protein expression by flow cytometry
The following mouse anti-human monoclonal antibodies and mouse isotype control antibodies 
were used: CD70PE (Ki-24) (BD Biosciences, Franklin Lakes, NJ, USA) (this antibody produced 
comparable results to 2F2); CD70 2F2 (0.2 µg/ml; kindly provided by R.A.W. van Lier) and 
IgG1 (0.2 µg/ml; R&D Systems, Minneapolis, MN, USA) followed by the goat-anti mouse 
IgAPC secondary antibody (BD Biosciences). FACS measurements were performed with the 
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FACSCalibur (BD Biosciences) and analyzed with the “BD Cell Quest ProTM” software (version 
5.2.1). Indicated fold expression data are the ratio between the geometric mean fluorescence 
intensity (geoMFI) of CD70 2F2 and the geoMFI of the isotype control. 
CD70 gene expression
CD70 gene expression was analyzed from genome-wide gene profiling data of osteosarcoma cell 
lines and patient’s tumor specimens as previously published [2].
Immunohistochemistry (IhC) and Immunofluorescence (If) 
Sections of 4 µm of representative tumor cryosections of resection specimens (Table 1) and of B 
cell lymphoma control tissue were fixed in acetone at -20°C for 10 min (for IHC: supplemented 
with 0.3% hydrogen peroxide (Sigma-Aldrich, St. Louis, MO, USA) to inactivate endogeneous 
peroxidase), followed by incubation in 10% normal goat serum (Dako, Glostrup, Denmark) in 
PBS buffer to block non-specific antibody binding. 
Immunohistochemical expression of CD70 was assessed using the mouse monoclonal anti-
CD70 2F2 (IgG1, 0.16 µg/ml) antibody followed by a polyclonal goat anti-mouse/rabbit/rat 
IgG HRP-linker antibody conjugate (Brightvision, DPVO-110HRP; Immunologic, Duiven, 
the Netherlands) and DAB+Substrate Chromogen System (Dako) detection. All sections were 
examined with an Olympus BX41 microscope and Cell^B acquisition software (Olympus, 
Tokyo, Japan). 
Immunofluorescent double-staining for CD3 and CD70 or CD3 and CD27 was performed 
with rabbit polyclonal anti-human CD3 (2.4 µg/ml; Dako), CD70 2F2 and mouse monoclonal 
anti-human CD27 137B4 (IgG1, 1:200; Novocastra, Leica Microsystems, Wetzlar, Germany) 
followed by goat anti-rabbit Alexa 488 or goat anti-mouse IgG1 Alexa 546 (1:300; Invitrogen, 
Carlsbad, CA, USA). All sections were examined with a Leica DM5000 fluorescence microscope 
and LAS-AF acquisition program (Leica, Solms, Germany). 
Statistical analysis
Statistical analyses were performed with Graphpad Prism version 5.04 (La Jolla, CA, USA). A 
P-value of <0.05 was considered statistically significant. 
ReSulTS
osteosarcoma cell lines exhibit highest expression of CD70 among pediatric solid 
cancer cell lines 
CD70 membrane protein expression was investigated on established osteosarcoma, Ewing 
sarcoma, neuroblastoma and rhabdomyosarcoma cell lines by flow cytometry. Expression of 
CD70 was detected on five out of seven established osteosarcoma cell lines, on HOS, HOS-143b, 
OSA, SAOS-2 and U2OS cells but not OHS or ZK-58 cells (Figure 1, panel A). The cell line 
OSA exhibited the highest expression of CD70 amongst all cell lines tested which was of similar 
intensity as detected on EBV-transformed B cells (EBV–B-LCL). In addition, four out of six 
primary osteosarcoma cultures derived from five osteosarcoma patients (Table 1) were positive 
for CD70 expression (Figure 1 panel B). 
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Noteworthy, of one patient (patient (p) 404) with cultures from consecutive tumors, the culture 
derived from the local recurrent tumor exhibited equally high CD70 expression as the culture 
derived from the primary tumor of this patient. The level of CD70 expression on the primary 
cultures was similar to the CD70 levels on established osteosarcoma cell lines (Figure 1, panel C). 
In contrast to CD70, its receptor CD27 was not detected on any of the osteosarcoma cell lines 
(data not shown). Moreover, CD70 was detected on few established Ewing sarcoma cell lines 
(5/15) at lower intensities than on osteosarcoma cell lines, while CD70 was hardly detected on 



























































































Figure 1: CD70 protein is abundantly 
expressed on osteosarcoma cells
CD70 protein expression on the surface of 
(A) established osteosarcoma cell lines and 
EBV-transformed B cell lymphoma (EBV-B-
LCL) cells and (B) patient-derived primary 
osteosarcoma cultures (Table 1) was analyzed 
by flow cytometry. Fold change of geoMFI of 
specific antibody stainings (bold solid line) 
compared to geoMFI of isotype control (light 
shade) is indicated in the representative FACS 
histogram plots. (C) CD70 protein expression 
(fold change geoMFI) on the surface of 
established osteosarcoma cell lines and 
patient-derived primary osteosarcoma cultures 
(geometric mean of three experiments), and 
of established Ewing sarcoma (geometric 
mean of two experiments), neuroblastoma 
(one experiment) and rhabdomyosarcoma 
(one experiment) cell lines. In addition to 
the indicated osteosarcoma cell lines, CD70 
expression was detected on the Ewing sarcoma 
cell lines CADO-ES, ET10, STA-ET2.1, 





CD70+ primary osteosarcoma cultures are generated from parental tumors containing 
CD70+ cells 
Since in particular most osteosarcoma cell lines and patient-derived primary osteosarcoma cultures 
exhibited high CD70 protein expression, it was examined whether CD70 was also expressed in 
(corresponding) osteosarcoma tumors. Detection of CD70 by immunohistochemistry in large 
tissue microarrays is hampered by the lack of commercially available anti-CD70 antibodies 
suitable for paraffin-embedded tissue [39]. Instead, CD70 detection in individual frozen 
specimens is feasible as tested and described for large diffuse B cell lymphoma tissue (Figure 2) 
[31]. Therefore, we analyzed and compared CD70 expression in available frozen specimens of 
our collection of parental tumor specimens (n=4) and corresponding primary cultures (Table 1). 
In addition, we compared CD70 expression between recurrent/metastatic lesions and primary 
tumors of the same patients (n=5) (Table 1). 
Overall, CD70 expression tended to be more frequently detected in recurrent (2/4) and 
metastatic (1/3) tumors than in primary osteosarcoma tumors (1/5) (Table 1). CD70 was 
heterogeneously expressed in the tumors in a membranous pattern (Figure 2). Of the tumor-
primary culture combinations, parental tissue of L2531 (p363) exhibited CD70-expressing cells 
in focal regions. The high CD70 intensity of these cells was consistent with the strong CD70 
expression of the corresponding primary culture (Figure 1, panel B). Of L2792 (p369), CD70 











Figure 2: Heterogeneous CD70 
protein expression in osteosarcoma 
lesions
Immunohistochemical CD70 
protein staining in one specimen of 
diffuse large B cell lymphoma and 
four osteosarcoma specimens of 
three osteosarcoma patients (L2531 
of p363; L2792 of p369; L2826 and 
L3312 of p404) (Table 1) Brown-
colored CD70 staining patterns 
and counterstaining with Mayer’s 
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was neither detected in the parental tissue nor on the primary culture. Notably, of the one patient 
(p404) with tissue and primary cultures from consecutive tumors, a majority of cells of the local 
recurrent tumor (L3312) showed strong CD70 expression, whereas only a few cells were weakly 
positive in the primary tumor (L2826). Of this patient, the primary cultures of both tumors were 
strongly positive for CD70. In the residual four patients with combinations of consecutive tumor 
specimens, one metastatic tumor (L437, p47) contained CD70-expressing cells, while there were 
no CD70-expressing cells detectable in the primary tumor (L1046) of the same patient (Table 1). 
Altogether, these results indicate that CD70 protein can be expressed in primary, recurrent and 
metastatic osteosarcoma lesions. CD70 expression was demonstrated on the majority of primary 
cultures and cell lines and only detected on primary cultures if these were derived from a tumor 
specimen containing CD70+ cells, indicating that CD70 expression was not caused by in vitro 
cell culture. Thus, these results suggest that CD70+ cells in the tumor preferentially grow out to 
CD70+ patient-derived cultures.
CD70 expression in osteosarcoma lesions is confined to tumor cells and does not 
influence patient survival
To determine whether CD70 expression on tumor cells would be associated with clinical outcome 
of patients with osteosarcoma, we needed to investigate CD70 expression levels in a large cohort 
of patients with data on follow-up. For this purpose, we wanted to use a public dataset on gene 
(mRNA) expression of a large collection of osteosarcoma biopsies. 
Therefore, it was first investigated whether CD70 mRNA expression correlated with protein 
expression in osteosarcoma cell lines. CD70 protein expression in osteosarcoma cell lines indeed 






























































Figure 3: CD70 gene expression in osteosarcoma lesions does not influence survival
(A) CD70 protein expression (fold change geoMFI) on the surface of established osteosarcoma cell lines, as analyzed by 
flow cytometry (Figure 1), was correlated with relative CD70 gene (mRNA) expression of these cell lines, as analyzed 
by microarray. The regression coefficient (r2) between CD70 protein and CD70 gene expression was 0.87 (P=0.002) 
as calculated by linear regression analysis. (B) CD70 relative gene (mRNA) expression in 83 biopsies of the primary 
tumor of 83 osteosarcoma patients depicted with the median and interquartile range. Elevated CD70 gene expression 
was evaluated as above the upper 25 percentile (16 patients, as indicated by the closed symbols). Asterix: biopsy L1372 
of osteosarcoma patient 88 with high CD70 gene expression and available frozen tissue for immunohistochemical and 
immunofluorescent protein stainings as depicted in Figure 4. (C) Metastasis-free survival of osteosarcoma patients during 
ten years of follow-up comparing survival with high and low CD70 gene expression. Of the 83 patients (n= 16: CD70high 
gene expression and n=67: CD70low gene expression) depicted in panel B, 13 patients with metastasis at time of diagnosis 
were excluded, resulting in the inclusion of 70 patients (n=15: CD70high, and n=55: CD70low) for this analysis. Mantel-




Next, CD70 gene expression was evaluated in diagnostic biopsies of 83 osteosarcoma patients. 
A subset of patients (16/83) showed significantly higher CD70 gene expression (above the 
upper 25 percentile as indicated) (Figure 3, panel B). Of note, high CD70 gene expression 
corresponded to strong CD70 protein staining in the tumor biopsy as assessed for one patient 
(p88) with available frozen tissue (L1372) (Figure 4, panel A; patient (p88) indicated by * in 
Figure 3, panel A). 
To investigate the association of CD70 expression by tumor cells with clinical outcome, we first 
assessed whether CD70 was expressed by tumor cells and not by tumor-infiltrating T cells in this 
biopsy with high CD70 gene/protein expression (L1372, p88), since activated T cells are known 
to express CD70 [13]. Strong immunofluorescent staining for CD70 was confined to tumor cells 
and did not co-localize with the T cell marker CD3 (Figure 4, panel B). In contrast to CD70, 
its receptor CD27 was detected neither in CD70+ nor CD70- osteosarcoma lesions and was not 
expressed by infiltrating T cells (Figure 4, panel C and data not shown). 
Next, it was determined whether higher CD70 gene expression was correlated with the 
occurrence of metastasis, which is the most important parameter for survival of osteosarcoma 
patients. Thirteen patients presenting with metastasis at time of diagnosis were excluded from 
this analysis. In the remaining 70 patients, the occurrence of overt metastasis (metastasis-free 
survival) during ten years of follow-up was not statistically different between patients with high 
or low CD70 gene expression (log-rank χ2=0.29, P=0.59) (Figure 3, panel C). As a reference, 
CD14 gene expression of the same patient cohort was substantially higher, and median CD14 
expression was positively correlated with metastasis-free survival in this specific cohort (log-rank 
χ2=7.48, P=0.006) as we have similarly previously reported (data not shown) [2]. There was no 
association between CD70 gene expression and a specific tumor location or histological subtype 
(data not shown). 






50 μm 50 μm
CD27
CD3
Figure 4: CD70 protein expression in osteosarcoma lesions is expressed on tumor cells and not on tumor-
infiltrating T cells
Immunohistochemical stainings for CD70 and immunofluorescent double stainings for CD70 (red) and CD3 (green) as 
well as CD27 (red) and CD3 (green) (cell nuclei in blue) was assessed in sequential specimens of the osteosarcoma biopsy 
L1372 (p88) with high CD70 gene expression as indicated by the asterix in Figure 3, panel A.
6
119
CD70 expression in osteosarcoma
DISCuSSIoN
We demonstrate that CD70 is expressed on the majority of osteosarcoma cell lines as well as 
patient-derived osteosarcoma cultures which were derived from CD70+ tumor tissue. CD70 
expression in tumor lesions was heterogeneous and restricted to tumor cells and not attributed 
to infiltrating T cells. CD70 gene expression in diagnostic biopsies was significantly higher in 
a subset of osteosarcoma patients but this difference was not correlated with metastasis-free 
survival. 
Among pediatric bone and soft tissue cancers, we found that CD70 is preferentially expressed 
on osteosarcoma cells (9/13). CD70 was detected on few Ewing sarcoma cells (5/15) and was 
virtually absent from neuroblastoma and rhabdomyosarcoma cells, indicating that CD70 
expression is restricted to certain cancer types like renal cell carcinoma and osteosarcoma and 
to a lesser extent brain cancers, larynx or pharynx cancer, melanoma, pancreatic cancer, ovarian 
carcinoma and Ewing sarcoma [7–9,33,34,39–41]. Among the osteosarcoma specimens we 
tested, CD70 expression was heterogeneous between patients as well as within the tumor. In a 
larger cohort of 83 osteosarcoma patients, a subset of tumor biopsies (19%) showed significantly 
higher CD70 gene expression. 
This raises the question whether CD70 exerts a biological function in certain cancer types or 
certain cancer cells. In some tumor-transformed B cells, CD70 (downstream) signaling may 
affect proliferation and apoptosis, [31,34,42]. In spite of this, in most studies, biological effects 
of CD70 have been demonstrated to be mediated by interactions of CD70 with its receptor 
CD27, which can have a dual role in regulating anti-tumor adaptive immune responses. Acute 
challenge with CD70+ tumor cells was shown to induce anti-tumor T cell-mediated immunity 
[29,43]. Similarly, CD70–CD27 interactions promote anti-virus and anti-tumor T cell responses 
[44–47]. On the contrary, co-culture of CD70+ tumor cells and CD27+ immune cells was shown 
to inhibit alloreactive T cell proliferation and induce T cell apoptosis [34,43,48,49]. Similarly, 
continuous CD70–CD27 co-stimulation in CD70-transgenic mice or in mice chronically 
infected with mouse choriomeningitis virus exhausts the naïve T cell pool in favor of effector 
memory T cells that ultimately results in T cell dysfunction unless relieved from the CD70–
CD27 brake [45,50,51]. In line with the latter observations, CD70+ tumor cells in renal cell 
carcinoma and B cell lymphoma may promote depletion of naïve CD27+ T cells and induce 
regulatory T cells in the tumor, respectively [52,53]. 
Hence, during a persistent tumor–immune cell interaction, CD70 expression on tumor cells 
may support tumor escape from immunosurveillance and thus be disadvantageous for patient 
outcome. However, to our knowledge, a significant association of CD70 expression on tumor 
cells with patient survival has not been described in these human tumors [41]. In our cohort 
of osteosarcoma patients, CD70 gene expression at the time of diagnosis did not correlate 
with metastasis-free survival, suggesting that at least in osteosarcoma, CD70 expression does 
not promote tumor progression. Moreover, CD27 was neither detected on tumor cells nor on 
infiltrating T cells in osteosarcoma lesions, suggesting that CD70 on tumor cells is not involved 
in CD27-dependent tumor–immune cell interactions. In spite of the ambiguous role of CD70 
in cancer development and progression, its substantial expression in certain cancers would 




expression of CD70 on immune cells and its virtual absence in normal non-hematopoietic 
tissue, which may limit side-effects of CD70 targeted treatment [7,9,39]. In this perspective, 
chimeric antigen receptor T cells (CD27-CD3ζ) have been reported to kill CD70Ztumor cells 
and mediate tumor regression in mice [54]. Moreover, therapeutic chimeric and humanized 
anti-CD70 antibodies are currently developed. In preclinical studies, anti-CD70 antibodies 
demonstrated indirect anti-tumor efficacy mediated by NK cells and macrophages involving 
antibody-dependent cellular cytotoxicity and tumor cell phagocytosis, respectively, as we have 
similarly recently reported using the clinically-approved anti-epidermal growth factor receptor 
antibody cetuximab [55-58] (this thesis, chapter 3, 4 and 5). In addition, if conjugated to 
cytotoxic drugs anti-CD70 antibodies can mediate direct anti-tumor effects [7,39,59]. Since 
we had no access to chimeric or humanized anti-CD70 antibodies, we could not test direct or 
indirect cytotoxicity against CD70-expressing osteosarcoma cells. Altogether, in osteosarcoma 
patients with CD70-postive tumors, CD70 may constitute an attractive candidate for novel 
targeted immunotherapy. 
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Discussion and Future Directions
Immune cells play a key role in the control of cancer development, referred to as cancer 
immunosurveillance. Cancer cells are rapidly dividing cells with inherent genomic instability 
which enables their potential to produce more or less immunogenic variants. In association with 
the pressure of immunosurveillance, this process favors the selection of cancer cells which are able 
to evade immune responses. Cancer escape is supported by the immunosuppressive milieu of the 
cancer microenvironment, restricting anti-cancer innate and adaptive immune responses [1;2]. 
As documented in this thesis and in addition to T cell-mediated anti-cancer responses, NK cells 
and macrophages have the potential to kill cancer cells and interfere with cancer cell growth, 
respectively. In view of counteracting tumor escape and immunosuppression and optimizing the 
anti-cancer potential of NK cells and macrophages against osteosarcoma and Ewing sarcoma, 
the following points are discussed below. (1) The cytolytic potential of NK cells may need to be 
improved and directed to cancer cells in such a way that it can resist inhibitory influences. (2) 
The anti-cancer potential of macrophages may need to be activated and improved. (3) It would 
be favorable to convert the immunosuppressive cancer microenvironment to a pro-inflammatory, 
immune cell-attracting milieu. 
1. how to enhance and Direct NK cell Cytotoxicity to Cancer Cells and Circumvent 
Immunosuppression?
In chapter 3 it is demonstrated that the cytotoxic activity of NK cells can be effectively enhanced 
and directed to osteosarcoma and Ewing sarcoma cell lines if the cancer cells are coated with a 
therapeutic antibody like cetuximab, targeting the epidermal growth factor receptor (EGFR) 
on the cancer cell surface. In the presence of cetuximab, FcγRIII/CD16–mediated NK cell 
cytotoxicity (ADCC) against autologous osteosarcoma cells was substantially enhanced and as 
effective as by cytokine (IL-15)–activated NK cells. Low EGFR expression levels on the cancer 
cell surface were sufficient to trigger ADCC by NK cells. 
However, despite their susceptibility to NK cell cytotoxicity in short-term NK cell-tumor cell 
interactions (in particular at high NK–tumor cell ratios), bone sarcoma cells may be able to 
inhibit NK cell activation and functionality during prolonged interactions (at low NK–tumor 
cell ratios). In chapter 4 it is illustrated that prolonged physical contact with certain sarcoma 
cell lines can trigger down-regulation of NK cell activating receptors, even in the presence of the 
NK cell activator IL-15. This inhibiting effect resulted in the impairment of NK cell cytolytic 
activity mediated through these receptors, and inhibited lysis of osteosarcoma and Ewing sarcoma 
cells. Notably, NK cells pre-activated with IL-15 for five days prior to sarcoma cell interaction 
were resistant to the immunosuppressive effects of sarcoma cells. Moreover, the FcγRIII/
CD16–mediated antibody-dependent cytotoxic potential of NK cells remained functional after 
prolonged sarcoma cell interactions. The membrane-bound factors expressed by some but not 
all sarcoma cells, conferring selective inhibition of NK cell functionality and leaving ADCC 
intact, remain to be further investigated. This might be achieved by manipulating the expression 
of known/unknown inhibitory genes/proteins using for instance RNA silencing techniques and 
subsequent screening for effects on NK cell function in response to gene-modified target cells. 
The identification of these inhibitory genes and proteins might result in the design of small 





The results of these two chapters imply that NK cell cytotoxicity may need to be (a) enhanced by 
cytokine stimulation prior to cancer cell encounter and/or (b) triggered by therapeutic antibodies 
to circumvent immunosuppressive influences of the cancer microenvironment. 
 (a) Cytokine treatment alone may be insufficient to enhance NK cell function in vivo and 
potentially toxic [3]. NK cells with improved anti-cancer reactivity could be introduced by 
adoptive transfer, as previously demonstrated using ex vivo IL-2–activated, haploidentical NK 
cells in patient with hematological malignancies [4;5]. This approach has not been reported to 
achieve objective responses in patients with solid cancers [3]. In fact, in the case of autologous 
NK cells which are more prone to be inhibited by KIR-ligand interactions, adoptively-transferred 
IL-2–pre-activated NK cells have been shown to lose cytolytic activity in recipients with 
melanoma [6]. Thus, to prolong functional NK cell persistence in the cancer microenvironment, 
NK cells need to be sufficiently pre-activated. It remains to be determined whether this could be 
achieved by IL-15 which rendered NK cells resistant to sarcoma-mediated inhibition in vitro as 
noted above. In this perspective, IL-15 is known to be an important factor for NK cell activation 
and NK cell survival and IL-15–activated NK cells have been shown to mediate tumor ablation 
in murine studies [7;8]. Other studies have recently suggested that functional NK cell persistence 
after adoptive transfer in mice can be further improved by combination of IL-15 with IL12+IL18 
+/- IL-2 [9;10]. 
 (b) Application of cancer-reactive antibodies like cetuximab might sustain NK cell cytotoxicity 
since ADCC remained functional after contact with sarcoma cells. Induction of ADCC has 
recently been proposed to trigger NK cell cytotoxicity in an otherwise immunosuppressive cancer 
microenvironment in melanoma patients [6]. Also, induction of ADCC may improve lysis of 
cancer cell variants poorly sensitive to antibody-independent NK cell cytotoxicity [11]. Notably, 
induction of ADCC by NK cells against sarcoma cells increased the activation status of NK cells, 
which may mobilize and improve NK cell functionality in vivo as suggested in previous studies 
[12-14]. Furthermore, NK cell activation by cetuximab-coated cancer cells can induce IFN-γ 
production which has been shown to stimulate dendritic cell maturation and priming of tumor 
antigen-restricted (EGFR and MAGE-3) CD8 T cell responses in vitro, associated with EGFR-
specific CD8 T cell expansion after cetuximab therapy in patients with head-neck cancer [15]. 
Thus, in response to antibody therapy, NK cells not only have the potential to directly kill cancer 
cells but may also contribute to the generation of systemic anti-cancer Th1 responses which 
could potentially be directed against a broad repertoire of naturally-selected cancer antigens. 
As compared to T cells, NK cells have limited capacity for proliferation and survival, restricting 
eradication of large tumors by NK cells. Thus, the contribution of NK cells in the initiation of 
potent anti-cancer adaptive immunity may be critical for tumor control and the clinical success 
of antibody therapy as recently highlighted in preclinical studies [16-18]. 
In chapter 6 it is documented that the immunoregulatory protein CD70 is expressed on 
some (primary) osteosarcoma cell lines and in (corresponding) tumor lesions of osteosarcoma 
patients. CD27, the receptor for CD70, was not detected on cancer cells or infiltrating T cells in 
osteosarcoma lesions, suggesting that CD70-CD27 interactions are not involved in interactions 
between CD70+ tumor cells and CD27+ immune cells in osteosarcoma. Overall, since CD70 
expression on normal cells is very restricted and transient, molecules like CD70 may act as 
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additional but more specific target antigens for direct or indirect immunotherapeutic approaches, 
for instance via anti-CD70 antibodies, with a reduced risk for off-target adverse effects.
2. how to Improve Anti-Cancer Activity of Macrophages? 
Macrophages frequently infiltrate solid cancers, and in osteosarcoma macrophage infiltration is 
correlated with favorable patient outcome [19], suggesting anti-cancer activity of macrophages 
in osteosarcoma. In chapter 5 it is demonstrated that M1 macrophages are able to inhibit 
osteosarcoma cell growth if activated with a bacterial stimulus like liposomal muramyl tripeptide 
(L-MTP-PE). Importantly, induction of anti-cancer activity by L-MTP-PE required the presence 
of IFN-γ, a notion which is relevant for improving the outcome of currently applied L-MTP-
PE therapy in osteosarcoma patients [20]. In addition, it is described that IL-10–polarized M2 
macrophages, which are considered to support cancer development, have the capacity to inhibit 
growth of some osteosarcoma cells if directed to antibody (cetuximab)-coated cancer cells. 
Thus, different types of macrophages, which are already present in osteosarcoma lesions, can be 
manipulated to exert anti-cancer responses if activated through factors reminiscent of an acute 
infection in the cancer microenvironment and/or in combination with therapeutic antibodies. 
It is noteworthy that the critical macrophage-priming stimulus IFN-γ could be provided by NK 
cells, since it has been shown that NK cells can produce significant IFN-γ amounts in response 
to cytokine activation and presumably also in response to therapeutic antibodies [9;15]. Hence, 
antibody therapy can mobilize multiple (innate) immune cells such as NK cells and macrophages 
which may cooperate in anti-cancer responses. 
3. how to Disrupt Immunosuppression and Improve Tumor-Infiltration by NK cells? 
To harness the cytotoxic potential of NK cells for immunotherapy, NK cell functionality needs to 
be modulated to withstand inhibitory influences of the cancer microenvironment. Alternatively, 
the immunosuppressive character of the cancer microenvironment needs to be abolished. An 
acute infection or infection-mimicking immunostimulators may facilitate the conversion of an 
immunosuppressive cancer microenvironment to a more pro-inflammatory milieu that supports 
recruitment and anti-cancer activity of immune cells [21;22]. In chapter 2 it is described that 
NK cells can become activated in response to an adenoviral infection, in particular adenovirus 
type 35. Phenotypic and functional activation of NK cells was reciprocally mediated by toll-
like receptor 9–dependent IFN-α production by plasmacytoid dendritic cells upon adenovirus 
exposure. Thus infections or constituents of infectious agents may not only induce anti-cancer 
activity of macrophages (chapter 5) but also rescue and enhance NK cell activation in interplay 
with other (innate) immune cells. Oncolytic viruses selectively infect and kill cancer cells, 
especially when shielded from neutralizing antibodies and delivered by tumor-homing cells; 
this can trigger recruitment and activation of NK cells and other immune cells, inducing anti-
cancer (but also non-tumor–directed anti-virus) innate and adaptive immune responses with the 
potential for objective responses in patients [23-29]. Thus, establishing an infection in the cancer 
microenvironment by oncolytic viruses which are able to infect and kill bone sarcoma cells may 
facilitate tumor elimination, increase the immunogenicity of the cancer microenvironment and 
enable cancer immunosurveillance. Finally, if able to resist inhibition, NK cell cytotoxicity itself 




For the success of NK cell-based immunotherapy it will be necessary that NK cells can migrate 
to and accumulate in the cancer microenvironment. However, since NK cell infiltration in solid 
cancers including osteosarcoma is generally poor [30-34] (and unpublished observation), future 
studies need to address how the infiltration of NK cells into the cancer microenvironment can 
be improved. Oncolytic viruses could be modified to over-express chemokines such as CCL5, 
CX3CL1, and CXCR3 ligands, which have been shown to regulate tumor infiltration and anti-
cancer responses of NK cells in murine studies [35-37]. In particular, chemerin has recently 
been reported to be down-regulated in several human solid cancers in association with dismal 
prognosis, while over-expression of chemerin in murine tumors can improve NK cell infiltration 
and NK cell-dependent tumor ablation [38]. Moreover, it has been shown that antibody-based 
immunotherapy in patients with breast cancer (trastuzumab) and B cell malignancies (rituximab) 
and tyrosine kinase inhibitor-based immunotherapy in patients with gastrointestinal stromal 
tumors can mediate mobilization and tumor infiltration of NK cells in vivo [13;32;39]. In 
murine studies it has recently been demonstrated that novel anti-EGFR antibodies can induce 
tumor-infiltration of NK cells (and macrophages) with superior efficacy than cetuximab [40]. 
4. future Directions
To better understand the biological relevance of NK cells and ADCC for anti-tumor effects in 
response to antibody (e.g., cetuximab) therapy, the effect of NK cell depletion (and adoptive 
transfer) may be elucidated in combination with analysis of the activation status of tumor-
infiltrating and peripheral NK cells as well as NK cell accumulation in (metastatic) tumor lesions. 
For these purposes murine xenograft or syngeneic mesenchymal stem cell–induced osteosarcoma 
models, the latter more closely resembling human osteosarcoma [41], could be employed. These 
models may allow to explore the effect of an established (immunosuppressive), bone-associated 
cancer microenvironment, as encountered by NK cells in patients, on NK cell functionality and 
the ability of NK cells to eliminate large solid tumor masses as compared to treatment-ablated 
minimal tumor numbers (minimal residual disease). 
In addition, a contribution of macrophages to tumor elimination in response to antibody therapy 
and/or activation by L-MTP-PE (+/- IFN-γ) could be clarified in these osteosarcoma models. It 
may be investigated whether these activating stimuli can influence macrophage polarization and 
macrophage recruitment to the tumor. In future clinical studies, it could be determined whether 
treatment with L-MTP-PE results in more pronounced clinical responses in osteosarcoma 
patients with higher macrophage infiltration in tumor lesions. It should be addressed whether 
L-MTP-PE therapy can be improved by the presence of endogenously-induced or exogenously-
delivered IFN-γ (e.g., by integration in MTP-PE–containing liposomes) and how this treatment 
affects the phenotype and infiltration of macrophages in (consecutive metastatic) tumor lesions.
In view of harnessing the antibody-dependent cytotoxic function of NK cells, it will be of 
interest to determine whether NK cells penetrating bone sarcomas retain functional FcγRIII/
CD16 expression as observed for NK cells from peripheral blood of osteosarcoma patients. To 
delineate NK cell responses to antibody therapy in patients, it would be of interest to explore 
the distribution as well as phenotypic and functional activation of NK cells in blood and 
(consecutive metastatic) tumor lesions of patients with osteosarcoma or other solid cancers. Since 
tumor infiltration of NK cells needs to be improved, it will be of interest to investigate whether 
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(a) therapeutic antibodies, inducing ADCC and NK cell activation like anti-EGFR cetuximab, 
(b) cytokine-induced NK cell activation or (c) even the application of oncolytic viruses can 
modulate NK cell trafficking to bone sarcoma lesions using murine osteosarcoma models and by 
analyzing patient tumor specimens. 
Overall, to exploit the cytotoxic potential of NK cells against bone sarcomas, antibody therapy 
should be scheduled in the presence of endogenous or pre-activated adoptively-transferred NK 
cells to sustain NK cell functionality, which might contribute to the generation of potent and 
enduring anti-cancer adaptive immunity. Finally, NK cell anti-cancer function may be more 
effective in a less or non-immunosuppressive cancer microenvironment. Thus, NK cells may be 
harnessed to eliminate residual cancer cells which have survived after conventional anti-cancer 
therapies. 
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Summary of this Thesis
SuMMARy of ThIS TheSIS
Introduction
Osteosarcoma and Ewing sarcoma are the most common bone cancers in children and young 
adults. Despite advanced surgical techniques and multi-drug chemotherapy, one-third of the 
patients still succumb to recurrent disease with poor prognosis. Likewise, patients with metastatic 
and chemotherapy-resistant disease have a poor outcome. Thus, novel targeted therapies are 
needed that combine potent and specific anti-cancer activity with limited toxicity toward normal 
tissues. 
Previous research lines have provided evidence that natural killer (NK) cells and macrophages, 
both cell types of the innate immune system, are able to contribute to anti-cancer responses 
against osteosarcoma and Ewing sarcoma cells. NK cells are able to eliminate virus-infected and 
tumor-transformed cells and can support adaptive immune responses. The cytotoxic function of 
NK cells is not MHC class I-restricted; thus, while being able to evade cytotoxic T lymphocyte 
responses, tumor cells with reduced MHC class I expression can be recognized by NK cells. 
NK cells are additionally attractive for the design of anti-tumor immunotherapies, since NK 
cells have not been associated with severe adverse effects such as graft-versus-host disease if 
therapeutically introduced into patients. During cancer development, cancer cells are presumed 
to evolve immune escape variants, a process which is supported by the immunosuppressive milieu 
of the cancer microenvironment, inhibiting anti-cancer immune responses. Thus, to harness NK 
cells and macrophages for immunotherapeutic approaches, their anti-cancer potential may need 
to be induced in such a way that it can resist inhibitory influences. 
In the introductory chapter 1, clinical and biological properties of osteosarcoma and Ewing 
sarcoma are discussed followed by an overview of cancer immunology and immunotherapy. 
The results of the preclinical studies described in the chapters 2–6 are further discussed in the 
concluding chapter 7, addressing implications for anti-cancer immunotherapeutic strategies 
involving NK cells and macrophages. 
Results
In chapter 2, an experimental model for measuring NK cell activation is explored in response to 
a prototypical viral infection by adenovirus type 5 (HAdV5) and HAdV35. It is described that 
increased expression of the NK cell activation marker CD69 and enhanced NK cell cytotoxic 
activity in response to HAdV5 relied on the contribution of T cells and IL-2. In contrast, NK 
cell activation in response to HAdV35 occurred in the absence of T cells and was mediated by 
the significantly higher production of interferon-α by pDC. Interferon-α production by pDC 
was dependent on toll-like receptor-9 signaling and was enhanced by the reciprocal interaction 
of NK cells and pDC. 
In the following research chapters it is explored how the anti-cancer potential of NK cells 
and macrophages can be enhanced and directed to osteosarcoma and Ewing sarcoma cells. In 
chapter 3 it is shown that the cytotoxic activity of NK cells can be more specifically directed 
to sarcoma cell lines if the cancer cells are coated with a therapeutic antibody like cetuximab, 




of cetuximab, FcγRIII/CD16-mediated, antibody-dependent NK cell cytotoxicity (ADCC) 
against autologous osteosarcoma cells was substantially enhanced and as effective as by cytokine 
(IL-15)–activated NK cells. ADCC by NK cells required only minimal EGFR expression on 
the cancer cell surface. Thus, NK cells are able to exert substantial cytolytic activity against 
osteosarcoma and Ewing sarcoma cell lines as demonstrated in short-time 4-hour cytotoxicity 
assays. 
However, as illustrated in chapter 4, prolonged two-day sarcoma–NK cell interactions, potentially 
occurring in the cancer microenvironment in vivo, can alter NK cell functionality. It is shown 
that certain sarcoma cell lines can trigger down-regulation of NK cell-activating receptors, such 
as NKG2D, DNAM-1 and NKp30, even in the presence of the NK cell activating cytokine 
IL-15. This inhibiting effect was dependent on physical contact and resulted in impaired NK 
cell cytotoxicity mediated through these receptors, inhibiting lysis of osteosarcoma and Ewing 
sarcoma cells. Notably, when activated with IL-15 for five days prior to sarcoma cell interaction, 
these pre-activated NK cells were resistant to the immunosuppressive effects of sarcoma cells. 
Moreover, the FcγRIII/CD16-mediated antibody (cetuximab)-dependent cytotoxic potential of 
NK cells remained functional after prolonged sarcoma cell interactions. Hence, a combination 
of cytokine activation with therapeutic antibodies may improve and sustain the capacity of 
NK cells to contribute to cancer cell elimination in a potentially immunosuppressive cancer 
microenvironment. 
Macrophages frequently infiltrate solid cancers. In osteosarcoma, macrophage infiltration is 
correlated with favorable patient outcome, suggesting anti-cancer activity of macrophages in 
osteosarcoma. In chapter 5 it is demonstrated that human M1-type macrophages are able to 
inhibit osteosarcoma cell growth if activated with a bacterial stimulus like liposomal muramyl 
tripeptide (L-MTP-PE). Importantly, induction of anti-cancer activity by L-MTP-PE required 
the presence of IFN-γ, a notion which is relevant for improving the outcome of currently applied 
L-MTP-PE therapy in osteosarcoma patients. IL-10–polarized M2 macrophages, which are 
considered to support cancer development, were able to inhibit growth of some osteosarcoma cells 
if directed to antibody (cetuximab)-coated cancer cells. Hence, tumor-infiltrating macrophages 
may be manipulated to exert anti-cancer responses if activated through factors reminiscent of 
an infection in the cancer microenvironment and/or by the application of cancer cell-reactive 
therapeutic antibodies. 
In chapter 6, it is documented that the immunoregulatory protein CD70 is expressed on the 
majority of osteosarcoma cell lines and patient-derived osteosarcoma cultures, whereas only 
few Ewing sarcoma cell lines expressed CD70. CD70 expression in primary and recurrent 
osteosarcoma lesions was heterogeneous and restricted to tumor cells and not attributed to 
tumor-infiltrating T cells. CD27, the receptor for CD70, was expressed neither on tumor cells 
nor on tumor-infiltrating T cells in CD70-positive or CD70-negative osteosarcoma lesions. 
CD70 gene expression did not correlate with the occurrence of metastasis and survival of 
osteosarcoma patients. Since CD70 expression in normal tissue is restricted and transient, CD70 
may represent a novel, more cancer-specific target for anti-cancer immunotherapy in patients 
with CD70 positive tumors. 
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Conclusion
The research performed in this thesis demonstrates that human NK cells and macrophages have 
the potential to exert anti-cancer responses if sufficiently activated by immunostimulators, and 
directed to osteosarcoma and Ewing sarcoma by therapeutic antibodies. These findings may 
help to improve currently applied therapies and design novel immunotherapeutic strategies 
which counteract potential cancer escape and immunosuppression and contribute to cancer 
cell elimination. For an effective contribution of NK cell-based immunotherapy to cancer cell 
elimination, it will be important to further investigate how tumor cell escape from immune 
control can be overcome and how the migration and penetration of NK cells into the cancer 






Samenvatting van het Proefschrift
SAMeNVATTINg VAN heT PRoefSChRIfT
Inleiding
Osteosarcoom en Ewing-sarcoom zijn de meest voorkomende kwaadaardige bottumoren bij 
kinderen en  jong volwassenen. Ondanks  chirurgische verwijdering van de tumor in combinatie 
met hoge dosis combinatie chemotherapie, zal een derde van de patiënten recidiveren waarna de 
prognose slecht is. Ook patiënten met gemetastaseerde tumoren of tumoren die niet reageren 
op chemotherapie, hebben slechte overlevingskansen. Nieuwe behandelmethoden, die specifiek 
tegen de tumorcellen maar niet tegen gezonde weefsels gericht zijn, dienen ontwikkeld te worden.
In eerder onderzoek was aangetoond, dat Natural Killer (NK) cellen en macrofagen, beide 
behorende tot het aspecifieke immuunsysteem, anti-tumor activiteit bezitten tegen osteosarcoom 
en Ewing-sarcoom cellen. NK-cellen zijn in staat  virus-geïnfecteerde cellen en kankercellen 
te lyseren. Daarnaast kunnen NK-cellen de activatie van het specifieke immuunsysteem 
ondersteunen. Tumorcellen ontsnappen soms aan herkenning door cytotoxische T-lymfocyten 
door de expressie van MHC klasse I moleculen te verlagen. NK-cellen daarentegen herkennen 
juist cellen die geen of weinig MHC klasse I tot expressie brengen. Omdat er tot op heden nog 
geen relatie tussen NK-cel therapie en klinisch ongunstige effecten zoals graft-versus-host ziekte 
en toxiciteit is gerapporteerd, zijn NK-cellen een aantrekkelijke optie om immunotherapie op 
te baseren. 
Voor een effectieve immunotherapie is het verder nog noodzakelijk dat de effector cellen 
ongevoelig zijn voor de immuun-onderdrukkende eigenschappen van de tumor. Zowel de tumor 
cellen zelf als het stromale weefsel rondom de tumor kunnen de effector cellen onderdrukken of 
ontsnappen aan herkenning. 
In het inleidende hoofdstuk 1 worden de klinische en biologische kenmerken van het 
osteosarcoom en Ewing-sarcoom besproken. Aansluitend volgt er een overzicht waarin het 
veld van de tumorimmunologie en de verschillende immuuntherapieën wordt beschreven. De 
resultaten van de preklinische studies, beschreven in de hoofdstukken 2–6, worden in het 
afsluitende hoofdstuk 7 samengevat, met daarbij de implicaties voor immuuntherapieën die op 
NK-cellen en macrofagen gebaseerd zijn.
Resultaten
In hoofdstuk 2 wordt een experimenteel model behandeld om de activiteit van NK-cellen te 
meten, gestimuleerd door twee verschillende serotypen van het adenovirus. Wanneer bloedcellen 
geïnfecteerd werden met humaan adenovirus type 5 (HAdV5), was zowel de verhoogde expressie 
van de NK-cel activatie marker CD69 als de hogere cytotoxische activiteit van NK-cellen, 
afhankelijk van T-cellen en met name hun interleukine-2 productie. NK-cellen gestimuleerd 
door infectie van bloedcellen door een ander serotype, namelijk HAdV35, werden daarentegen 
onafhankelijk van T-cellen geactiveerd. In dit geval werd NK-cel activatie geïnduceerd door 
verhoogde productie van interferon-α door plasmacytoïde dendritische cellen (pDC). De 
pDC herkenden het virus-DNA via hun DNA-sensor, toll-like receptor 9. Bovendien werd de 
interferon-α productie versterkt door de wederzijds interactie tussen pDC en NK-cellen.  
In hoofdstuk 3 is uitgezocht hoe het cytotoxische potentieel van NK-cellen tegen osteosarcoom 




sarcoomcellen beter herkend en gelyseerd kunnen worden door NK-cellen als de tumorcellen 
met therapeutische antilichamen zoals cetuximab (gericht tegen de receptor voor epidermale 
groei factor (EGFR)) beladen zijn. In aanwezigheid van cetuximab was de cytotoxische activiteit 
van NK-cellen, ook die van patiënten die een osteosarcoom hebben, significant verhoogd tegen 
autologe EGFR-postieve osteosarcoom cellen, dat wil zeggen tumorcelkweken die uit dezelfde 
patiënten gegenereerd zijn. De cytotoxiciteit van NK-cellen, gemedieerd door cetuximab, was 
even effectief als die van NK-cellen, die gestimuleerd waren met het sterk activerende cytokine 
interleukine-15 (IL-15). Zelfs bij lage hoeveelheden EGFR op de tumorcellen, was de lyserende 
werking van NK-cellen reeds maximaal; er werd geen dosis-effect relatie gevonden. 
Op deze manier zijn NK-cellen in staat om substantiële cytotoxische activiteit tegen osteosarcoom 
en Ewing-sarcoom cellijnen uit te oefenen, zoals aangetoond in de korte vier uur durende 
chroom-release experimenten. Maar, zoals beschreven in hoofdstuk 4, kunnen langdurige 
interacties (zoals twee dagen) tussen sarcoomcellen en NK-cellen, die mogelijk bij de patiënt 
in het omliggende tumorweefsel plaatsvinden, de activiteit van NK-cellen tegen sarcomen 
verminderen. Sommige sarcoom cellijnen kunnen down regulatie van activerende receptoren 
zoals NKG2D, DNAM-1 en NKp30 op NK-cellen veroorzaken, zelfs in aanwezigheid van 
het sterk activerende cytokine IL-15. Deze lagere expressie van receptoren werd gemedieerd 
door fysiek contact tussen de tumorcel en de NK-cel, en had als gevolg dat de cytotoxische 
activiteit van NK-cellen verminderde, dus een remmend effect had op de functie van NK-cellen. 
Opvallend was dat de antilichaam-gemedieerde cytotoxische capaciteit van NK-cellen ongevoelig 
was voor de remming door sarcoomcellen. Wanneer de NK-cellen vóórdat ze in contact kwamen 
met de sarcoomcellen met IL-15 geactiveerd waren, was hun cytotoxische activiteit bestand tegen 
de remmende effecten van de tumorcellen. Een combinatie van NK-cel activatie door middel van 
cytokinen en toevoeging van therapeutische antilichamen zou de functionaliteit van NK cellen 
in patiënten zodanig kunnen versterken dat eliminatie van tumorcellen, ondanks inhiberende 
factoren van de tumor(omgeving), effectief blijft. 
In solide tumoren is vaak infiltratie te zien van macrofagen en hoewel bij vele tumoren dit 
een negatieve prognostische factor is, is deze infiltratie in osteosarcoom patiënten gecorreleerd 
met een betere prognose. Deze observatie suggereert dat macrofagen anti-tumor activiteit tegen 
het osteosarcoom bezitten. In hoofdstuk 5 wordt beschreven dat M1-type macrofagen in staat 
zijn de groei van osteosarcoom cellen te remmen, als deze macrofagen geactiveerd zijn met een 
bacteriële stimulus, zoals liposomal muramyl tripeptide (L-MTP-PE). De inductie van anti-
tumor activiteit van M1-type macrofagen door L-MTP-PE was wel afhankelijk van co-stimulatie 
met het cytokine interferon-γ. Inductie van interferon-γ tijdens macrofaag activatie door 
L-MTP-PE zou dus belangrijk kunnen zijn om het effect van L-MTP-PE therapie in patiënten 
met osteosarcoom te verbeteren. Bovendien waren IL-10–gepolariseerde macrofagen, waarvan 
over het algemeen beschreven wordt dat die de tumorontwikkeling ondersteunen, in staat 
osteosarcoom celgroei te remmen, als het antilichaam cetuximab aanwezigheid was. De anti-
tumor activiteit van tumor-infiltrerende macrofagen zou dus gestimuleerd kunnen worden door 
factoren die op een infectie in de kanker omgeving lijken, namelijk een bacterieel bestanddeel in 
een interferon-γ rijke omgeving, of door toediening van een therapeutische antilichaam. 
In hoofdstuk 6 wordt beschreven dat het immuunregulerende eiwit CD70 tot expressie 
gebracht wordt op een meerderheid van de osteosarcoom cellijnen en primaire  osteosarcoom 
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celkweken. Op Ewing-sarcoom cellijnen was daarentegen nauwelijks CD70 aantoonbaar. In 
zowel diagnostisch als in recidief osteosarcoom weefsel is CD70-expressie heterogeen en beperkt 
zich tot de tumorcellen. CD27, de receptor voor CD70, werd niet gedetecteerd op tumorcellen. 
Infiltrerende T-cellen in tumorweefsel waren negatief voor zowel CD70 als CD27-expressie, 
onafhankelijk van CD70 expressie in het tumorweefsel. CD70-gen expressie was niet gecorreleerd 
met het ontstaan van metastasen of de overlevingskansen van osteosarcoom patiënten. Gezien 
het feit dat expressie van CD70 in gezond weefsel heel beperkt en transient is, zou CD70 een 
nieuw en tumor specifieke target kunnen zijn voor immuuntherapieën in patiënten met CD70-
positieve tumoren.  
Conclusies
Het onderzoek beschreven in dit proefschrift illustreert dat humane NK-cellen en macrofagen in 
staat zijn anti-tumor activiteit ten toon te spreiden als deze immuuncellen geactiveerd zijn door de 
juiste stimuli of in aanwezigheid van therapeutische antilichamen. Deze resultaten kunnen helpen 
om de huidige therapieën te verbeteren en de ontwikkeling van nieuwe immuuntherapieën te 
stimuleren. Daarbij zal in het bijzonder aandacht gegeven dienen te worden aan de gevoeligheid 
van deze therapieën voor immuun-onderdrukkende effecten van de tumor of tumor omgeving. 
Om eliminatie van tumorcellen door een NK cel immunotherapie effectief te laten zijn zal in 
de toekomst enerzijds onderzocht dienen te worden hoe de ontsnapping van tumorcellen aan 
het immuunsysteem kan worden voorkomen en anderzijds hoe de migratie van NK cellen in de 









Das Osteosarkom und das Ewing-Sarkom sind Knochenkrebsarten, die am häufigsten bei 
Kindern und jungen Erwachsenen auftreten. Trotz fortschrittlicher Operationstechniken zur 
Entfernung von primärem Tumorgewebe und Tumormetastasen, sowie eines breiten Spektrums 
an chemotherapeutischen Substanzen bricht die Krebserkrankung bei einem Drittel der Patienten 
nach vielversprechender erster Behandlung erneut aus, was eine deutliche Verschlechterung der 
weiteren Prognose dieser Patienten nach sich zieht. Gleichermaßen ist die Lebenserwartung 
von Patienten, die bereits in einem frühen Stadium Tumormetastasen oder Therapie-resistente 
Tumore aufweisen, sehr eingeschränkt. Um die Perspektive dieser Patienten zu verbessern, 
werden daher neue Therapiemethoden benötigt, die Krebszellen gezielt angreifen, dabei jedoch 
gesundes Gewebe möglichst wenig beinträchtigen.  
In früheren Forschungsansätzen wurde gezeigt, dass Natürliche-Killerzellen (NK-Zellen) und 
Makrophagen, beides Zelltypen des sogenannten angeborenen Immunsystems, anti-Tumor–
Aktivität gegenüber Sarkomzellen besitzen bzw. begünstigen. NK-Zellen sind in der Lage 
infizierte Zellen sowie Krebszellen zu lysieren und können Immunantworten des erworbenen 
Immunsystems unterstützen und modulieren. NK-Zellen erkennen Zielzellen, die im Vergleich 
zu gesunden Körperzellen meist eine verminderte Anzahl an deaktivierenden MHC-Klasse-I–
Molekülen und zudem eine erhöhte Anzahl an aktivierenden Signalmolekülen exprimieren: 
dies trifft vor allem auf gestresste und transformierte Zellen zu. Daher können NK-Zellen auch 
die Tumorzellen bekämpfen, die sich der Kontrolle des erworbenen Immunsystem und somit 
T-Lymphozyten entziehen. Der Einsatz von NK-Zellen für immuntherapeutische Ansätze ist 
auch deshalb vielversprechend, da NK-Zellen keine gefährlichen Nebenwirkungen wie Graft-
versus-Host Reaktionen hervorrufen, wenn NK-Zellen zu therapeutischen Zwecken in Patienten 
infundiert werden.  
Es wird angenommen, dass im Laufe der Krebsentstehung, unter dem Selektionsdruck des 
Immunsystems, Tumorzellvarianten hervorgebracht werden, die in der Lage sind anti-Tumor–
Immunantworten zu unterlaufen oder auch entgegenzuwirken. Dieser Prozess wird durch die 
immununterdrückenden Eigenschaften der Tumorzellen selbst aber auch durch das umliegende 
Gewebe der Tumorumgebung begünstigt, wodurch Immunantworten gegenüber Krebszellen 
gehemmt werden.  Um folglich NK-Zellen und Makrophagen für immuntherapeutische Ansätze 
zu verwenden, muss das anti-Tumor–Potential dieser Immunzellen derart verstärkt werden, dass 
dieses in der Tumorumgebung nicht mehr gehemmt wird. 
Im einleitenden Kapitel 1 dieser Dissertation werden die klinischen und biologischen 
Eigenschaften des Osteosarkoms und Ewing-Sarkoms vorgestellt. Auf diesen Abschnitt folgt 
ein Überblick über das Feld der Tumorimmunologie sowie verschiedener Immuntherapien. 
Die vorklinischen Forschungsergebnisse dieser Arbeit werden in den Kapiteln 2–6 beschrieben 
und im abschließenden Kapitel 7 übergreifend zusammengefasst; Schlussfolgerungen und 






In Kapitel 2 wird ein experimentelles Modell zum Messen der Aktivität von NK-Zellen als Antwort 
auf eine Virusinfektion durch den Adenovirus Subtyp 5 (HAdV5) und HAdV35 aufgestellt. Die 
Ergebnisse dieser Experimenten zeigen, dass eine Aktivierung von NK-Zellen durch Stimulierung 
mit HAdV5 – ermittelt anhand einer erhöhten Expression des Aktivierungsmarkers CD69 auf 
der Oberfläche von NK-Zellen als auch einer erhöhten zytotoxische Aktivität der NK-Zellen – 
nur in Gegenwart von T-Zellen und von dem durch T-Zellen produzierten Zytokin (Botenstoff ) 
Interleukin-2 erfolgen konnte. Im Gegensatz hierzu konnten NK-Zellen durch HAdV35 ohne 
den Einfluss von T-Zellen aktiviert werden. Dies wurde durch die vermehrte Ausschüttung des 
Zytokins Interferon-α (IFN-α) durch Plasmazytoide Dendritische Zellen (pDC) vermittelt. 
Die vermehrte Ausschüttung von IFN-α durch mit HAdV35 infizierte pDC war abhängig von 
der Aktivierung des Toll-like Rezeptor-9 (Detektor für Virus-DNA) und wurde darüber hinaus 
durch die wechselseitige Interaktion zwischen NK-Zellen und pDC verstärkt.       
In den folgenden Forschungsprojekten wird untersucht, auf welche Weise das anti-Tumor–
Potential von NK-Zellen und auch Makrophagen gesteigert und zielgenauer auf Osteosarkom- 
und Ewing-Sarkomzellen gerichtet werden kann. In Kapitel 3 wird gezeigt, dass die zytotoxische 
Aktivität von NK-Zellen spezifischer auf Sarkomzelllinien gelenkt werden kann, wenn die 
Krebszellen mit bestimmten therapeutischen Antikörpern wie zum Beispiel Cetuximab bedeckt 
sind, welche in diesem Fall den Rezeptor des epidermalen Wachstumsfaktors (EGFR) auf der 
Oberfläche der Krebszellen binden. Cetuximab induziert die sogenannte FcγRIII/CD16-
vermittelte, Antikörper-abhängige Zytotoxität von NK-Zellen. Dadurch wurde in Gegenwart 
von Cetuximab die Lyse von aus Osteosarkom-Patienten kultivierten Krebszellen durch autologe 
NK-Zellen vervielfacht: d.h. durch NK-Zellen, die ebenfalls aus diesen Patienten isoliert 
worden waren. Die durch Antikörper (Cetuximab) induzierte zytotoxische Aktivität der NK-
Zellen war vergleichbar mit jener von IL-15–aktivierten NK-Zellen und war selbst bei geringer 
Expression von EGFR auf der Krebszelloberfläche wirkungsvoll. Diese Experimente legen dar, 
dass NK-Zellen in kurzzeitigen, vierstündigen Experimenten substantielle zytotoxische Aktivität 
gegenüber Osteosarkom- und Ewing-Sarkomzellen besitzen. 
Wie jedoch in Kapitel 4 veranschaulicht wird, sind längere, zwei Tage andauernde Interaktionen 
zwischen Sarkomzellen und NK-Zellen, wie sie potentiell eher den Bedingungen in der 
Tumorumgebung von Patienten entsprechen, in der Lage die Funtionalität von NK-Zellen zu 
beinflussen. In diesem Abschnitt wird gezeigt, dass bestimmte Sarkomzelllinien nach Kultivierung 
mit NK-Zellen eine verminderte Expression von aktivierenden NK-Zell–Rezeptoren wie z.B. 
von NKG2D, DNAM-1 und NKp30 bewirken können, und dies sogar wenn die NK-Zellen 
gleichzeitig mit dem aktivierenden Zytokin IL-15 behandelt wurden. Weiterhin wurde durch 
diesen negativen Effekt auch die zytotoxischen Aktivität der NK-Zellen und somit die Lyse von 
Sarkomzellen vermindert, da diese von der Funktionalität der oben genannten NK-Zellrezeptoren 
abhängt. Dieser hemmende Effekt beruhte auf dem physischen Kontakt zwischen Tumorzellen 
und NK-Zellen. Wenn die NK-Zellen allerdings vor der Interaktion mit Sarkomzellen über 
einen Zeitraum von fünf Tagen mit IL-15 aktiviert worden waren, wurden diese voraktivierten 
NK-Zellen nicht mehr durch die immununterdrückenden Eigenschaften der Sarkomzellen 




abhängige Zytotoxität von NK-Zellen durch die anhaltende Interaktion mit Sarkomzellen nicht 
gestört. Diese Ergebnisse lassen vermuten, dass eine Kombination von aktivierenden Zytokinen 
und therapeutischen Antikörpern die zytotoxische Kapazität von NK-Zellen aufrechterhalten 
und soweit verstärken könnte, dass NK-Zellen auch unter Einfluss von immununterdrückenden 
Faktoren in der Tumorumgebung die Eliminierung von Krebszellen unterstützen könnten. 
Es ist bekannt, dass Makrophagen häufig solide Tumore infiltrieren. In einer früheren Studie 
an Osteosarkom-Patienten wurde festgestellt, dass Patienten mit einer höheren Anzahl an 
Makrophagen im Tumorgewebe eine bessere Prognose aufweisen. Diese Ergebnisse legen nahe, 
dass Makrophagen im Osteosarkom an anti-Tumor–Reaktionen beteiligt sind. In Kapitel 5 
wird dargestellt, dass humane M1-Typ Makrophagen in der Lage sind das Zellwachstum von 
Osteosarkomzellen zu hemmen, sofern diese Makrophagen zuvor mit bakteriellen Substanzen 
wie z.B. liposomalen Muramyltripeptiden (L-MTP-PE) aktiviert wurden. Die Induktion der 
anti-Tumor–Aktivität durch L-MTP-PE erforderte allerdings die gleichzeitige Zugabe von 
IFN-γ, eine Beobachtung, die für die Optimierung der gegenwärtig angewendeten L-MTP-PE-
Therapie bei Osteosarkom-Patienten relevant ist. Auch IL-10–polarisierte M2-Typ Makrophagen, 
welche die Entstehung und das Wachstum von Tumoren vermutlich begünstigen, konnten 
in die Lage versetzt werden, das Wachstum von Osteosarkomzellen zu hemmen, jedoch nur 
wenn die Krebszellen mit Antikörpern (Cetuximab) behandelt waren. Diese Ergebnisse deuten 
darauf hin, dass Tumor-infiltrierende Makrophagen möglicherweise auch in Patienten für anti-
Tumor–Antworten mobilisiert werden könnten, durch Zugabe von Tumorzell-markierenden 
therapeutischen Antikörpern und/oder von aktivierenden Faktoren, die eine Infektion in der 
Tumorumgebung simulieren. 
In Kapitel 6 wird dokumentiert, dass das immunregulatorische Protein CD70 auf einer Mehrzahl 
von Osteosarkomzelllinien und aus Patienten gewonnenen Osteosarkomzellkulturen exprimiert 
wird, während CD70 nur auf wenigen Ewing-Sarkomzelllinien nachweisbar ist. Untersuchungen 
verschiedener Gewebeproben von primären und erneut auftretenden Osteosarkomtumoren 
ergaben, dass die Expression von CD70 in diesen Tumoren heterogen ist, auf Tumorzellen 
begrenzt und nicht assoziert ist mit Tumor-infiltrierenden T-Zellen. CD27, der natürliche 
Rezeptor für CD70, wurde weder auf Krebszellen noch auf Tumor-infiltrierenden T-Zellen in 
CD70-positiven oder CD70-negativen Osteosarkomproben nachgewiesen. Die Genexpression 
von CD70 im Tumorgewebe hatte keinen Einfluss auf das Auftreten von Metasasen und somit 
auf die Überlebensrate dieser Patienten. Da die Expression von CD70 im gesunden Gewebe sehr 
eingeschränkt bzw. kurzlebig ist, könnte CD70 daher in Patienten mit CD70-positiven Tumoren 
ein neues, Krebszell-spezifischeres Zielprotein für Immuntherapien darstellen.   
fazit
In dieser Arbeit wird dargelegt, dass humane NK-Zellen und auch Makrophagen das Potential für 
anti-Tumor–Antworten besitzen, wenn diese Immunzellen hinreichend mit immunstimulierenden 
Faktoren aktiviert und/oder mit therapeutischen Antikörpern auf Osteosarkom- und Ewing-
Sarkomzellen gelenkt werden. Diese Ergebnisse mögen zur Verfeinerung derzeit angewendeter 
Therapien sowie zur Entwicklung neuer immuntherapeutischer Behandlungsansätze beitragen, 
die den immununterdrückenden Faktoren der Tumorumgebung entgegenwirken und die 
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